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1. Background
Bone defects have a significant impact on the individual quality of life, as well as on overall 
health care costs. Annually, more than 500,000 bone grafting procedures are performed 
in the United States alone and worldwide this procedure accounts for approximately 2.2 
million operations. This number of procedures will increase vastly as a result of aging 
and growth of the population, and by the increasing wealth in the western world. Bone 
grafts are used to treat defects caused, for instance, by trauma, oncological surgery or 
congenital skeletal malformations. In addition, bone grafts are also used for a relative 
small number of cosmetic procedures.1
2. Bone tissue 
The bone tissue itself is a very dynamic structure, which is highly vascularized and 
naturally remodeled during the entire adulthood. The main role of bone is to provide 
structural support for the body, but it also serves as a mineral reservoir, it protects 
internal organs and it supports muscle contraction. Bone is composed of both organic 
and inorganic components. About 35% of the dry bone weight constitutes the organic 
part, composed of polysaccharides, glycoproteins, proteoglycans, sialoproteins and cells. 
The most abundant protein is collagen type I, which accounts for approximately 90% of 
the organic matrix. The inorganic part, about 65% of the dry bone weight, is composed 
of the mineral hydroxyapatite. This component is predominantly crystalline, though it 
may be present in amorphous forms.2 Bone tissue is being formed and disintegrated in 
response to physical and hormonal factors. Three major cell types are involved in these 
processes, i.e. osteoblasts, osteoclasts and osteocytes. Osteocytes make up more than 
90-95% of all bone cells in the adult skeleton, whereas osteoblasts compose less than 5% 
and osteoclasts less than 1%. Osteoblasts are responsible for the synthesis, deposition 
and mineralization of bone. When osteoblasts become entrapped in the mineralized bone 
matrix, they transform into osteocytes, which regulate bone matrix turnover by activating 
osteoblasts and osteoclasts in response to various mechanosensory mechanisms. 
Osteoclasts participate in bone resorption and they stimulate osteoblastic cells to form 
new bone.3, 4
3. Bone morphogenetic proteins
When bone damage occurs, for instance through fracture, a cascade of tissue responses 
is initiated resulting in the removal of tissue debris, restoration of the vascularity and 
reconstruction of the bony matrix. Interleukins and growth factors play a major role in this
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cascade by the recruitment of cells like lymphocytes, macrophages, osteoclast precursors 
and stem cells. A subset of members of the transforming growth factor-β (TGF-β) 
superfamily have been implicated as the predominant growth factors in fracture healing, 
namely the bone morphogenetic proteins (BMPs).5-7 These proteins were reported to 
induce chemotaxis, migration, proliferation and mainly differentiation of mesenchymal 
stem cells, providing sufficient numbers of osteoblasts for the formation of new bone 
at the fracture site.5, 7, 8 BMPs signal through binding to heterodimeric type I and II 
serine/threonine kinase complexes and they are formed by cleavage of large precursor 
proteins.6, 8, 9 After cleavage, the proteins are tightly folded to form active BMPs existing in 
homodimeric and heterodimeric forms. Disulfide bonds between the subunits strengthen 
the tight folding and provide them stability. Some heterodimer proteins were reported to 
have higher specific activities than their homodimeric counterparts, but induced newly 
formed bone is qualitatively equal.9, 10 Systemic clearance of BMPs in the body is high, 
therefore administration of BMPs for bone reconstructive purposes is best done locally, 
were the effect is desired.5 Also the dosage of the BMPs is of importance, since the bone 
forming activity of BMPs is described to be dose responsive. Low doses result in inadequate 
bone formation, but extreme high doses can result in an acceleration of osteoinduction 
that is higher than desired. The correct dosage is depending on the clinical application 
and on the type of BMP that is used10. Pre-clinical and clinical studies have described a 
highly osteoinductive potential for BMP-2 and 7, what makes them very suitable for bone 
reconstructive purposes.5, 6 
4. Bone grafts
In the event of bone damage resulting in defects larger than a fracture, or non-
healing fractures, it may be clinically necessary to apply a natural or synthetic bone 
graft. Autologous bone is still considered the golden standard for grafting procedures. 
However, this type of graft also beholds some major drawbacks of. Autografts usually 
are harvested from the iliac crest and thus the amount and size is limited. Furthermore, 
obtaining the graft requires an additional painful surgery and might be associated with 
donor site morbidity.1, 2, 11 In some patients like elderly, pediatric patients, or patients with 
a metastatic disease, autologous bone resection is even impossible. As a substitute to 
autografts, allografts from human cadavers are available at the bone bank. These can 
be obtained in various forms (e.g. chips, blocks, paste, gels or putties) and preparations 
(e.g. frozen or freeze-dried). However, the use of allografts is often accompanied by 
immunogenic responses and is associated with the risk of viral and bacterial infections.1, 
2 Applying freezing or freeze-drying processes lowers the risks of disease transmission 
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and immune rejection, but also lowers the osteoinductive properties of the graft. Therefore, 
clinical results for the use of allografts can be unpredictable. The failure rate of allograft 
cages for instance approaches 30%.2 Due to the limitations of auto- and allografts, 
synthetic bone grafts were developed. The ideal synthetic bone graft should comply 
with several intrinsic properties. First, the material should be biocompatible, i.e. should 
not provoke an inflammatory reaction, or fibrous tissue encapsulation, preventing direct 
connection to the bone. Secondly, the material should be biodegradable, to support the 
healing bone when necessary, while degrading in time as the healing subdues. A third 
characteristic of the material should be osteoconductivity, i.e. the surface characteristics 
of the material should permit bone cells to proliferate on the surface. Also, osteoinductive 
materials are described with the capacity to induce proliferation of undifferentiated cells 
and differentiation of pluripotent cells into osteoprogenitor cells. Osteogenic materials 
could even provide a reservoir of skeletal stem and progenitor cells that are necessary for 
the formation of new bone.1, 12, 13 Finally, the architecture, porosity, pore wall roughness and 
pore interconnectivity of the graft should support intrusion of the bone cells into the graft 
and vascularization to provide accurate diffusion of nutrients, gases and osteoinductive 
proteins necessary for the cells to produce bone matrix.14 
Currently, various materials including metals, polymers, ceramics and composites are 
used as synthetic bone grafts. Synthetic materials have proven their functionality as good 
alternatives of autologous bone grafts for the repair of small bone defects. However, 
these grafts achieved only limited success for the repair of long bone defects. The poor 
mechanical properties (such as flexural strength, bending strength, elasticity modulus 
and toughness) compared to natural bone, and the poor invasion of bone forming cells, 
resulting in poor bone formation in the graft, are regarded as the main causes of this 
limited success.1, 12
Development of advanced scaffold materials, for instance with the use of novel 
nanomaterials, might overcome these problems. With the upcoming interest in 
nanomaterials various definitions on the size and structure of nanomaterials were made. 
However, the most commonly accepted size range lies between the 1-100 nm for the basic 
structural units of nanostructured materials, like the crystalline solids in nanocrystals, the 
coating thickness in nanocoatings, the particles in nanopowders and the diameters of 
nanofibers.2 Nanomaterials have been explored and proven beneficiary in several research 
fields, including the field of bone tissue engineering. They are capable of improving the 
mechanical properties as well as the osteoconductivity of bone grafts.2, 15-20 Still, concerns 
exist on the biological fate of nanomaterials in the body, and possible toxicity responses.21-24
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5. Objectives of this thesis
This thesis describes several studies performed to develop new and improved bone 
graft substitutes, constituting nanomaterials and growth factors, resulting in superior 
mechanical, osteoconductive and osteoinductive properties. Furthermore, some of the 
properties of the nanomaterial used in the graft, like the in vivo distribution pattern after 
release from a degrading scaffold and the possible adverse effects on human health, were 
intensively examined as well.
The following research questions were covered:
1. What is the current state of the art in nanomaterials for bone reconstruction?
2. What are the effects of different growth factors with varying concentrations, and 
in different combinations, on the proliferation and differentiation of bone marrow 
derived osteoblast-like cells in vitro?
3. What are the release and bioactivity profiles of BMP-2, released from a porous 
poly(L-lactic acid) (PLLA) scaffold with incorporated carbon nanotubes (CNTs) and 
microhydroxyapatite (µHA)?
4. What are the properties of CNTs, labeled with gadolinium (gadonanotubes), for 
magnetic resonance imaging (MRI) purposes?
5. What are the effects of porous CNT and µHA doped PLLA scaffolds, on the in vitro 
genetic expression profiles of osteoblast-like cells, in the presence of BMP-2?
6. What current information is available on toxicological aspects of CNTs?
12
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1. Nanomaterials for bone reconstructive composites
In a natural environment, the cells of our body interact with the extracellular matrix (ECM) 
that is surrounding them. When examined from a topographical point-of-view, it becomes 
apparent that this ECM is structured as a mixture of pores, ridges, and fibers, which all 
are sized in the nanoscale range.1-3 From this perspective, it has been suggested that 
it could be worthwhile to develop man-made materials of similar dimensions. Such bio-
mimetic nanomaterials could harbor great promise in advanced medical applications, and 
in this chapter we will focus on the relationship between such nanomaterials and tissue 
engineering procedures for bone reconstructive purposes. The placement and subsequent 
tissue integration of a bone implant or tissue engineered construct requires symbiosis 
between a biological and a non-biological system. Nanotechnology that is applied to create 
biomimetic features can serve as a “lubricant” to enhance the reactions between both 
systems. In this, it is vital to understand that nanomaterials have physicochemical and 
biological properties that can be totally different from their “macroscopic” counterparts. 
Various nanomaterials are currently described in literature, but not all materials possess 
the appropriate criteria to be incorporated into, or placed onto, a bone implant or tissue 
engineered construct. Ongoing research on nanomaterials for bone implants is mainly 
focused on three materials: nanohydroxyapatite (nHA), nanofibers, and carbon nanotubes 
(CNTs). Some of these materials are already proven materials on a microscale level, while 
others are fairly new in the bone tissue engineering field.
2. Nanohydroxyapatite
Natural bone tissue consists of a high percentage of nanosized needle-like calcium 
phosphate crystals of approximately 5-20 nm in width and 60 nm in length, combined 
with a poorly crystallized non-stoïchiometric apatite phase, containing CO2-3, NA
+, F-, and 
other ions, embedded in a collagen matrix.4 Resembling the naturally occurring calcium 
phosphate crystals, nHA might be a perfect material to use in bone implant materials 
(Figure 1). Microscale HA, previously used for this purpose, has already shown to be 
osteoconductive.5, 6 However, the use of nHA has several advantages over the conventional 
ceramic microsized HA formulations; it enhances proliferation and differentiation of bone 
forming cells, as well as synthesis of the mineralized matrix. These beneficial features of 
nHA are a direct effect of the nanometer grain size, and surface wettability. On top of this 
considerable impact on osteoblast function, the nanometric dispersion has also shown to 
induce absorption of specific proteins important for osteoblast adhesion.7-10
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2.1 Preparation of nanohydroxyapatite 
To prepare HA nanocrystals several techniques are known, all based on precipitation 
reactions. In the following sections all techniques to produce nHA powders as well as nHA 
coatings are described. 
One of the methods to create nHA powders is wet chemical deposition. For this method, 
the characteristics of the nHA created depend on the reaction formula, temperature, time, 
and addition rate of the reactant. The most commonly used reaction formula is the one 
defined by Bouyer et al.15
10Ca(OH)2 + 6H3PO4 → Ca10(PO4)6(OH)2 + 18H2O
The purity can be controlled by the reactant addition rate while the crystallinity is determined 
by the reaction temperature, where low temperatures (T≤60°C) result in monocrystallinity, 
and high temperatures (T>60°C) result in polycrystallinity. The Ca2+ ion concentration was 
found to play a dominant role on the final morphology of the synthesized nHA, as described 
by Kumar et al..16 Another wet chemical deposition formula is based on the reaction 
between calcium nitrate (Ca(NO3)2.4H2O and ammonium hydroxide (NH4HPO4).
5 Here, 
the nHA grain size can be controlled by changing the reaction time and temperature.8, 9 
Figure 1: (A) A transmission electron micrograph of nHA, and (B) a scanning electron micrograph of 
a nHA-coating.
nHA can be used in two configurations, as a coating material or mixed in a composite 
material, and both approaches, improve the osteoconductivity of implant materials. When 
used as a coating material, nHA can be applied onto implant materials by electrostatic 
spray deposition (ESD) of a nHA precursor solution, direct precipitation using a biomimetic 
depositing technique, or an electrocrystallization technique from dilute electrolytes.6, 11-14
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Further, Janackovic et al. reported on a wet chemical precipitation reaction according to 
the following formula:
Ca(EDTA)2- + 3/5HPO4
2- + 2/5H2O → 1/10Ca10(PO4)6(OH)2 +HEDTA3- + 1/5OH-
Urea is added instead of NaOH, which leads to a more homogenous monetite precipitation, 
followed by transformation to HA due to pH changes. Crystal growth can be modified by 
changing the reaction temperature between 125 ºand 160 ºC, changing the reaction time, 
or changing the precursor concentration.17 A final method to produce nHA by wet chemical 
deposition is by mixing H3PO4 with Ca(OH)2 and C3H6O3 at pH 10 under continuous stirring 
at room temperature until a Ca/P ratio of 1.67 is reached. This is followed by the addition 
of NH4OH to start the crystallization reaction. After 24 hours the final product is sintered at 
1100°C for 1 hour to obtain nHA.18
Besides wet chemical precipitation, a second method to create nHA is by the sol-gel 
process. This technique is based on a precipitation reaction as well, but the densification 
of the HA is achieved at lower temperatures. These temperatures are dependent on 
the calcium and phosphorous precursor solutions that are used. Pure HA phases can 
be formed by mixing calcium diethoxide (Ca(OEt)2) and triethyl phosphate (PO(OEt)3) 
solutions at temperatures above 600°C, with ageing times longer than 24 hours.19, 20 Also, 
solutions of calcium acetate and triethyl phosphate can be blended at 775°C, creating a 
mixture of HA and CaO. Subsequent purification of the HA is performed by leaching the 
mixture with hydrochloric acid.21 A final and more recent sol-gel technique to produce HA 
is a two-step procedure. In this procedure triethyl phosphate is hydrolyzed with water 
for 24 hours, followed by the addition of an aqueous nitrate solution. The resulting gel is 
transformed into a low-crystallized nanoscale apatitic structure at temperatures between 
300 ° and 400 °C.22
2.2 Nanohydroxyapatite composite materials
To obtain optimal composite materials for bone tissue engineering purposes, several 
natural and synthetic derived materials have been mixed with nHA. For instance, a porous 
scaffold of gelatine-starch enriched with nHA was fabricated through a microwave vacuum 
drying process, followed by cross-linking with trisodium citrate. Addition of nHA increased 
the biocompatibility and mechanical properties of the material.23 Another composite material 
of chitosan mixed with nHA was prepared by a chemical method in which nHA formed in 
situ. This preparation method ensured the nHA to be tightly bound to the scaffold, and the 
scaffold was shown to be biocompatible.24 Also, collagen matrices with embedded nHA 
were fabricated and proved to be biocompatible and osteoconductive, but the weakness of
19
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these scaffolds was the mechanical strength.25 Furthermore, silk fibroins were mixed with 
nHA into a composite material by a co-precipitation and freeze-drying method. The nHA 
provided the material an excellent compressive modulus and strength, especially after 
adding high amounts of nHA (up to 70% w/w).26
Besides natural materials, nHA has also been combined with synthetic materials. Porous 
composite materials of the synthetic polymers poly(L-lactic-acid) (PLLA) and poly(lactic-co-
glycolic-acid) (PLGA) were mixed with nHA by in situ polymerisation and thermally induced 
phase separation methods. Both scaffolds had a high ability to absorb water and excellent 
mechanical properties.27, 28 Another composite material, fabricated of polyamide (PA) and 
nHA, resulted in a porous scaffold material with good biocompatibility and a compressive 
strength equal to the upper limit of cancellous bone.29 Finally, mixing poly(caprolactone) 
(PCL) with nHA by a layer manufacturing process produced biocompatible scaffolds as 
well, with a high porosity and well interconnected microsized pores.30
In addition to these solid pre-shaped materials, a bone filler based on nHA has also been 
developed, i.e. Ostim® (aap Biomaterials GmbH & Co; Dieburg). This synthetic paste 
consists of nHA and 40% water, and is biocompatible and fully degradable after hardening. 
The possibility to inject and shape the paste inside bony defects and to mix it with other 
materials like morselised bone grafts (MCB) and tricalcium phosphate-HA (TCP-HA) to 
provide better handling of the granules are the major advantages of this material.31
Figure 2: Experimental set-up of the electrostatic spray deposition technique.
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2.3 Nanohydroxyapatite coatings
A common method to prepare nHA coatings on biomaterials is by spontaneous nucleation 
and growth of nanosized “bone-like” HA in metastable synthetic body fluid (SBF). SBF 
contains an inorganic salt composition similar to that of human blood plasma, which 
facilitates the growth of nHA at physiological pH and temperature in time.32-35 This biomimetic 
coating technique can be used to evenly coat porous or smooth implants or scaffolds, 
and the major advantages of this technique are the possibility to incorporate biologically 
active agents in the coating by co-precipitation and to control the release of the factors. 
Potential incorporated biologic agents are antibiotics to prevent local infections after 
surgical procedures or osteoinductive (growth) factors.36-38 SBF with a modified composition 
containing calcium nitrate tetrahydrate and diammonium hydrogen phosphate salts can also 
be used in a chemical precipitation technique to produce nHA powders. Precipitation takes 
place at 37°C and pH 7.4, and the precipitate is transformed into HA with sub-micron sizes 
after sintering at 1200 °C for 6 hours.35 
Electrocrystallization from dilute electrolytes (Ca+ and PO4
3-) is another method to create 
ultrafine-grained nHA coatings. The electrolytes are prepared by dissolving Ca(NO3)2 and 
NH4H2PO4 in de-ionized water, and the deposition takes 2 hours at a physiological pH 
and at a temperature of 85 ºC. Using this technique the nHA is deposited directly onto the 
cathode when using very low calcium and phosphate concentrations.39
As a final example, the ESD technique can be used to create nHA coatings. This technique 
requires a precursor solution containing nHA that is pumped through a metal nozzle. Under 
the influence of a high voltage between the nozzle and the substrate, a spray of highly 
charged droplets is formed, which is attracted to the grounded substrate (Figure 2).40-45 By 
this technique, monodisperse and even porous coatings can be created. As an example, 
Huang et al. described the electrospraying of a nHA precursor solution which resulted in a 
biocompatible coating composed of nHA particles with a hexagonal shape and a particle 
size below 80 nm.46 The compositional and morphological properties of the coating can 
be tailored by choosing the appropriate deposition parameters. For instance, the flow rate 
and voltage applied over the nozzle control the droplet size, which can vary between 
hundreds of micrometers and several tens of nanometers, and the applied voltage also 
controls the motion of the droplets.40, 41, 46 Next to the ability to control the properties of the 
coating, this technique also allows the incorporation of biologic agents. 
3. Nanofibers 
A second category of nanomaterials, extensively studied by bone tissue engineers, are 
nanometric fibres of natural and synthetic polymers. Synthetic polymers can be divided 
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into two groups, i.e. degradable and non-degradable polymers. For tissue engineering 
purposes degradable polymers are favoured as they can be resorbed over a period of 
time, thereby avoiding long-term complications of a foreign substrate in the body.47 Both 
natural and degradable synthetic polymers have already found applications in the field 
of tissue engineering, and the choice of polymer type depends on the characteristics 
the construct should possess. Natural polymers mostly resemble the ECM compounds, 
but occasionally they are immunogenic or exhibit unsuitable mechanical properties.48 
Synthetic degradable polymers, on the other hand, possess a higher mechanical strength 
and are mostly non-immunogenic. Polymers can easily be shaped into porous scaffolds by 
several techniques like self-assembly, phase separation, solvent casting and particulate 
leaching, freeze-drying, melt molding, template synthesis, gas foaming, and solid free 
forming. Most of these techniques, however, are incapable of synthesizing scaffolds with 
nanosized features. Therefore, researchers are recently focusing on fabrication of such 
materials into nanosized fibrous scaffolds. These nanofibrous constructs provide, besides 
their morphological similarity to natural matrices, a high porosity with controlled pore size 
and pore geometry, and a controlled fiber dimension and spatial orientation. The high 
surface to volume ratio offers a good environment for cell contact.3, 48
The conventional technique to produce fibers is by mechanical spinning. However, this 
technique produces fibers with a low specific surface area and relatively large diameters 
(above two microns in diameter), which are much larger than the diameters of ECM 
components encountered in nature. Also melt-blowing techniques can be used to produce 
fibers, but they too have large diameters (slightly below one micrometer) that are, aside 
from their large diameter, discontinuous or highly non-uniform as well. Actual nanofibers 
can be produced by electrospinning, self-assembly, or phase separation techniques, with 
the electrospinning technique being favoured, for it is the only technique that consistently 
produces continuous polymeric nanofibers.3, 49
Figure 3: Experimental set-up of the electrospinning technique, with three different types of collectors 
(plate, disc and cylinder collector).
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Figure 4: Scanning electron micrographs of (A) random, and (B) aligned deposited PLLA electrospun 
nanofibers.
Table 1: Natural and synthetic biodegradable polymers used in electrospinning scaffold tissue 
engineering
Naturally derived Synthetic
Collagen Starch Poly(lactic acid)
Gelatin Silk fibroin Poly(glycolic acid)
Chitosan Fibrinogen Poly(lactic-co-glycolic acid)
Chitin Hyaluronan Poly(ε-caprolactone)
Cellulose Poly(lactide-co-caprolactone)
Elastin Poly(vinyl alcohol)
3.1 Fabrication of nanofibrous scaffolds by electrospinning
Composite, hollow, and liquid containing nanofibers, electrospun from natural or synthetic 
polymers with diameters ranging from a few microns to tens of nanometers, can be tailor-
designed to create a tissue-matching mechanical compliance.50-52 By collecting fibres after 
continuous spinning layers with a porosity of more than 90% and a pore diameter up to 110 
µm can be created.  The disadvantages of this technique are that it is time consuming and 
that it is still not possible to create very thick three dimensional scaffolds.53
Electrospinning is based on the ejection of a fine charged jet of polymer solution by gravity 
or mechanical pumping from a nozzle of a capillary tube. The jet moves subsequently 
into an external electric field and elongates according to the applied forces. Finally, the 
jet segments are deposited onto a collector in the form of random or (partially) aligned 
nanofibers, depending on the collector type.54 Three types of collectors are known: the 
plate type, on which fibers are deposited randomly; the cylinder type, on which fibers are 
deposited partially aligned; and disc type, on which fibers are deposited in a highly aligned 
manner (Figures 3 and 4). This last collector type, however, still poses problems in trying 
to produce high quality nanofibrous constructs.53
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Figure 5: Scanning electron micrographs of randomly aligned electrospun (A) PLGA , (B) PCL 
blended with gelatin, and (C) PCL.
To date more than 200 synthetic or natural polymers have been successfully electrospun 
into nanofibers, and over 30 have been used for a variety of tissue engineered applications 
(Figure 5).54, 55 Some of the frequently used synthetic polymers are listed in Table 1.
The diameter and morphology of electrospun polymers can be accurately controlled 
by varying the concentration and the molecular weight of the polymer. Other properties 
influencing the jet flow, and thereby the morphology, of the fibers are: nozzle size, 
surface tension, quality of the solvent, diffusion coefficient, flow rate, and temperature. 
Some of these properties may be altered by the addition of salt or surfactant.48 In Table 
2, an overview is given of the physical properties of some frequently used polymers for 
electrospinning.
Table 2: Physical properties of some polymers used for electrospinning of tissue engineering 
constructs. 
Material
Fiber diameter 
(nm)
Stress 
(MPa)
Tensile 
modulus (MPa)
Collagen type I56 250 - -
Collagen type I 1:50 polyethyleneoxide57 100-150 0.37 12
Gelatin58 200 5.77 499
Poly(lactide-co-glycolic acid) (85:15)59 500-800 22.7 323
Poly(lactide-co-glycolic acid) (75:25)60 550 4.67 111
Poly(ε-caprolactone)61 200-600 - -
Poly(lactide-co-ε-caprolactone)62 470 6.30 44
3.2 Modification of nanofibrous scaffolds 
Considering the everlasting demand for further innovation of scaffold materials, there is a 
possibility to improve nanofibrous scaffolds to a greater extent by several modifications. 
For instance, mechanical strength and stability of the scaffolds can be improved by cross-
linking the polymers, and biocompatibility of the construct might be improved by introducing 
proteins and ligands into the scaffold. As an example, addition of poly(ε-CBZ-L-lysine) to 
PLLA scaffolds resulted in increased binding of collagen type II, which is a component of
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the ECM, by exposure of free NH2 adherence groups.
63 Incorporation of collagen itself and 
glycosaminoglycans (GAGs), has been shown to improve cell growth on the scaffold.64 
GAGs are, like collagen, ubiquitous components of the extracellular matrix that exert various 
biological effects. Besides collagen, there is little focus in the literature on incorporation 
of other proteins, since denaturation of macromolecules occurs rapidly. Nevertheless, two 
other proteins, bovine serum albumine (BSA) and human β-nerve growth factor, have 
been successfully blended into poly(vinyl-alcohol) (PVA) and PCL scaffolds respectively.65, 
66 Another possibility to modify the fibrous matrices is by the incorporation of bioactive 
agents, like drugs and plasmid DNA. Successful incorporation of the low molecular weight 
drugs Ibuprofen, Cefazolin, Rifampin, Paclitaxel, Itraconazol, Mefoxin and tetracycline 
hydrochloride has already been reported. Usually, these drugs are released in a “burst 
release mode”, meaning an instant release of the total amount of incorporated drugs. 
Therefore, current research is focusing on controlling this release.67-73
Finally, blending different types of polymers or blending polymers with substances like nHA 
amorphous tricalcium phosphate (ATCP), bioactive glass, calcium carbonate (CaCO3), or 
polysaccharides might be useful in producing scaffolds with superior properties compared 
to the pure materials, i.e. by increased mechanical properties or biocompatibility.47, 74-77
4. Carbon nanotubes
With regard to nanomaterials in (bone) tissue engineering, a third material that is attracting 
a lot of attention is carbon nanotubes (CNTs). The unique physical-chemical properties 
of CNTs might enhance the mechanical, electrical and thermal characteristics of tissue 
engineering constructs extremely.78, 79 Subsequently, CNTs might also be used as a carrier 
system for drug delivery, or as a cell tracking system to expand our knowledge on cell 
behaviour.80-82 Already many reports on the effects of CNT incorporation into composite 
materials, regarding the mechanical properties and biological behaviour, can be found in 
literature.83, 84
Figure 6: (A) Single-walled, and (B) multi-walled CNTs.
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There are two groups of carbon nanotubes: single-walled carbon nanotubes (SWCNTs) 
and multi-walled carbon nanotubes (MWCNTs) (Figure 6 and 7).85 Sometimes, fullerenes 
are also listed among the CNTs, but their closed ball-shaped structure excludes them from 
further discussion in this chapter. SWCNTs are composed of only one sheet of graphene, 
while MWCNTs contain a multiple coaxial structure. Different existing chiralities, i.e. the 
armchair, the zigzag, and the chiral chirality (Figure 8) of the graphene sheet in SWCNTs 
determine the electrical properties as a function of helicity and tube diameter.86 Aside from 
these basic structural features, defects present in the tube-walls were found to determine 
the Young’s modulus of the CNTs, and they also provide the possibility for covalent or non-
covalent functionalization of the tubes.87
Figure 7: (A) A scanning electron micrograph, and (B) a transmission electron micrograph of CNTs.
Until now, the most common functionalization for CNTs is to decrease their hydrophobicity, 
since otherwise they tend to aggregate into bundles. Aggregated CNTs are difficult to 
handle and also result in loss of function.88 The group of Shi et al. demonstrated this 
by reporting on much better dispersion of fluoride functionalized SWCNTs throughout 
poly(propylene fumarate) (PPF) scaffold materials resulting in increased reinforcement 
of the materials.82 However, there are also other reasons for functionalizing CNTs. For 
instance, functionalization with gadolinium has been shown to result in an excellent 
contrast agent for magnetic resonance imaging (MRI).89-91 In the near future, it may also be 
interesting to functionalize the CNTs with biological agents, in order to gain biocompatibility 
or osteoconductivity of scaffold materials to prevent immune responses at the site of 
implantation, or to use the nanotubes as drug delivery systems.
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Figure 8: Models of SWCNTs 
at molecular level with 
different chiralities. (A) The 
armchair chirality, (B) the chiral 
conformation, and (C) the 
zigzag arrangement.
4.1 Preparation of carbon nanotubes
Fullerenes were discovered in 1985 by Richard E. Smalley at Rice University in Houston 
TX. With this discovery, he was granted the 1996 Nobel prize in chemistry. After fullerenes, 
nanocages (also termed graphitic onions) were presented in 1980, followed by MWNTs in 
1991, and lastly, SWCNTs were discovered.86, 92 
At present, there are several methods to produce MWCNTs and SWCNTs. The first 
described was the arc-discharge method. This method is based on the self assembly 
(growing) of CNTs in an inert gas atmosphere between carbon, or catalyst-containing 
carbon, electrodes.93-95 Highly crystalline MWCNTs with diameters ranging from 2 nm to 
30 nm, and a length up to 30 µm can be grown on the cathode, at a pressure of 500 torr.86 
SWCNTs can be synthesized by arcing graphite electrodes containing a metal catalyst in 
a methane-argon or helium atmosphere.96 As metal catalysts, Fe, Co-Ni, Gd, Co-Ru, Co, 
Ni-Y, Rh-Pt, and Co-Ni-Fe-Ce are optional choices.86
Later, other CNT manufacturing procedures were discovered like laser vaporization, 
chemical vapor deposition (CVD), and pyrolytic methods. Production of MWCNTs by the 
laser vaporization method is achieved by firing a high power laser toward a graphite target 
inside a furnace at 1200 ºC.97, 98 Addition of Ni or Co to the graphite target or using a 
CO2 laser focused on a graphite-metal target results in the production of SWCNTs.
86, 99 
Ultrafast laser pulses were found to be most effective to increase the produced quantities 
of SWCNTs.100
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The CVD method is used to produce well aligned MWCNTs and SWCNTs with good 
uniformity in size. Besides these advantages over the arc-discharge and laser vaporization 
methods, this production process can also be scaled-up.101 CVD is based on exposure of 
metal particles to a medium containing hydrocarbon gases, in which the formation of CNTs 
is catalyzed. In the near future, there will hopefully be precise control over the nanotube 
orientation, position, density, and joining.102
Finally, the pyrolytic method is based on heating hydrocarbons, or any organic precursor 
containing carbon, in the presence of a transition metal catalyst such as nickel, cobalt 
or iron. This method is used to produce MWCNTs, as well as SWCNTs, and the 
production process depends strongly on the type and dimension of the metal particles, the 
temperature, the amount of hydrocarbons, and the type of gases involved in the process.86 
A well-characterised pyrolytic production process is the HiPco® process. Here, SWCNTs 
are produced by thermolysis of Fe(CO)5 in the presence of CO at elevated pressures (less 
than 10 atm) and temperatures (800 º-1200 ºC). This extremely efficient method is very 
applicable to produce bulk amounts.103
5. Nanomaterial-cell interaction: health issues
To conceive a better understanding of the interactions between cells and nanomaterials 
created for bone tissue engineering, it is important to know that there are three levels of 
structures in bone. The nanostructure, which consists of non-collagenous organic proteins, 
fibrillar collagen, and embedded minerals with an average grain size of 20-50 nm in length 
and 2-5 nm in diameter. This is followed by the microstructure, consisting of lamellae, 
osteons and the Haversian systems, and finally the macrostructure, which consists of the 
cortical, and cancellous bone.104
After contact of a tissue engineered construct with body fluids, proteins are immediately 
adsorbed onto the surface. These proteins determine the cell type that interacts with 
the construct, since the proteins interact with specific cell membrane receptors. This 
interaction is dependent on the type, concentration, and conformation of the proteins. 
The surface chemistry, hydrophilicity, hydrophobicity, charge, topography, roughness, and 
energy determine the type of protein that absorbs to the implant. Smooth surfaces have 
been shown to favor fibrous tissue integration, which ultimately encapsulates implants. 
Therefore, a bone-like surface topography is often regarded being of great importance 
when designing implant materials.7, 105-109
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5.1 Nanohydroxyapatite-cell interaction
Considering the nanostructured bone surface, it is best to mimic this situation, thereby 
invoking the correct proteins to adsorb and avoiding fibrous tissue encapsulation. Cellular 
responses to HA particles have been demonstrated to depend on physical and chemical 
properties such as particle size, morphology, crystallinity, and chemical composition. A 
nanostructured topography increases the surface space enormously, thereby increasing 
protein and cell attachment. Better adherence of osteoblasts was reported with the use of 
several types of nanomaterials (i.e. nHA and CNTs) either deposited onto the surface or 
mixed into composite materials.53 Regarding particle size, the ability of nanophase ceramics 
to promote bone cell function was found to be limited below 100 nm.8 The nanometer 
HA grain size topography, in combination with the high surface wettability, promotes 
increased selective vitronectin adsorption, and also affects the protein conformation, 
thereby enhancing osteoblast functions.4, 8 This conformational change implies unfolding 
of the proteins to a greater extent, presenting more epitopes for osteoblasts to adhere to. 
Other proteins that are known to particularly increase osteoblast functions are fibronectin, 
vitronectin, laminin and collagen.7, 8, 104
5.1.1 In vitro studies on nanohydroxyapatite 
Many coated and composite bone tissue engineering materials have been investigated 
with regard to their in vitro and in vivo biocompatibility. Here, some in vitro study results 
of different nHA composite- or coated materials are summarized, starting with a porous 
chitosan/nHA composite scaffold, seeded with MC 3T3-E1 cells. Compared to a porous 
chitosan scaffold, the composite scaffold showed a better cytocompatibility, in terms of 
cellular proliferation and morphology.24 Addition of nHA to porous silk fibroin scaffolds, 
seeded with MG63 cells resulted in an elevated cytocompatibility as well, as determined 
by a MTT assay.26 The addition of nHA to collagen scaffolds increased proliferation and 
redifferentiation of cells, originating from rat bone fragments, towards osteogenic lineages. 
Migration of the cells throughout the network of the porous scaffold was also increased.110
Synthetic materials can also be improved by the incorporation of nHA, as demonstrated by 
PLGA/nHA and PCL/nHA scaffolds seeded with mesenchymal stem cells, which obtained 
better cytocompatibility compared to their counterparts without nHA. They showed a higher 
alkaline phosphatase (ALP) activity and an increased rate of matrix mineralization.27, 30 
Seeding polyamide/nHA (PA/nHA) scaffolds with mesenchymal stem cells did not result in 
an increase, nor a decrease, in cell proliferation and differentiation.29
Besides nHA composite materials, also nHA-coated scaffolds have been studied. nHA, 
coated onto collagen beads did not alter the proliferation of MG63 cells but increased ALP 
activity and expression of osteocalcin (a component of the extracellular matrix) compared 
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to non-coated collagen beads. So, nHA seemed to switch the MG63 cells from the 
proliferation stage to the differentiation stage.6 Other studies, comparing nHA coatings 
with conventional micro sized HA coatings, showed an increased osteoblast adhesion. The 
underlying mechanism was supposed to be an increase in specific protein absorption, thus 
increasing osteoblast adhesion.8, 9 However, a study contradicting these positive findings 
on nHA was reported by Zhu et al., who observed that cell attachment and spreading 
was decreased when smooth titanium implants were coated with nHA compared to non-
coated implants.111 In addition to the Zhu study, Ostim® was also shown to have a negative 
effect on cells in vitro, as primary osteoblasts were not able to grow on the material. This 
however was hypothesized to be primarily due to the high amount of free water in the 
product and not to the presence of nHA.112
Although there is no complete uniformity between all studies, the data show that in an in 
vitro situation the addition of nHA into, or onto bone tissue engineering constructs mostly 
provides the construct an increased cytocompatibility, as confirmed by increased adhesion 
and differentiation of the cells.
5.1.2 In vivo studies on nanohydroxyapatite
In an in vivo situation nHA was reported to improve the performance of bone tissue 
engineering constructs as well. PA/nHA constructs, produced by Wang et al., showed 
adequate bone ingrowth in rabbit mandibles, with a bone density almost equal to the 
host bone. Enriching the construct with rabbit mesenchymal cells before implantation 
resulted in even more and earlier bone formation.29 The commercial product Ostim® also 
proved to be biocompatible in most in vivo studies, in contrast to disappointing results 
from in vitro studies. After injecting Ostim® in the dorsal skin chambers of hamsters, 
biocompatibility was shown by the absence of leukocyte activation, a more pronounced 
angiogenic response and an increased microvessel density, when compared to a synthetic 
hydroxyapatite bone substitute.113 Injecting Ostim® in a critical size defect in the calvaria of 
minipigs resulted in bone formation in the defects, which also indicates the biocompatibility 
of the material.114 On the other hand, a study with Ostim® injected in fresh extraction 
sockets in dogs revealed a remaining gap up to 0.2 mm in the graft surrounding tissue, 
which indicated that the use of this material does not always lead to positive results.112, 115 
Also, in a study of Meirelles et al., in which titanium nHA coated implants were compared 
to non-coated implants, no obvious positive effect of nHA was observed. The implants 
were implanted in a gap healing model in rabbit tibia, and for both implants there was no 
difference in gap closure.116 This proves that not all results from in vitro studies can be 
extrapolated to an in vivo situation. 
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5.2 Nanofiber-cell interaction
Electrospun materials facilitate, or even enhance cell growth and differentiation, thereby 
qualifying these fibers as an excellent material for tissue engineering purposes. The 
interaction between cells and scaffold material is dependent on material properties like 
the degradation rate and the flexibility. Slow degrading polymers provide scaffolds a 
longer lasting stability. Flexibility of the materials allows cells to migrate through the matrix 
by pushing the fibers aside, which is important since the pores created in nanofibrous 
materials are often smaller than the size of a single cell.13, 47, 77 
5.2.1 In vitro studies on nanofibrous constructs 
Many nanofibrous materials from nature-derived, as well as synthetic polymers, have been 
elaborately tested for their suitability as tissue engineering scaffolds. For example, collagen 
type I, electrospun into a fibrous scaffold, showed excellent proliferation and infiltration of 
smooth muscle cells in several studies, even though the pore diameter was smaller than the 
cell diameter.53, 56 These studies were followed by seeding chondrocytes onto a collagen type 
II scaffold, on which the cells proliferated and were evenly distributed, after one week.47, 117 
The disadvantage of using collagen, however, is the possibility of immunogenic reactions.48
A second material of choice is chitosan because of its known biocompatibility, degradability, 
and even an antimicrobial and antifungal activity. The physical characteristics provide 
this material with favourable plasticity and adhesiveness for many applications.48 When 
blended with nHA and seeded with human fetal osteoblasts (hFOB), this scaffold 
significantly stimulated proliferation and mineral deposition after 15 days.118
In addition, fibrous gelatin scaffolds are biocompatible and bio-resorbable, and when 
blended with nHA and PCL, good attachment and proliferation of bone marrow stromal 
cells (BMSCs) was shown.47, 48, 119
Finally, the natural material silk has also been shown to be cytocompatible. Seeding 
electrospun silk/polyethyleneoxide (PEO) scaffolds with human MSCs resulted in proliferation 
of the cells, and addition of nHA and bone morphogenetic protein 2 (BMP-2) to the scaffold 
resulted in high calcification values. It was therefore concluded that the addition of nHA 
and BMP-2 significantly improves the osteoconductivity/inductivity of this specific type of 
scaffold.47, 77
PLLA is one of the synthetic polymers often used for bone tissue engineering purposes 
because it is biocompatible, biodegradable, and has a high tensile strength. When seeded 
with 3T3-E1 osteoblastic cells, nanofibrous PLLA films showed an increase in differentiation 
of the cells, as evidenced by higher ALP activity, an increase in bone sialoprotein (BSP) 
gene expression, and a decrease in proliferation of the cells, compared to flat PLLA films.120 
To overcome the low pore size and lack of interconnectivity that is present in conventional
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electrospun PLLA scaffolds, Leong et al. created PLLA nanofibrous scaffolds with large 
interconnected pores by using a low temperature electrospinning technique first described 
by Simonet et al. with ice crystals serving as removable templates.121, 122 Subsequently, 
the scaffolds were seeded with 3T3/NIH fibroblasts, and as a result good infiltration of 
the cells up to 50 μm thickness was observed.121 PLLA fibers can also be blended with 
other substances. For instance, in a study by Kim et al. PLLA fibers were mixed with fibers 
spun from bioactive glass. The scaffold created exhibited an even distribution of both 
fibers. When seeded with 3T3-E1 osteoblasts the cells showed favourable attachment 
and proliferation, as well as an improved differentiation and mineralization behaviour, as 
compared to cells seeded onto pure PLLA scaffolds.123  Also PLGA is a biocompatible 
material and has a tuneable biodegradability, depending on the ratio of lactic to glycolic 
acid.53, 59 Seeding fibrous PLGA scaffolds with MSCs was found to result in good 
proliferation in the first week of culturing. However, after this week, no further effect of 
the scaffolds on the cells was noted.48, 53 Like PLLA, PLGA can also be blended with other 
substances, for instance with αTCP nanoparticles as described by Schneider et al. After 
immersing the scaffolds in SBF, and subsequent seeding of the scaffolds with human 
MSCs, an increase in proliferation and differentiation of the cells was seen, as compared 
to pure PLGA electrospun scaffolds.124
Another frequently used synthetic polymer for electrospinning is PCL. MSCs seeded 
onto electrospun PCL microporous scaffolds were reported to migrate through the entire 
scaffold, to differentiate into osteoblastic cells, and to form a calcified matrix.53, 61 Blending 
PCL with a high CaCO3 content during the electrospinning procedure and subsequent 
seeding of the material with osteoblasts resulted in low proliferation of the cells and high 
mineralized matrix formation.125 Another material blended into PCL nanofibrous constructs 
was nHA. Seeding of these scaffolds with human osteoblasts however was not successful 
yet and resulted in comparable proliferation to plain PCL scaffolds.126
5.2.2 In vivo studies on nanofibrous constructs
In addition to in vitro studies, several in vivo experiments with nanofibrous constructs 
have been performed. Implanting electrospun scaffolds of silk fibroin material in critical 
sized calvarial defects in New Zealand White rabbits showed complete healing of the 
defects without observing any inflammatory reaction, thereby proving the material to be 
osteoconductive as well as biocompatible.127
Synthetic electrospun PLLA scaffolds with large interconnected pores were produced by 
low temperature spinning with ice crystals serving as removable templates and were also 
tested in vivo. As a control, conventional spun PLLA scaffolds with small non-connected 
pores were used. After 14, 28, and 56 days of subcutaneous implantation in rats, the 
scaffolds were histologically examined. Both materials showed good biocompatibility,
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but the scaffold with large interconnected pores showed higher cell infiltration and 
proliferation.77
Another synthetic scaffold, produced from PLGA, with or without incorporation of nHA and 
BMP-2, was implanted in the long tibia bone of nude mice. Both scaffolds were biocompatible, 
and the best bone healing was observed for the scaffolds with added nHA and BMP-2.128
PCL fibrous scaffolds were also tested in vivo. Before implantation into the omenta of 
rats the scaffolds were seeded with MSCs. Histological examination after four weeks 
showed collagen type I formation throughout the scaffold and mineralization of the 
scaffold. This indicated that the scaffold was biocompatible, and that the pre-seeded cells 
provided the scaffold osteoinductivity, since ectopic mineralization of the scaffold was 
observed.129  Finally, electrospun scaffolds of PCL, with or without the incorporation of the 
bone formation stimulating drug simvastatin, were implanted in 8 mm critical sized cranial 
defects in rats. Histological examination after 1, 3, or 6 months showed biocompatibility 
and osteoconductivity of all scaffolds, with a significant increase in bone formation for the 
drug-containing scaffold.130
The in vitro as well as the in vivo studies often show increased cyto- or biocompatibility 
of electrospun nanofibrous scaffolds in comparison to the bulk polymer. Therefore, these 
nanomaterials are regarded very promising in future bone tissue engineering applications.
5.3 Carbon nanotubes-cell interaction
Nanomaterials, produced from natural or synthetic polymers are often degradable materials 
that are broken down and systemically removed from the body.131, 132 Nanoceramic 
materials are remodeled and also generally regarded as non-hazardous, since they 
are naturally occurring materials in the body. Carbon nanotubes however, might pose 
a problem for future applications. Therefore, many recent research studies focus on the 
interaction between cells and CNTs in in vitro and in vivo situations. In light of this emphasis 
in literature, the current review will mainly describe CNTs with regard to risks involved (not 
necessarily only on bone cells or tissue, since incorporation of CNTs into bone implants 
and tissue engineered constructs may also introduce the possibility of exposure to other 
tissues). 
CNTs are non-degradable and body-foreign, but the vast applications of this material make 
it still very popular. Various toxicity issues proved to be related to the properties of this 
material, such as structure, length, surface area, degree of aggregation, extent of oxidation, 
surface topology and bound functional groups. It can be argued that these are the same 
physical and chemical properties, which make the use of CNTs so interesting. Besides the 
physico-chemical properties, also the concentration or dose to which cells and tissues are 
exposed to this material were found to be of great importance concerning safety risks.78, 83
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Safety aspects start with the production process of the material, which may already be 
hazardous, since CNT containing aggregates might become airborne during production 
and remain airborne for long periods, causing health risks to lungs and dermis. The HiPco® 
process, for instance, forms aerosols that easily break down into smaller particles, leading 
to higher airborne concentrations. In contrast, laser vaporization forms compact aerosols 
that are more difficult to break down into smaller particles.85, 133 Another hazard of CNTs is 
the accumulation along the food chain. Oberdorster et al. studied the possible accumulation 
of SWCNTs ingested by round worms (C.Elegans). In this model SWCNTs were shown to 
move through the digestive tract, and were not absorbed by the animals.134 Another study 
in compliance with these results, reported detection of unsolubilized SWCNTs, ingested by 
fish, in faecal material.135 However, even though these studies indicate that SWCNTs are 
not absorbed by these animals, there is still a possibility of CNTs moving up the food chain. 
5.3.1 In vitro studies on carbon nanotubes
Initial studies examining the toxicity of CNTs involved mainly unpurified and non-
functionalized CNTs. One of the first studies reported exposure of human epidermal 
keratinocytes to pristine SWCNTs to result in accelerated oxidative stress, as indicated 
by the formation of free radicals and accumulation of peroxidative products, depletion 
of total antioxidant reserves, an increase of lipid peroxidation products, and loss of cell 
viability.136 In another study, addition of unpurified MWCNTs to dermal keratinocytes 
resulted in reduced cell viability and an undesirable increase in interleukine-8 (IL-8) up to 
six times.137 When added to skin fibroblasts, cell cycle arrest was induced, and apoptosis 
and necrosis were increased.138 Also, non-functionalized aggregated SWCNTs and (raw) 
aggregated MWCNTs incubated with murine lung alveolar macrophages resulted in severe 
toxic effects, even comparable to asbestos, within a short term of 48 hours.139 According 
to studies by other research groups this toxicity, however, was indicated to be mainly 
resulting from the metal catalysts present in the used unpurified CNTs. Metal catalysts are 
known to lead to the formation of hazardous reactive oxygen species.137, 138, 140-142
In time, knowledge of purification, but also of functionalization of CNTs increased. Due 
to their extreme hydrophobic nature CNTs aggregate almost immediately, which makes 
them difficult to handle and increases their toxicity on cells.143, 144 Therefore, CNT 
functionalization, by surface treatments and coatings, is being investigated with great 
interest. In a biological model system it was shown that well-dispersed SWCNTs were less 
cytotoxic than micrometer sized aggregates.144 However, the effect of functionalization 
on cell behaviour is difficult to predict, since these treatments do not only alter their 
solubility, but also their cell-interaction. In most cases, as reported in several studies, 
functionalization increases the solubility of CNTs, and therefore decreases their toxicity, as
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mainly the hydrophobic character is associated with their toxicity.145 For instance, addition 
to neurons of functionalized MWCNTs with an increased hydrophilic character increased 
the number of branches grown per neuron, compared to pristine MWCNTs.146 The group 
of Nimmagadda et al. hypothesized that the toxicity of non-functionalized, hydrophobic 
CNTs is linked to their high potential to penetrate and aggregate within the hydrophobic 
cell membrane, leading to rupture and cell death.147 Zanello et al. stated that neutrally 
charged CNTs resulted in optimal osteoblast proliferation and bone matrix forming 
functions, compared to sidewall functionalization that introduced a positive or negative 
net charge.148 Besides the type of sidewall groups, the amount of sidewall groups also 
influences the cytotoxicity, for there is an inverse relationship between toxic potential and 
degree of sidewall functionalization.78, 85, 149 Another important parameter related to toxicity 
appeared to be the mass of the CNTs. Short MWCNTs showed higher cytototoxicity than 
long ones. Also short SWCNTs displayed a higher toxic behaviour than short MWCNTs.150, 
151 Finally, even though toxicity decreases with an increase in purification and sidewall 
functionalization, toxic behaviour of CNTs is still concentration, dose- and time dependent, 
as shown in a study by Cui et al. Here, cell proliferation of human embryo kidney cells was 
inhibited, and cell adhesive ability decreased, in a dose- and time-dependent manner after 
addition of suspended SWCNTs.85, 137, 140 
However, we should stress that literature is not consistent, and frequently contradictory 
results are described. Ingestion of MWCNTs and SWCNTs by macrophages for instance, 
leads to necrosis and degeneration, as described in a study by the group of Jia et al., 
while it does not lead to any signs of toxicity in a study by the group of Cherukuri et 
al.150, 152 Also the addition of three types of SWCNTs, namely purified SWCNTs, SWCNTs 
functionalized with 4-tert-butylphenylene, and ultra-short SWCNTs, to a fibroblast culture 
did not result in any cytotoxicity in a study by the group of Shi et al.153 Another noticeable 
report is the favourable positive cellular interaction, as well as the sustained cell viability, 
of macrophages and leukemia cells, after the addition of functionalized SWCNTs in 
suspension.152, 154 Finally, Bottini et al. found an increase in toxicity to be correlated to 
a decrease in hydrohobicity of CNTs, thus contradicting the earlier reported opposite 
correlation.155
5.3.2 In vivo studies on carbon nanotubes
The large surface area of nanoparticles allows easy entrance to the body, and makes them 
more biologically active than their larger counterparts.135 Potential routes for CNTs to enter 
the body are by inhalation, through the skin, ingestion or by injection/infusion. Although 
we mainly focused on nanomaterials incorporated into bone constructs in our in vivo 
experiment sections, for a full overview of the pathological effects of CNTs, it is necessary 
to mention data on inhalation toxicity, which is the most studied administration route.
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In vivo studies with MWCNTs, as well as with SWCNTs, show pulmonary responses after 
inhalation to be of immediate concern. Intratracheal instillation of MWCNTs and SWCNTs 
in mice, guinea pigs, and rats lead to a dose-dependent formation of granulomas, fibrosis 
or necrosis, inflammation, and lethality. Additionally, instillation of MWCNTs also lead 
to a non-specific interstitial pneumonia-like reaction, and instillation of SWCNTs lead to 
a decreased bacterial clearance and a loss of pulmonary function.83, 85, 156-159 A study by 
Lam et al. proved these pathologic reactions to be independent of metal impurities.160 In 
contrast, an earlier study by the group of Huczko et al. reported no evidence of inflammatory 
reactions, or perturbation of lung function, after instillation of MWCNTs in guinea pigs. 
However, also this study is disputed due to the absence of lung pathology examination.157
Since intratracheal instillation is not a correct representation of the natural entrance 
of materials into the lungs, Li et al. compared instillation of SWCNTs in the lungs with 
systemic inhalation, and showed less severe effects from inhalation of the material. This 
is probably due to an altered aggregation size and distribution in the lungs.161 This theory 
is further supported by other studies, in which administration of agglomerated nanotubes 
led to the mechanical blockage of airways.156, 159 On the other hand, pharyngeal aspirated 
SWCNTs caused severe granulomatous inflammations and accumulation of oxidative 
stress markers.162 In addition to the administration route of CNTs, physico-chemical and 
environmental factors like the particle size, the free particle life, and the residence time in the 
lungs, were also found to determine the toxicity to a great extent.13, 135, 163 One of the studies 
investigating the effects of the particle size on toxicity was performed by Muller et al., who 
instilled grinded and non-grinded MWCNTs intratracheally in rats. The non-grinded MWCNTs 
remained longest in the airways and resulted in granulomas in the bronchi, while the grinded 
MWCNTs were better dispersed in the lung tissue and showed a higher degree of pulmonary 
inflammation with fibrotic granulomas in the alveolar space.151 Since there are many other 
administration routes besides instillation and inhalation, toxicity studies were performed for 
these routes as well. It is very likely that CNTs will be in contact with the bloodstream, after 
degradation or remodelling of a bone tissue engineered construct. When entered into the 
bloodstream, CNTs were found to induce thrombosis by platelet aggregation and to provoke 
vascular effects related to mitochondrial oxidative modification and accelerated artheroma 
formation.164 However, implantation of degradable poly(propylene fumarate; PPF) scaffolds 
with incorporated ultra-short SWCNTs in a rabbit model showed no toxic effects of the 
released ultra-short SWNTs, as compared to animals that received pure PPF scaffolds. In 
contrast, a drastic favourable increase in bone ingrowth was reported.165
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Figure 9: (A) Molecular representation of a functionalized SWCNT with the contrast agent gadolinium, 
and (B) magnetic resonance imaging slices of a subcutaneously implanted PLGA scaffold containing 
such gadolinium labeled SWCNTs on day 1, 7, 11, 18, and 25. The marking on the day 1 slide 
indicates the scaffold and the marking on the day 18 slide indicates the tissue surrounding the scaffold 
that has an increased intensity due to the released SWCNTs after degradation of the scaffold.
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While toxicity is being investigated elaborately, there is almost no knowledge on the 
distribution of CNTs in the body after release from scaffold materials. Part of the problem 
is that the small size of the particles makes it impossible to visualize them microscopically 
unless they are agglomerated. Oberdorster et al. reported that nanoparticles located in the 
lung translocate into the pulmonary interstitium, which indicates that the particles might also 
damage other tissues in the body.135 Also, translocation of nanosized TiO2, and iridium-192 
labelled particles from the lung into the bloodstream and to secondary organs was reported.166, 
167 To gain insight in the CNT distribution, iodine-125 labelled SWCNTs were injected into 
mice. They were shown to be distributed throughout the whole body, except the brain, and 
accumulated in bone.158 However, a contradictory result was reported by the group of Singh 
et al., who administered diethylentriaminepentaacetic (DTPA) functionalized SWCNTs, 
labelled with indium-111, into the bloodstream. A rapid clearance rate and no retention of the 
SWCNTs in any of the secondary organs, like liver or spleen, was observed. The SWCNTs 
were excreted as intact nanotubes through the renal excretion route.168 Another possible 
solution for visualization of CNT distribution can be the use of gadolinium labelled CNTs, as 
produced by Sitharaman et al., in an MRI experiment.89, 90 Blending these labelled CNTs in a 
degradable bone tissue engineered construct, followed by implantation in an animal model, 
gives the opportunity to follow the labelled CNTs over a period of time by MRI (Figure 9). 
It can be concluded that there is still a lot of controversy about the use of CNTs. More 
research into the biological interactions between the body and CNTs is an absolute necessity 
before application in bone substituting materials as such can be considered. However, with 
increased knowledge on minimizing or completely eliminating toxicity of this material, it might 
be possible to take advantage of the unique characteristics of CNTs for tissue engineering 
applications.
6. Summary
From this overview it can be concluded that nanomaterials can play an important role 
in future (bone) tissue engineering applications. Already many positive reports on nano-
ceramics, -fibers, and CNTs exist. The materials have the ability to improve biocompatibility, 
mechanical, and electrical properties of bone tissue engineering constructs. These 
constructs can even be further modified by incorporation of biological agents. On the other 
hand toxicological issues associated with the nanoscale size of these materials might 
have a negative effect, which is most evident for CNTs. Therefore, extensive research on 
each new application of nanomaterials is required.
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1. Introduction
For the regeneration of large bone defects resulting from trauma, pathology, or congenital 
malformations, synthetic bone substituting materials have been developed, some of 
which incorporate one or more of the biological features of an autologous bone graft. 
These features include osteoconductive and osteoinductive properties, in addition to 
viable osteoprogenitor cells.1 Bone tissue engineering techniques can be used to grow 
osteoprogenitor cells on synthetic or natural scaffolds,2, 3 while growth factors like the 
Insulin-like Growth Factors (IGFs) and members of the Transforming Growth Factor-β 
(TGF-β) superfamily, TGFβ-1, TGFβ-2, TGFβ-3, BMP-1, BMP-2, BMP-7 (aka OP-1) are 
able to grant scaffolds osteoinductive properties.1
One of the TGF-β superfamily members is TGFβ-1, which is expressed at high levels 
during bone development, growth and healing. Osteoblasts produce TGFβ-1, which is 
incorporated into mineralized bone matrix.1 In vitro, TGFβ-1 has been observed to both 
inhibit and stimulate osteoblastic cell proliferation depending on TGFβ-1 concentration, 
cell density, and the stage of differentiation.1, 4, 5 In vivo, TGFβ-1 appears to play a decisive 
role in the early phase of bone synthesis.6
Bone morphogenetic proteins (BMPs) form a unique group of proteins within the TGF-β 
superfamily. BMP-2 promotes differentiation of osteoprogenitor cells into osteoblasts and 
matrix formation, thus making it a suitable growth factor to use for bone tissue engineering.4, 
7-10 The expression of BMP-2 and TGFβ-1 is thought to be regulated by a positive feedback 
mechanism of these two growth factors.1
Although recombinant growth factors are potent, the high expense poses a problem for 
clinical treatment. To solve this problem also alternative sources of growth factors are 
examined, for instance, COLLOSS® E. This is a lyophilized complex of extracellular 
matrix proteins extracted from (equine) long bones. The preparatory methods are similar 
to those originally used by Urist and Strates to isolate BMPs.11 The main constituents of 
COLLOSS® E are collagen type I chains in combination with TGFβ-1, BMP-2, BMP-7, 
VEGF, IGF-1, TGFβ-2 and BMP-3 and several other, not yet determined, growth factors. 
COLLOSS® E is proven to be osteoinductive in an in vivo situation.12-16 However, the 
use of COLLOSS® E as a stimulus for mesenchymal stem cells for a tissue engineering 
approach is not yet described.
The aim of this study was to compare the effects of different growth factors at various 
concentrations, and in different combinations, on rat bone marrow (RBM) cells in vitro. TGFβ-
1, BMP-7 and BMP-2 are commercially available; however, in this study only TGFβ-1 and 
BMP-2 are used to reduce parameters. It is hypothesized that TGFβ-1 mainly stimulates 
the proliferation, and BMP-2 the differentiation of the cells, whereas together they obtain an
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additive or even synergistic effect on cell growth and differentiation. COLLOSS® E is 
expected to function likewise as TGFβ-1 combined with BMP-2. 
Therefore, in the current study set-up RBM cells were seeded onto 24-well dishes and 
cultured in medium for 24 days, with added growth factors for the first 8 days. The effect of 
the growth factors was evaluated by DNA content assay, ALP activity assay, and calcium 
assay and by scanning electron microscopy (SEM) on days 1, 4, 7, 16 and 24. In addition, 
on day 7, the effect of the growth factors on mRNA expression of osteocalcin, collagen 
type I, alkaline phosphatase and bone sialoprotein was evaluated with quantitative PCR. 
2. Materials and methods
2.1 Osteoblast-like cell isolation and culture
RBM cells were isolated and cultured as described by Maniatopoulos et al..2 Briefly, RBM cells 
were obtained from the femora of two 40- to 43-day-old male Wistar WU rats. The femora were 
washed three times in alpha Minimal Essential Medium (α-MEM; Gibco BRL, Life Technologies 
B.V. Breda, The Netherlands) supplemented with 0.5 mg/ml gentamycin (Gibco) and 3 μg/
ml fungizone (Gibco). Epiphyses were cut off and diaphyses flushed out with 15 ml culture 
medium (α-MEM supplemented with 10% fetal calf serum (Gibco), 50 μg/ml gentamycin, 50 
μg/ml ascorbic acid (Sigma, Chemical Co., St. Louis, MO)), 10 mM Na-β-glycerophosphate 
(Sigma) and 10-8M Dexamethasone (Sigma). 
To obtain osteoblast-like cells, the RBM suspension was divided over six culture flasks (75 
cm2), and incubated in a humidified atmosphere of 95% air, 5% CO2 at 37 °C. The following day, 
culture medium was refreshed to remove all nonadherent cells. After 7 days of primary culture, 
cells were detached using trypsin/EDTA (0.25% (w/v) trypsin/0.02% EDTA), resuspended, 
and seeded at 10,000 cells/cm2 onto 24 well plates (Greiner, Bio-One, Alphen aan den Rijn, 
The Netherlands). After 4 h, the culture medium was replaced with fresh culture medium with 
added growth factors (Table 1). The concentrations of TGFβ-1 and BMP-2 were determined 
from previous literature.8, 9, 17 COLLOSS® E is known to contain 38.62 ng/mg TGFβ-1 and 4.12 
ng/mg BMP-2, as well as a multiplicity of other growth factors.  All samples for each condition 
and each time point were present threefold, and the entire experiment was performed twice.
2.2 DNA content
After 1, 4, 7, 16 and 24 days of culture, total DNA content was determined to obtain 
information about cellular proliferation, since the DNA content directly correlates to the 
amount of the cells. Medium was removed and the cell layer washed twice with PBS. 
Subsequent addition of 1 ml MilliQ deionised water to each well and sonication for 10 min 
lysed the cells. Samples were stored at –20°C until further use.  
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For analysis, a PicoGreen dsDNA Quantitation Kit (Molecular Probes, Leiden, The 
Netherlands) was used. A standard curve was generated using serial dilutions of lambda 
DNA ranging from 0 to 2000 ng/ml. Briefly, 100 μl of sample and 100 μl PicoGreen working 
solution were added to a 96-well plate (Greiner).  The plate was incubated at room 
temperature in the dark for 5 min. The plate was then read at 480-520 nm and the DNA 
content was determined with the aid of the standard curve. Samples and standards were 
assayed in duplicate. 
Table 1. Concentrations and combinations of growth factors used in this experiment in ng/ml (TGFβ-
1 and BMP-2), and in μg/mL (COLLOSS® E)
Group TGFβ-1 (ng/ml) BMP-2 (ng/ml) COLLOSS® E (μg/ml)
1 5.0 (first 8 days) - -
2 - 100.0 (first 8 days) -
3 5.0 (first 4 days) 100.0 (day 4 to 8) -
4 5.0 (first 8 days) 100.0 (first 8 days) -
5 - - 2.5 (first 8 days)
6 - - 5.0 (first 8 days)
7 - - 10.0 (first 8 days)
8 (control) - - -
2.3 Alkaline phosphatase (ALP) activity
The ALP activity was measured after 1, 4, 7, 16 and 24 days, with the same samples as 
used in the DNA-content assay. For the assay, 80 μl of sample and 20 μl of buffer solution 
(5 mM MgCl2 0.5M 2-amino-2methyl-1-propanol, (Sigma)) were added to 96-well plates. 
Subsequently, 100 μl of substrate solution (5 mM paranitrophenylphosphate, (Sigma)) was 
added and the plate was incubated for 1 h at 37 °C. The reaction was stopped by the addition 
of 100 μl 0.3M NaOH, and finally, the plate was read at 405 nm. With the aid of a standard 
curve (4-nitrophenol (4-NP; Sigma)), serial dilutions ranging from 0 to 25 nM, the ALP activity 
was determined in nmol 4-NP produced per hour per nanogram DNA. Samples and standards 
were assayed in duplicate.
2.4 Calcium
To obtain information about mineralized matrix formation, the calcium (Ca) content was 
determined after 7, 16 and 24 days of culturing. The samples originated from the same 24-
well plates as used for the DNA content, and ALP activity assays. Ca content was determined 
using the ortho-cresolphtalein complexone (OCPC, (Sigma)) method. The 24-well plates were 
rinsed twice with PBS followed by the addition of 500 μl acetic acid (0.5N) and overnight 
incubation at room temperature. Samples were frozen at -20 °C until further use. 
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OCPC solution was prepared by the addition of 80 mg of OCPC to 75 ml of demineralized 
H2O with 0.5 ml KOH (1M) and 0.5 ml acetic acid (0.5N). To prepare the sample solution, 
5 ml of OCPC solution was added to 5 ml 14.8M ethanolamine-boric acid buffer (pH 11), 
2 ml of 8-hydroxyquinoline (5 g in 100 ml 95% ethanol), and 88 ml of demineralized water. 
Three-hundred microliters of this sample solution was added to 10 μl of sample. The plate 
was incubated at room temperature for 10 min and read at 575 nm using a microplate 
reader. A standard curve was made from serial dilutions of CaCl2, ranging from 1-200 μg/
ml. Samples and standards were assayed in duplicate. 
2.5 Realtime-PCR 
First, RNA was isolated from the cells after 7 days of culture (six wells were pooled) with 
the RNeasy isolation kit (Qiagen Benelux B.V., Venlo, The Netherlands). Subsequently, a 
reverse transcriptase (RT) reaction was performed by supplementing 1 μg of total RNA, 
1 μl (50-250 ng) of random primers and 1 μl dNTP mix (10 mM each) in a total volume 
of 15 μl RNase-free water. The mixture was heated to 65 °C for 5 min and quickly chilled 
on ice. The contents of the tube were collected by brief centrifugation and 4 μl 5x First 
Strand Buffer (250 mM Tris-Cl, pH 8.3, 375 mM KCl, 15 mM MgCl2) and 2 μl 0.1M DDT 
were added. This mixture was incubated for 10 min at 25 °C, followed by the addition of 1 
μl (200 units) of SUPERSCRIPT II and incubation for 50 min at 42 °C. The reaction was 
inactivated by heating the mixture at 70 °C for 15 min. The cDNA was used as a template 
in the real-time polymerase chain reaction (Q-PCR).
iQ SYBR Green Supermix (12.5 μl; 2x mix contains; 100 mM KCl, 40 mM Tris-HCl, pH 
8.4, 0.4 mM each dNTP (dATP, dCTP, dGTP, dTTP), 50 U/ml iTaq DNA polymerase, 6 
mM MgCl2, SYBR Green I, 20 nM fluorescein and stabilizers; BioRad, Hemel Hempstead, 
UK), 1.5 μl Forward Amplification Primer (10 μM; see Table 2), 1.5 μl Reverse Amplification 
Primer (10 μM; see Table II) 2 μl cDNA, and 7.5 μl RNase-free water were added to a PCR 
reaction plate to a final volume of 25 μl per sample. The contents of the plate were mixed 
gently, and collected by brief centrifugation.
The plate was placed in the Q-PCR MyiQ Single-color Real Time detection system and 
the reaction started after a heat reaction of 94 °C for 3 min. The measurements were 
performed by the following calculations, with GAPDH serving as a control:
	 	 1.   ΔC
T
 = C
T,gene of interest
 - C
T,GAPDH
  2.   ΔΔC
T
 = ΔC
T,sample
 - ΔC
T,control
  3.   2-ΔΔCT 
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Table	2.	Amplification	primers	used	for	the	Q-PCR	of	osteoblast-like	cells
Amplification Primer 1 
(forward)
Amplification Primer 2 
(reverse)
Osteocalcin (OC) GGCTTCCAGGACGCCTACA CATGCCCTAAACGGTGGTG
Collagen type I (Col I) TGGAATCTTGGATGGTTTGGA GCTGTAAACGTGGAAGCAAGG
Alkaline Phosphatase 
(ALP)
GCTTCACGGCATCCATGAG GAGGCATACGCCATGACGT
Bone sialoprotein (BSP) ACTTCCCTTCGCAAGCTTAGG AAACTTCCCGCGTATGTTGG
Glyceraldehyde-
3-phosphate 
dehydrogenase (GAPDH)
GCCTAAATGATACCCCACCGT GCTGGCACTGCACAAGAAGA
2.6 SEM
Samples were taken after 1, 4, 7, 16 and 24 days, and washed three times with PBS. 
Fixation of the cells was carried out for 5 min in 2% glutaraldehyde. Then, the substrates 
were washed for 5 min with 0.1M sodium-cacodylate buffer (pH 7.4), dehydrated in a 
graded series of ethanol and dried with tetramethylsilane. The substrates were sputter-
coated with gold and examined using a Jeol 6310 SEM.
2.7 Statistical analysis
The complete experiment was performed twice. Every sample was present in three fold 
and measured in duplicate. Statistical analysis was performed using an ANOVA with post-
hoc Tukey test. Calculations were performed in InStat software (v 3.05 Graphpad, Inc).
3. Results
In general, the results of all assays were largely comparable between both individual 
experiments. All depicted results are derived from the second experiment.
3.1 DNA content 
The results from the DNA assay are shown in Figure 1. The control group gave a 
significant increase in DNA content until day 16. After day 16, a decrease in DNA content 
was observed. A similar growth pattern like that of the control group was seen for all 
other groups. However, the combined TGFβ-1/BMP-2, and the 2.5 μg/ml COLLOSS® 
E groups reached maximum values at earlier time points. Following the control group, 
the highest DNA content was observed for the BMP-2 group. The TGFβ-1 combined with 
BMP-2 groups gave the lowest contents. The DNA content of the COLLOSS® E and the 
TGFβ-1 groups was just above the TGFβ-1 combined with BMP-2 groups and peaked 
around day 16. At day 16 a significant difference was observed between the control and 
BMP-2 group and the other groups.
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Figure 1. Cell proliferation curve by a total DNA measurement; results are in ng/ml.
3.2 Alkaline phosphatase (ALP) activity
Results of the ALP activity measurement are depicted in Figure 2. The control group 
showed a significant increase in activity with time, with the highest measurements 
between days 7 and 16. On days 7 and 16, a significant upregulation of ALP activity, with 
a maximum around day 16, was observed for the TGFβ-1 combined with BMP-2 groups 
when compared to the control group. The ALP activities of the TGFβ-1 and COLLOSS® 
E groups lay below those of the TGFβ-1 combined with BMP-2 groups; the upregulation 
of TGFβ-1 was significant on days 7 and 16 compared to the control group. They reached 
their maxima around day 16. A maximum peak in ALP activity was seen early for the 
BMP-2 group at day 7 and at that time point, the ALP activity was significantly upregulated 
compared with the control group.
3.3 Calcium
Results from the Ca measurement are depicted in Figure 3. No calcium content was 
detectable before day 16. On day 16, the content started to increase significantly up to day 
24 for the control group. The measurements of the BMP-2 group seemed to increase at an 
earlier time point. The TGFβ-1 group showed no mineralization at day 16 and a significantly
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Figure 2. ALP activity measurement results. The ALP activity was determined in nmol 4-NP produced 
per hour per ng DNA (nmol/h/ng). ALP is an early differentiation marker and correlates to the 
differentiation of the cells.
lower value at day 24, compared to the control group. The calcium content of the TGFβ-
1 combined with BMP-2 and the COLLOSS® E groups were between the control and 
TGFβ-1 group, with little mineralization for the TGFβ-1 combined with BMP-2 groups and 
no mineralization for the COLLOSS® E groups at day 16. On day 24 the calcium content 
of the control and BMP-2 group are similar, and seems to be lower in the other groups. 
However, this difference is not significant except for the TGFβ-1 group.
3.4 Realtime-PCR 
The quantitative PCR results are depicted in Table 3. The TGFβ-1 group showed an 
increase in mRNA for Col I, whereas all other differentiation markers (ALP, OC and BSP) 
were down-regulated. The BMP-2 group gave exactly opposite results; all differentiation 
markers were up-regulated, however Col I could not be detected. The TGFβ-1 + BMP-2 
group showed a small decrease in OC and an increase in BSP and especially in ALP. 
The TGFβ-1 followed by BMP-2 group also showed a small decrease in OC and high 
increases in ALP and especially BSP. The COLLOSS® E groups in general showed a 
down-regulation of all differentiation markers, and mostly resembled the TGFβ-1 group.
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Figure 3. Concentration 
of calcium in μg/
ml. Calcium is a late 
differentiation marker 
and correlates to the 
late differentiation of the 
cells
3.5 Scanning electron microscopy
Representative scanning electron micrographs are depicted in Figure 4 (A,B) (control 
samples, day 4 and 24), Figure 5 (A,B) (BMP-2 samples, day 4 and 24), and Figure 6 (A,B) 
(COLLOSS® E 10.0 µg/ml samples, day 4 and 24). The control group showed a pattern 
of cell growth and differentiation starting with cell attachment, spreading and proliferation 
at days 1-4, matrix formation around days 7-16, and calcification of the matrix after day 
16, which was expected. This pattern of growth and differentiation was also observed for 
all other groups. However, the TGFβ-1 combined with BMP-2 groups started to calcify 
the matrix before day 16 and as a general remark, it could be said that the BMP-2 group 
displayed a confluent monolayer and an even distribution of matrix like the control group, 
whereas all other groups showed patches of cells with matrix formation and calcification. 
Table 3. Q-PCR results in percentages. 
OC Col I ALP BSP
TGFβ-1 49.0% 181% 51.8% 46.0%
BMP-2 167% N/A 126% 343%
TGFβ-1 followed by BMP-2 78.5% N/A 255% 784%
TGFβ-1 + BMP-2 76.8% 111% 460% 136%
COLLOSS® E 2.5 μg/ml 22.5% N/A 99.3% 85.3%
COLLOSS® E 5.0 μg/ml 17.1% N/A 44.4% 32.5%
COLLOSS® E 10.0 μg/ml 8.20% 85.0% 77.4% 41.8%
Samples	are	compared	to	the	control	sample	and	corrected	for	the	household	gene:	Glyceraldehyde	
-3-phosphate	dehydrogenase	(GAPDH)	
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Figure 5: Scanning electron micrographs of the BMP-2 samples at day 4 (A) and 24 (B) at 250x 
magnification. Note, the extensive cell attachment and spreading on day 4 as well as the calcification 
of the extracellular matrix at day 24, as also seen for the control samples (Figure 4(A, B))
Figure 4: Scanning electron micrographs of the control samples at day 4 (A) and 24 (B) at 250x 
magnification. The control samples show cell attachment and spreading on day 4 and calcification of 
the extracellular matrix at day 24
Figure 6: Scanning electron micrographs of the COLLOSS® E 10.0 μg/ml samples at day 4 (A) and 
24 (B) at 250x magnification. This group showed a cell attachment and spreading on day 4 and 
calcification of the extracellular matrix at day 24, as also seen for the control samples (Figure 4(A, B))
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4. Discussion
Expansion of knowledge concerning growth factors is a necessity when preparing 
osteoinductive scaffolds. In the current investigation, a number of relevant growth factors 
were examined individually and in combinations. The focus of this project was on the 
effects of the growth factors on proliferation and differentiation of osteoblast-like cells. Good 
proliferation and differentiation rates were seen after BMP-2 application and increased 
differentiation rates were observed for the TGFβ-1 combined with BMP-2 groups. 
Regarding our study setup, some variance in proliferation and differentiation onset of the 
cells, between the first and the second experiment was observed. However, although the 
differentiation of the cells, matrix formation and calcification started somewhat later in the 
first experiment, the growth and differentiation curve between all groups corresponded 
in both experiments. Since data were reproducible, valid conclusions can be made. The 
phenomenon of differing growth and differentiation rates between experiments is due to 
the use of primary cells; earlier studies already reported about the use of these primary cell 
lines, which did not produce the exact same results.9, 18 Another technical remark has to be 
made on the addition of the growth factors. All growth factors except BMP-2 had a marked 
effect on the morphology of the cell layer, in comparison to the control group. The cell 
layer was always less confluent and cells appeared more rounded. This effect was most 
markedly visible in the COLLOSS® E groups. COLLOSS® E contains high concentrations 
of TGFβ-1, compared to the other growth factors present in COLLOSS® E, which is known 
to influence the morphology and attachment of bone-like cells. Possibly, this effect is even 
enhanced by other, yet undetermined growth factors present in COLLOSS® E.
The decrease in DNA content, that is seen in all groups after day 16, happens when these 
cells are cultured for a period longer than 16 days.19 The reason for this lies in the fact that 
the cells have differentiated by this time point and therefore do not proliferate anymore, 
combined with a lower efficiency of DNA extraction, because of embedding of the cells in 
the extracellular matrix. 
Earlier studies suggest that BMP-2 especially stimulates the differentiation of osteoblast-
like cells.7-9 This theory is supported by the early significant upregulation of ALP activity 
and the upregulation of differentiation markers in the quantitative-PCR at day 7 and the 
high calcium content that was found at day 24. Also, the initial cell seeding density can 
significantly influence the final behavior of the cell cultures. For instance, in the study of van 
den Dolder et al. 20,000 cells/cm2 were used, which is twice as high as the concentration 
used in this study. The effects of growth factors are always related to the number and 
differentiation stage of the cells.
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The proliferation results of the cells stimulated with BMP-2 were significantly higher than 
those of the other groups that received growth factors, however they were always lower 
than the control group. A possible explanation for this phenomenon is the stimulation of 
differentiation of the cells by BMP-2, which causes an earlier start of differentiation of the 
cells that would otherwise proliferate for a longer time period. 
In contrast to BMP-2, literature is more divided about the effect of TGFβ-1 on osteoblast-
like cells. Some investigations show that TGFβ-1 stimulates cell proliferation and inhibits 
differentiation,20, 21 whereas in other articles exactly the opposite is reported.17, 22, 23 These 
contradictory findings can also be due to differences in cell concentration and origin.9 In 
our study, differentiation was stimulated by the addition of TGFβ-1, whereas proliferation 
was decreased.  
Many growth factors play a role during the bone healing process. However, the interaction 
between these growth factors is not completely understood and not much information is 
available about the combined effect of growth factors in vitro. This was the reason that in 
our study also, combinations of growth factors were examined. The addition of TGFβ-1 
and BMP-2 at the same time or followed by each other was supposed to induce synergistic 
effects on matrix formation and calcification. Although the ALP-activity measurements as 
well as the quantitative PCR measurements of ALP and BSP indicated an increased cell 
differentiation, the complimentary use of two factors did finally not result in a confluent 
layer with a high degree of calcification. This can be due to the low proliferation of the 
cells during the initial incubation phase. Interestingly, almost no differences were found 
between the COLLOSS® E groups. Apparently, all used concentrations are in the same 
order of magnitude and therefore exhibit similar effects.
The effect of COLLOSS® E was hypothesized to correspond to the effect of TGFβ-
1 combined with BMP-2, since COLLOSS® E contains both growth factors, although, 
some differences can be expected, since the growth factors in COLLOSS® E are 
bound to collagen. The concentrations of TGFβ-1 and BMP-2 present in COLLOSS® 
E are also lower than those of the TGFβ-1 and BMP-2 groups in this study, however, 
multiple other factors present in COLLOSS® E could possibly compensate for these 
differences in concentration.24 In contrast to our initial suggestion, cell proliferation was 
higher, and differentiation lower than seen in the TGFβ-1 combined with BMP-2 group. 
Evidently, this is due to a large difference in concentration balance between growth 
factors in the COLLOSS® E material, as recently it has been shown that 38.62 ±13.57 
ng/mg TGFβ-1 and 4.12 ± 1.32 ng/mg BMP-2 is present in COLLOSS® E. Apparently, 
the high concentration of TGFβ-1 overrules the effect of BMP-2. The differences, as 
found between the TGFβ-1 combined with BMP-2 and the COLLOSS® E groups, can 
even be enhanced because numerous other growth factors like VEGF, IGF-1, TGFβ-2, 
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BMP-7 and BMP-3 are present in COLLOSS® E. Direct or indirect effects of these growth 
factors on the behaviour of osteoblasts are proven in earlier studies. The direct effect of 
VEGF, IGF-1 or TGFβ-2 on the proliferation of osteoprogenitor cells is unknown, but a 
direct positive effect on the differentiation of osteogenic cells was confirmed for VEGF, 
TGFβ-2,25, 26 and IGF-1.1, 27 BMP-7 promotes proliferation as well as differentiation of 
osteoblastic cells and stimulates bone apposition in certain in vivo situations.28, 29   Although 
all these growth factors have a stimulatory effect on bone formation, BMP-3 has an inhibitory 
effect on other BMPs. BMP-3 is a receptor antagonist that competes for common signaling 
pathway components in the BMP signaling pathway, thereby inhibiting bone formation.30, 31 
Therefore, differentiation of the RBM cells can be very well inhibited by BMP-3.
In summary, the aim of the current study was to examine the effects of different potential 
cell and bone-like matrix stimulating growth factors on osteoblast-like cells. Increased 
proliferation, compared to the groups that received growth factors, and differentiation 
rates were seen for cell cultures supplemented with BMP-2. The addition of TGFβ-1 
combined with BMP-2, TGFβ-1 and all COLLOSS® E to the cell culture medium resulted 
in a decrease in proliferation rate and an increase in differentiation rate. On basis of these 
findings, it can be concluded that, in agreement with our initial hypothesis, BMP-2 is the 
most suitable candidate of these (combinations of) growth factors for the early osteogenic 
stimulation of RBM cells in the used experimental settings. In disagreement with our initial 
hypothesis, additive or synergistic effects of mutual or successive application of TGFβ-1 
and BMP-2 were not observed in this cell culture model and COLLOSS® E did not show 
effects resembling those of combined TGFβ-1 and BMP-2. COLLOSS® E showed effects 
that mostly resembled the addition of TGFβ-1, probably caused by the fact that TGFβ-
1 is the predominant growth factor component present in COLLOSS® E, although the 
potential effects of other growth factors present in COLLOSS® E cannot be excluded.
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1. Introduction
Poly(L-lactic acid) (PLLA) is a widely used biocompatible and biodegradable polymeric 
scaffold material, used in bone tissue engineering. However, a major drawback of 
(porous) PLLA scaffolds is insufficient mechanical strength. As a consequence, various 
composite materials based on PLLA have been developed. Carbon nanotubes (CNTs) 
and hydroxyapatite (HA), incorporated into polymeric scaffolds are both described to 
significantly improve the compressive modulus, as well as the osteoconductivity of the 
scaffold.1-7 Subsequently, addition of a relevant growth factor, such as BMP-2 to the 
composite improves the osteoinductivity of the material (i.e. the material induces the 
proliferation of undifferentiated cells and differentiation of cells into osteoblasts).8 However, 
polymeric scaffolds are known to release growth factors relatively fast, while a slower and 
controlled release is regarded more favourable.9 
In the literature, several studies have been described in which the addition of HA to a 
polymeric scaffold was used to affect the release and bioactivity profiles of growth factors. 
For instance, poly(lactic-co-glycolic acid) (PLGA) scaffolds with incorporated HA have 
been described to be adequate BMP-2 delivery vehicles, while maintaining the BMP-2 
bioactivity in vitro2, 10 and in vivo.11 Furthermore, HA inclusion into chitosan scaffolds has 
been described to result in a slower and more prolonged release of basic fibroblast growth 
factor (bFGF) in vitro.12 Similarly, several proteins are described to spontaneously bind 
to CNTs in a non-specific manner through hydrophobic interactions.13, 14 Since BMP-2 
contains highly hydrophobic regions, e.g. in the receptor binding regions, it was postulated 
that BMP-2 will preferentially bind to the CNTs, thereby influencing the release rate of the 
BMP-2.15
Therefore, the goal of this study was to examine whether CNTs and HA together, 
incorporated into a PLLA scaffold, could influence the in vivo release profile of BMP-2. 
Furthermore, the bioactivity of BMP-2 after release from such a composite scaffold was 
studied in vitro. We hypothesized that the release rate and total release of BMP-2 from the 
composite scaffold would be decreased due to the additions, which have the potential to 
retain BMP-2, without altering BMP-2 bioactivity.
2. Materials and methods
2.1 Scaffold fabrication and characterization
PLLA with an average molecular weight of 104 kDa (Absorbable Polymer Technologies, 
Pelham, Alabama, USA), single-walled CNTs, over 90% pure, having diameters of about 2 
nm and lengths of several microns (Thomas Swan & Co.Ltd, Consett, UK) and microsized
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sintered hydroxyapatite powder (µHA; Plasma Biotal, Tideswell, Derbyshire, UK), with a 
mean particle size of 5 µm, were used to produce porous scaffolds using a liquid-liquid 
phase-separation technique (TIPS). Briefly, 0.08% (w/v) CNTs and 0.08% (w/v) µHA 
powder were dispersed in a 87/13 (v/v) mixture of 1,4-dioxane (Sigma Aldrich, St. Louis, 
MO, USA) and distilled deionized water by sonication for 15 min. Subsequently, 8% (w/v) 
PLLA was dissolved in the CNT/µHA suspension by heating above the cloud point (ca. 63 
ºC). The homogeneous dispersion was then fast-frozen at -16 ºC overnight and finally the 
solvents were removed by freeze-drying for 6 days. By this method, cylindrical scaffolds 
with a diameter of 10 mm and a height of 15 mm and disk shaped scaffolds with a diameter 
of 6 mm and a height of 1 mm were prepared. The same process, but without the addition 
of the CNTs and µHA powder, was used to produce plain PLLA control scaffolds. 
Porosity of the materials was measured by mercury intrusion porosimetry (Autopore 9220, 
Micromeritics Co., Norcross, GA, USA.). The internal pore structure and morphology of 
the scaffolds were analyzed using scanning electronic microscopy (SEM, JEOL JSM-
5910 LV, Tokyo, Japan) on fracture-frozen cross-sections of the scaffolds. Furthermore, 
the Young’s modulus and maximum stress of the materials were tested with an Instron 
5500R mechanical tester (Instron Co., Norwood, MA, USA). The cylindrical samples were 
compressed to 10% at a crosshead speed of 20 mm/min and the compressive modulus 
was defined as the initial linear modulus. 
Before loading BMP-2 onto the disk-shaped scaffolds, they were pre-incubated in 70% 
ethanol for 1 h, followed by 2 h in 1% gentamycin/fungizone (Invitrogen, Breda, The 
Netherlands) in phosphate-buffered saline (PBS). Finally, they were incubated for 1-2 
hours at 37 °C in α-minimal essential medium (α-MEM; Invitrogen) supplemented with 
10% fetal calf serum (FCS; Invitrogen).
2.2 Radioiodination of BMP-2
BMP-2 was labelled with 131I according to the Iodogen method.16 Briefly, 125 µg 
recombinant human (rh) BMP-2, (Peprotech, Rocky Hill, NJ, USA) was dissolved in 100 
μl PBS and transferred to a 0.5 ml Eppendorf tube coated with 100 μg 1,2,4,6-tetrachloro-
3α,6α-diphenylglucouril (Iodogen; Pierce, Rockford, IL, USA). After the addition of 10 
µl 0.5 M phosphate buffer (pH 7.4) and 75 µl 131I (6 mCi; GE Healthcare, Waukesha, WI, 
USA) the vial was incubated at room temperature for 15 min. Then, the reaction mixture 
was quenched with 100 µl of saturated tyrosine solution and separated on a pre-rinsed 
disposable Sephadex G25M column (PD10; GE Healthcare). The column was eluted with 
PBS-BSA 0.1% and the 131I-BMP-2 containing fractions were pooled. Labelling efficiency 
was 91%, resulting in a specific activity of 40 μCi/µg and a radiochemical purity exceeding 
90%, as determined by instant thin layer chromatography (ITLC). 
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2.3 BMP-2 activity assay
The activity of released BMP-2 from the composite scaffold was determined in vitro 
according to a previously described W20-17 cell-assay.17 Active BMP-2 has the potential 
to differentiate W20-17 cells into the osteoblastic lineage, thereby starting to produce the 
early differentiation marker alkaline phosphatase (ALP). The activity assay was divided 
into four parts and the complete assay was performed in duplicate:
1.  W20-17 cell culture. W20-17 cells were cultured in growth medium (αMEM; 
supplemented with 10% FCS and 50 µg/ml gentamycin). Cells were passaged one 
day before the assay and plated into a 96 well plate at a concentration of 10.000  
cells/cm2 to ensure exponential cell growth.
2.  Preparation and incubation of the composite scaffolds with W20-17 cells. 72 h 
before incubation with the W20-17 cells, composite scaffolds, with and without 100 
ng loaded BMP-2 (each present in five-fold), were placed in growth medium at 37 
°C (5% CO2, 95% humidity). On day 0, the medium was removed and added to 
the W20-17 cells in the 96 well plate. The plate was incubated for 4 days. Then, 
the culture medium was removed from the cell layer, the cells were washed twice 
with PBS and disrupted in 1 ml deionized water by sonication for 10 min. The effect 
of the added medium on the W20-17 cells was correlated with those of a dilution 
series of BMP-2 (range from 0-2.4 µg/ml) in growth medium.
3.  DNA content measurement. The DNA content directly correlates with the amount 
of cells, which is mandatory information for the ALP activity calculation. For DNA 
analysis, a PicoGreen dsDNA Quantitation Kit (Molecular Probes, Leiden, The 
Netherlands) was used. Briefly, 100 μl sample and 100 μl PicoGreen working 
solution were added to a 96-well plate and incubated in the dark for 5 minutes. The 
plate was read at 480-520 nm. The DNA content was determined with the aid of a 
standard curve, which was produced by using serial dilutions of λ DNA in the range 
of 0-2.000 ng/ml. 
4.  ALP activity measurement. The ALP activity was measured for each sample (using 
the same samples as used for the DNA content measurement). The activity was 
calculated in nmol 4-nitrophenol (4-NP; Sigma) produced/hour/ng DNA. In brief, 
80 µl sample, 20 µl of buffer solution (5 mM MgCl2, 0.5 M 2-amino-2methyl-1-
propanol; Sigma) and 100 µl substrate solution (5 mM p-nitrophenylphosphate; 
Sigma) were added to a well in a 96-well plate (Greiner, Bio-One, Alphen aan den 
Rijn, The Netherlands). After incubation of the plate for 1 h at 37 °C, the reaction 
was stopped by addition of 100 µl stop solution (0.3 M NaOH, Sigma) to each well. 
Finally, the plate was read at 405 nm in a microplate reader. Serial dilutions of 4-NP 
in the range of 0-25 nM was used as a reference curve. 
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2.4 In vivo BMP-2 release
Aliquots of 250 µl PBS, 0.1% BSA containing 5 µg 131I-BMP-2 (200 µCi) were drop-loaded 
onto PLLA and composite substrates. The substrates with applied 131I-BMP-2 were frozen 
at –20 °C and lyophilized overnight. 
Five healthy adult male Wistar rats, weighing approximately 250 g (~8 weeks old) were 
used. The animals were housed in compliance with the Dutch guidelines for animal 
experimentation and the study was performed under the Animal Ethical Committee number 
DEC-2007-137. Anaesthesia was induced and maintained by isoflurane inhalation. The 
dorsal skin was prepared by shaving, washing and disinfection with iodine. Then, two 
longitudinal incisions (1 cm long) were made vertebrally at the left and right side of the 
spine of the animals. Subcutaneous pockets were created by blunt dissection with scissors. 
Into these pockets, parallel to the dermis, a PLLA and a composite scaffold, both loaded 
with 131I-BMP-2, were placed and the wounds were closed with steel staples. 
Directly after implantation (day 0) and after 2, 7, 14, 21, 28 and 35 days, scintigraphic 
images were acquired using a single-head gamma camera (Orbiter, Siemens Medical 
Systems Inc., Hoffman Estates, IL, USA) equipped with a parallel-hole high-energy 
collimator. The animals were immobilized in a ventral position onto the collimator of the 
camera under general inhalation anaesthesia (isoflurane/O2, N2O). Images of 50,000-
300,000 counts/image were acquired and digitally stored in 256x256 matrices. These 
images were quantitatively analyzed by drawing a standardized region of interest (ROI) 
over the implanted scaffolds. Subsequently, the measurements were corrected for 
radioactive decay and background activity and the release was expressed as a percentage 
of the initial dose.
2.5 Statistical analysis
All scaffolds for the mechanical characterization and release and activity measurements 
were present in five fold. Unpaired two-tailed t-tests were used to statistically analyze 
the differences in mechanical strength and growth factor release between both types of 
scaffolds and to statistically analyze the differences in BMP-2 activity before and after 
release from the composite scaffold. All data were tested on normal distribution and 
p values of 0.05 or less were considered to indicate significance. Calculations were 
performed in InStat software (v 3.05, Graphpad, Inc).
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3. Results
3.1 Scaffold characterization
The produced scaffolds had a mean pore diameter of 66 µm and a porosity of 85% for 
the PLLA scaffold and a mean pore diameter of 103 µm and a porosity of 87% for the 
composite scaffold (Figure 1). Mechanical testing of the scaffolds resulted in a compressive 
modulus of 10.9 (±2.3) MPa and a maximum stress of 0.30 (±0.02) MPa for the PLLA 
material. The composite material had a non-significantly higher compressive modulus of 
12.5 (±2.0) MPa and a significantly higher maximum stress value of 0.39 (±0.02) MPa, 
when compared to the plain PLLA scaffold. No differences in absorption of the 131I-BMP-2 
solution were noticed during growth factor loading onto the scaffolds.
Figure 1: Scanning electron micrographs of (A) PLLA and (B) PLLA/CNT/µHA scaffolds. 
Magnification, 100x.
3.2 BMP-2 activity assay
The W20-17 cell assay proved that released BMP-2 from the composite scaffolds was 
still bioactive. The results are given in Table 1. The measured ALP activity, induced by 
the released BMP-2, correlated to the maximum measured ALP activity of the standard 
dilution series. The ALP activity of the control samples without BMP-2 showed no induction 
of ALP activity. 
Table 1: ALP activity measurement results
Average ALP activity (nM 4-NP produced/h/ng DNA)
First assay Second assay
Released BMP-2 4.93 3.95
Negative control (no BMP-2) 0.42 0.59
Maximum ALP activity in 
standard dilution series 5.50 3.78
ALP activity measurement results. The ALP activity was determined in nmol 4-NP produced per hour 
per ng DNA (nmol/h/ng).
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3.3 In vivo BMP-2 release
During the in vivo scaffold implantation (Figure 2) and BMP-2 release evaluation, all 
animals (n=5) remained healthy. No weight loss or signs of wound healing complications 
were observed during the experiment. Scintigraphic images of the rats on day 0 clearly 
visualized the 131I-BMP-2-loaded PLLA and composite scaffolds as dark regions (Figure 
3). In time, the surface activity in, and intensity of these regions decreased, indicating 
release and clearance of 131I-BMP-2. The growth factor was released in a ‘burst release’ 
of 60% between 2 and 7 days (Figure 4). Thereafter, small amounts of growth factor were 
gradually released up to 28 days, at which time all 131I-BMP-2 had been released from 
the scaffolds. No differences in release pattern between the PLLA and composite scaffold 
were observed at any of the time points.
Figure 2: Overview of the subcutaneous implantation of the scaffolds on the back of a rat. A) The 
surgical area was prepared by shaving, washing and disinfecting the skin with iodine. B) Two 
longitudinal incisions were made at the left and right side of the spine. C) Subcutaneous pockets 
were created by blunt dissection with scissors and filled with the scaffolds. D) The wounds were 
closed with steel staples.
Figure 3: A) Schematic overview of the scaffold 
placement in the rat and of the scintigraphic 
analysis area. B) Scintigraphic image of the in 
vivo measurement of released 131I-labelled BMP-
2 in rat 5 at 14 days after implantation. The PLLA 
scaffold is visible on the left side and the PLLA/
CNT/µHA scaffold on the right side. The circles 
indicate the regions of interest in which the 
amount of labeled BMP-2 was measured.
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Figure 4: In vivo release profile of 131I-labelled BMP-2 from a PLLA and a PLLA/CNT/µHA scaffold in 
percentages of the originally loaded amount of BMP-2 against the time (days). A burst release phase 
was followed by a more sustained gradual release phase, with a 100% release of BMP-2 after 600 
hours.
4. Discussion
The clearance rate of BMP-2 by diffusion in the body has been described to be very high. 
When BMP-2 is injected subcutaneously, it is almost completely cleared from the site of 
injection within 24 h,18 whereas for bone tissue engineering a prolonged retention of BMP-
2 may be regarded as beneficial to bone formation. Since CNTs and µHA were described 
to be able to retain BMP-2 for a prolonged period of time, in this study we chose to 
examine a scaffold type containing both additions on the probability of a prolonged growth 
factor retention time. To avoid differences in degradation pattern that might compromise 
the results of the study, we chose PLLA for scaffold production. Degradation of the used 
high molecular weight PLLA starts after a prolonged time period, even when porosity is 
present.19, 20 Also incorporation of either CNTs or µHA has not been described to increase 
degradation.21, 22
The bioactivity of released BMP-2 from the composite material was measured to exclude 
the possibility of the material compromising the growth factor activity. PLLA scaffolds are 
well known to function as excellent carriers for BMP-2 delivery, thereby maintaining the 
bioactivity of the growth factor.9 However, a composite material, as used in this study, 
has not been described before. As hypothesized, the results from this study clearly 
demonstrated that the material did not affect the activity of BMP-2.
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However, in contrast with our hypothesis, the in vivo release results showed no differences 
in release pattern or total release of BMP-2 between the composite and plain PLLA 
scaffolds. This finding was unexpected on basis of current literature and therefore leads 
to the question of whether the CNTs and µHA were actually present on the surface of the 
scaffolds. Composite polymeric scaffolds prepared by the same technique, including HA, 
have been shown to have HA directly available on the surface.23 However, the influence 
of additional CNTs to such materials has never been described. In literature, non-
functionalized CNTs have been shown to bind strongly to polymers through hydrophobic 
interactions.24, 25 In response to these strong interactions, it might be possible that the µHA 
and CNTs are completely encapsulated by the polymer, resulting in a scaffold with a plain 
PLLA surface. The suggested equal wettability behaviour of both scaffolds during growth 
factor loading supports this theory. 
Nevertheless, although incorporated CNTs and µHA in a PLLA scaffold do not alter the 
release pattern of BMP-2 in vivo, they still can provide composite scaffolds with several 
other beneficial characteristics. Incorporation of µHA or CNTs into a scaffold material 
has been reported to affect bone formation positively3, 5, 7, 26-28 and, as shown previously, 
the compressive modulus of polymeric scaffolds can also be improved.4, 5, 29 Accordingly, 
in this study, the maximum stress values of the composite scaffolds were significantly 
increased. On the other hand, the compressive modulus of the composite scaffolds was 
not significantly higher. Still, a previous study reported an increase in compressive modulus 
of a polymeric scaffold after CNT incorporation in similar concentrations as used here.4 
Probably, the higher porosity and pore diameter of the composite scaffolds in the current 
study, as compared to the plain PLLA scaffolds, minimized the difference in compressive 
modulus between both scaffold types to a non-significant level.
As a final remark, biosafety issues concerning the use of CNTs should not be disregarded. 
There are many positive reports on the use of CNTs,30-32 but toxicity studies with a 
negative outcome have also been reported.33-35 These studies however, focused mainly 
on the administration of highly concentrated unpurified CNTs through transdermal, 
transmucosal or inhalational routes. Purification of toxic residual metal catalysts36, 37 and 
functionalization33, 38 of the CNTs have already shown reduce toxicity significantly and, thus 
far, no studies have been published on CNT containing implanted scaffolds describing 
adverse reactions. Of special concern is the fate of the non-degradable CNTs released 
from the degrading scaffold. Currently, there is no generally accepted method available 
to precisely monitor the (extremely small) CNTs in vivo. Histological examination will not 
detect CNTs unless aggregated to large extent. Therefore, efforts have been made to 
label CNTs with the MRI contrast agent Gadolinium.39, 40 Upon implementation of such 
CNTs-containing scaffolds, the CNTs seemed to be cleared from the body systematically.40
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From the results of this study, it can be concluded that both a plain PLLA scaffold and 
a porous composite scaffold, containing CNT and µHA, comprehend the same in vivo 
release properties for BMP-2. BMP-2 was released in a burst-like manner, followed by a 
sustained release without altering the bioactivity of the BMP-2. Incorporation of CNTs and 
µHA did not prolong BMP-2 retention in the composite material.
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1. Introduction
Single-walled carbon nanotubes (SWCNTs) possess a number of unique characteristics 
that make them desirable for biomedical application.1 One of their proposed applications 
is as reinforcing agents in synthetic polymers due to their excellent mechanical properties 
(~640 GPa in modulus and ~40 GPa in tensile strength) and high aspect ratio.2, 3 Our 
laboratory has developed SWCNT-based nanocomposites for bone tissue engineering.4-7 
The SWCNTs, especially ultra-short SWCNTs (US-tubes) induce a significant reinforcement 
of the polymeric scaffold and show good biocompatibility in vitro and in vivo.8, 9 Therefore, 
US-tube nanocomposites may hold exceptional potential for bone-tissue engineering.
Although these carbon nanotubes-based nanocomposites offer promising properties for 
bone tissue engineering scaffolds, little is known about the biocompatibility and long-term 
biodistribution of the carbon nanotube materials upon their release from the polymer upon 
degradation in vivo. It has been shown that debris released from orthopaedic implants 
can accumulate to cause pathologies in vital organs.10, 11 Recently, microparticle and 
nanoparticle aggregates of exogenous origin were discovered in the kidneys, liver, and 
colon of humans suffering from various illnesses.12, 13 The accumulated particles damaged 
these organs in a few cases. The origin of these substances is still to be determined. 
Nevertheless, these studies raise concern about any new nanomaterials-based implants, 
such as our SWCNT and US-tube nanocomposites.
Recently, we reported that Gd3+-encapsulated carbon nanotube structures (gadonanotubes) 
possess unique nanoscalar properties exhibiting superior performance as MRI contrast 
agent (CA) and thus, show promise for molecular imaging and other advanced 
applications.14-16 The high contrast agent efficacy of the gadonanotubes should allow 
noninvasive monitoring of their release from a polymeric scaffold upon degradation and give 
better insight about their biodistribution characteristics in vivo. However, before one can 
perform such extensive in vivo studies, in vitro cytotoxicity testing needs to be performed 
as they often provide valuable information for further evaluation of biocompatibility. In vitro 
MRI studies are also essential to optimize the gadonanotube/polymer nanocomposites for 
the in vivo studies and to optimize the imaging parameters. Towards this end, in this report 
we present (a) the in vitro cytotoxicity of the gadonanotubes and their nanocomposites 
with PLGA, (b) the in vitro phantom MRI of the gadonanotubes and gadonanotubes/PLGA 
nanocomposites and (c) the in vivo small animal MRI of the gadonanotubes.
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2. Experimental methods
2.1 Generation of US-tubes
SWCNTs were cut into US-tubes by a previously developed method by Gu et al..17 Briefly, 
this method involves fluorination of solid SWCNT sample for 2 h at 50 °C under 1% 
gaseous fluorine diluted in helium followed by pyrolysis at 1000 ºC for 1 h under an inert 
atmosphere that leads to spontaneous cutting of the micron-long SWCNT into ultra-short 
SWCNTs (diameter = 1.4 nm and length = 20-80 nm).14 This procedure also purifies US-
tubes from the catalyst impurity. Because of their great flexibility and high surface energy, 
SWNT tend to aggregate into large bundles and the US-tubes are present as bundles 
that contain hundreds of individual US-tubes.  Although US-tubes can be debundled into 
individual US-tubes,18 bundled US-tubes were used in our study.
2.2 Synthesis of gadonanotubes
Solution-phase filling of the Gd3+ inside the US-tubes was achieved by a protocol previously 
developed in our lab.14 Briefly, this method involved stirring US-tubes and anhydrous 
GdCl3 (1:1 ratio by weight) in HPLC grade water at pH 3, followed by sonication for 1 h. 
The solution was then left undisturbed overnight, whereupon the Gd3+-loaded US-tubes 
flocculated from the solution. The supernatant solution was then decanted off and the 
sample was washed with fresh water followed by sonication to remove any unabsorbed 
GdCl3. This procedure of flocculation and washing with fresh deionized (DI) water was 
repeated several times. The sample was then air-dried and an inductively-coupled plasma 
optical emission spectrometry (ICP-OES) analysis showed that the Gd content of solid 
gadonanotubes was 3.06% (m/m). 
For the relaxivity measurements, a saturated solution of 10 mg of the gadonanotubes in 
10 ml of a 1% biologically-compatible 1% Pluronic F127 surfactant solution was prepared. 
Approximately 10% of the gadonanotubes dispersed and formed a stable solution. The 
[Gd] concentration of this supernatant (suspension) solution was then confirmed by ICP. 
This suspension was used as the stock solution and diluted with 1% Pluronic F127 to obtain 
the [Gd] concentrations used for the cytotoxicity, MRI (in vitro and in vivo) experiments with 
the gadonanotubes.
2.3 Preparation of the nanocomposites
The nanocomposites were prepared by dispersing the hydrophobic gadonanotubes at 2 wt% 
concentration into PLGA polymer (average molecular mass of 5 kDa) using an established 
procedure of high shear mixing, sonication and drying.4 PLGA of 50:50 lactic to glycolic acid 
copolymer ratio was used for the fabrication of these scaffolds. The nanocomposite material 
was finally cast into molds that produced discs of 6-mm diameter and 1-mm height.
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2.4 Cell culture
A Fischer rat fibroblast 3T3 like cell line (ATCC, CRL-1764, Manassas, VA) was grown 
in T-75 culture flasks  (Sigma-Aldrich, St. Louis, USA), using Dulbecco’s modified Eagle 
medium (DMEM, Gibco Life, Grand Island, NY, USA) supplemented with 10 vol% fetal 
bovine serum (FBS, Gemini Bio-Products, Calabasas, CA, USA) and antibiotics (100 
µg/ml penicillin, 100 U/ml streptomycin, and 0.5 μg/ml amphoterricin B, all from Gibco 
Life). Cell cultures were incubated at 37 oC, 95% room air, and 5% CO2. Cells of passage 
numbers 4-8 were used in this study. 
2.5 Preparations of the samples for the in vitro cytotoxicity studies
To evaluate the in vitro cytotoxicity of the gadonanotubes, PLGA polymer and the 
nanocomposites, the extracts of these materials were first tested in accordance with the 
International Standard ISO 10993-5 because neither PLGA nor the gadonanotubes are 
soluble in water. US-tubes were used as controls. All specimens were first sterilized by 
exposure to UV light for 3 h. Subsequently, PLGA and nanocomposite scaffolds were 
immersed in culture media at 1 ml media per 3 cm2 scaffold contact area, while the 
gadonanotubes and US-tubes were mixed with culture media at a concentration of 1 mg/10 
ml or 100 ppm. Following 24 h extraction at 37 oC, the supernatant medium above PLGA 
and nanocomposites was withdrawn and filtered with a 0.2 µm filter (Nalgen, Rochester, 
NY, USA). The extracted medium (1x dilution) and their 10- and 100-time diluted solutions 
were added to the 96-well plates containing 3T3 cells. In order to investigate the direct 
interaction between cells and gadonanotubes, medium containing gadonanotubes at a 
concentration of 1, 10, 100 ppm was also prepared.
2.6 In vitro cytotoxicity tests
For the cytotoxicity studies, the 3T3 fibroblasts were lifted from the T-75 culture flasks at 
80-90% confluency, trypsinized, and resuspended at a concentration of 1.5×105 cells/ml. 
The cells were then seeded in 96-well plates at 100 µl cell suspension/well with a seeding 
density of 4×104 cells/cm2, and allowed to attach for 24 h. The culture media was then 
replaced with the experimental solutions (described above) and cells were determined 
after 24 h of incubation (n=6 wells/treatment). 
Thereafter, the cells were washed with phosphate buffered saline (PBS, Gibco Life) and 
then 100 µl LIVE/DEAD reagent (2 µM calcein AM and 4 µM ethidium homodimer-1 
(EthD-1; Molecular Probes, Eugene, OR, USA) was added. Following 30 min incubation 
at room temperature, the fluorescence of each well was measured using a BIOTEK 
Instruments FLx800 plate reader (Winooski, VT, USA) equipped with filter sets of 485/528 
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nm (excitation/emission) for calcein AM (live cells) and 528/620 nm (excitation/emission) 
for EthD-1 (dead cells). For this test, cells which were only exposed to culture media 
served as the live control and cells exposed to 70 vol% ethanol solution for 30 min prior to 
addition of the LIVE/DEAD reagent served as the dead control. The fluorescence of each 
sample well was normalized by that obtained from the live and dead control groups, which 
was defined as the fractions of live and dead cells, respectively.19 After the fluorescence 
measurements, the live/dead cell populations of the representative wells were imaged 
using a Zeiss LSM 510 Axiovert microscope (Carl Zeiss, Jena, Germany). 
2.7 Magnetic resonance imaging
Magnetic Resonance Imaging experiments were performed on a 7-T/200mm horizontal-
bore magnet interfaced to an Surrey Medical Imaging System (SMIS) spectrometer and 
equipped with a gradient insert (gradient strength=150 mT/m; rise time=150 µs). 
For the phantom studies, vials containing gadonanotubes dispersed in biologically-
compatible 1% Pluronic F127 at a [Gd] of 0.15 mM were prepared.  As a reference, a vial 
containing plain 1% Pluronic F127 solution was also included within the imaging field-of-view 
(FOV). For the in vitro MRI of the nanocomposites, the discs were embedded into biological 
grade agarose and imaged after 2 h, 24 h and consequently on days 3, 5, and 7. PLGA 
scaffolds were used as controls. 
The phantom and nanocomposite discs were imaged with a homogenous RF birdcage coil 
(60-mm diameter) using a spin-echo pulse sequence. Imaging parameters were: image 
matrix size of 128×128, field of view (FOV) of 60×60 mm2, slice thickness (SLT) of 2 mm, 
6 slices, one signal average per phase-encoding step and a scan repetition time (TR) of 
1000 ms. The best slice containing all samples in 1 slice was then chosen and used for T2 
calculations. The echo time (TE) was varied to calculate T2 values of the gadonanotube 
phantom samples (TE=10, 12, 14, 16, 18 and 20 ms). The T2 values were calculated by 
exponential fitting of the datapoints.
The r2 was then calculated as (1/T2 (gadonanotubes) - 1/T2 (1% Pluronic solution))/[Gd].
Two healthy male Wistar rats weighing approximately ~200 g were used for the in vivo MRI 
study. Prior to the in vivo experiments, approval was obtained from the Radboud University 
Nijmegen animal ethics committee (RU-DEC 2007-096). The rats were immobilized in a 
ventral position in the MRI under general inhalation anesthesia (isoflurane in a O2, N2O 
mixture). Gadonanotubes were dispersed in 1% Pluronic F127 (100 μl gadonanotubes, 
[Gd]=0.15 mM) and were then injected subcutaneously in the back of the rats. The rats were 
subsequently imaged 2 h and 1 day after administration of the gadonanotube suspension. 
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For the in vivo MR imaging, a homebuilt dedicated RF microstrip coil and mechanical setup 
was used.20 The rat was placed in supine position to get the best signal-to-noise-ratio (SNR) 
in the disc area. Temperature of the rat was monitored using a fluoroptic rectal thermometer 
and kept at 37 ± 1 °C with a warm water bed. Breathing was monitored with a movement 
sensor and breathing was kept at 40 ± 5 times/sec by adjusting the anesthetics, which 
consisted of 1.5-2.5 % isoflurane mixed with a gas mixture of 50% O2 and 50% N2O. 
Images were obtained with a T2 weighted coronal (i.e. parallel to the coil) multi-slice spin-
echo (SE) sequence. Imaging parameters were: image matrix size of 256×256, field of 
view (FOV) of 120×120 mm, slice thickness (SLT) of 1 mm, 16 slices, one signal average 
per phase-encoding step and an echo time (TE) of 15 ms. To reduce breathing artifacts, 
respiratory gating was used, resulting in repetition times between 1.3–1.7 s, depending on 
the breathing cycle, which was kept between 35 and 45 times/min throughout the complete 
experiment. 
2.8 Statistical analysis
The nonnegative least square (NNLS) technique and the Levenberg–Marquardt (LM) 
nonlinear least squares algorithm were used to analyze the T2 relaxation data.21 All 
statistical comparisons were conducted with a 95% confidence interval (p<0.05). Single-
factor analysis of variance (ANOVA) was conducted to identify significant differences among 
treatment groups. The experimental data are expressed as means ± standard deviation.
3. Results
3.1 In vitro cytotoxicity 
The depictions of PLGA and the gadonanotubes are shown in Figure 1. Figure 2 shows 
the viability data for the cells directly contacting 100 ppm gadonanotubes, and US-tubes 
as well as cells exposed to 1x dilution extracts from gadonanotubes, US-tubes, PLGA
Figure 1: Depiction of PLGA gadonanotubes. The gadonanotubes picture is drawn not to scale and 
the dangling carbon atoms at the defect sites as well as the Gd3+ counterions are not shown.
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and the gadonanotube/PLGA nanocomposites. The fibroblasts directly contacting the 
gadonanotubes and US-tubes at 100 ppm concentrations for 24 h showed 100% viability. 
The fluorescent microscopy image of gadonanotube (Figure 3a) and US-tube media 
(Figure 3b) also demonstrated high density of live cells (green color) and very few dead 
cells (red color) comparable to that of the live control. Because of the hydrophobicity of 
the carbon nanotubes, they formed aggregates (arrows in Figure 3a, b) in the sizes of 
submicrometers to tens of micrometers within the confluent cell monolayer. The cells 
surrounding or attached to these aggregates did not show any signs of damage. Similar 
results were observed for cells directly in contact with gadonanotubes and US-tubes at 1 
ppm and 10 ppm concentrations respectively for 24 h (Table 1). The extracted solutions 
from the gadonanotubes and US-tubes at 10x and 100x dilutions also showed ~100 % cell 
viability after 24 h exposure (Table 1).  
Nearly 100 % cell viability was also detected for the cells exposed to 1x dilution of the 
extracts from PLGA or the gadonanotube/PLGA nanocomposites (Figure 2). Similar 
results were observed at 10x and 100x extracts (Table 1). The extraction media from 
gadonanotubes nanocomposite did not change the density and morphology of the 
fibroblasts over 24 h incubation (Figure 3c).
I. Gadonanotubes (100 ppm Direct contact)
II. US-tubes (100 ppm Direct Contact)
III. Gadonanotubes (1x Extract)
IV. US-tubes (1x extract)
V. Nanocomposite (1x Extract)
VI. PLGA (1x Extract)
Figure 2: Cell viability after 24 h incubation 
with the different groups. Error bars represent 
standard deviations; n=6.
Figure 3: Fluorescent microscopy images of the cells after 24 h incubation with experiment media and 
treated with LIVE/DEAD reagent: (a) 100 ppm gadonanotubes media, (b) 100 ppm US-tubes medi, (c) 
13 extracts of gadonantubes media. Arrows point to carbon nanotube aggregates.
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3.2 MRI
Representative T2 weighted images at 25 °C of samples containing gadonanotube 
suspension at 0.15 mM [Gd] and plain 1% Pluronic F127 surfactant solution clearly show 
the effect of the nanotubes on T2 relaxation (Figure 4). The multi-echo experiments on the 
gadonanotube suspension revealed an apparent T2 value of 11.5 ± 0.5 ms and a r2  value 
of 578 ± 20 mM-1s-1.  
Table 1: Fractions  of live cells and dead cells determined by LIVE/DEAD viability/cytotoxicity assay after 
24 h exposure to test media (mean ± standard deviation for n=6).
Test media Concentration
Fraction of live cells 
(%)
Fraction of dead cells 
(%)
Live control 100 ± 3 13 ± 6
Dead control 5 ± 3 100 ± 11
Gadonanotubes in direct 
contact with cells
100 ppm 96 ± 7 12 ± 4
10 ppm 98 ± 10 11 ± 4
1 ppm 101 ± 4 15 ± 2
US-tubes in direct contact 
with cells
100 ppm 97 ± 8 9 ± 4
10 ppm 99 ± 5 12 ± 4
1 ppm 96 ± 9 13 ± 2
Extract of gadonanotubes
1x dilution 101 ± 4 13 ± 2
10x dilution 102 ± 6 16 ± 4
100x dilution 97 ± 4 10 ± 3
Extract of US-tubes
1x dilution 103 ± 6 8 ± 5
10x dilution 99 ± 7 14 ± 3
100x dilution 103 ± 9 13 ± 3
Extract of gadonanotubes 
composite
1x dilution 102 ± 8 12 ± 2
10x dilution 105 ± 10 11 ± 4
100x dilution 96 ± 10 12 ± 2
Extract of PLGA
1x dilution 102 ± 7 11 ± 3
10x dilution 104 ± 6 14 ± 5
100x dilution 101 ± 5 12 ± 4
Figure 4: Representative T2 
weighted MRI phantoms of (a) 
gadonanotubes 0.15 mM [Gd] and 
temperature of 25 °C obtained by 
using a 7T SMIS MR imager. For 
comparative purposes, an MRI 
phantom of (b) Pluronic F127 
solution is shown (TE = 15 ms).
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The in vitro characterization of the nanocomposite discs and the degradation process by 
MRI is shown in Figure 5. Figure 5a shows a schematic picture of the nanocomposite disc 
configuration within the MR scanner and the orientation of one of the image slices. The 
corresponding MR images are shown in Figures 5b-f. Since the MR images are due to 
the signal from the water protons, no signal was obtained from the solid discs, while the 
area surrounding the discs was bright, due to the water in the agarose gel. Bright areas 
(as indicated by the red arrows in Figure 5) are caused by susceptibility artifacts. The MRI 
showed enhanced water penetration, which increased with time. Beyond day 1, the discs 
swelled considerably, the dark parts on the MRI slowly disappeared, and by day 5, there 
was an increase in image brightness throughout the disc indicating that the water was 
homogeneously distributed throughout the sample. Enhanced contrast (yellow arrows) was 
also noticed at the initial time point (Figures 5c-d) at the edges of the water front and at the 
later time points (days 5 and 7; Figures 5e-f) throughout the disc. 
The subcutaneous injection of the gadonanotubes 1% Pluronic F127 solution in rats showed 
excellent negative contrast. Figure 6 shows a representative MR image of the dorsal region 
of the rat 1 day after injecting 100 µl of the gadonanotubes 
([Gd]=0.15 mM). The dark spot seen in the right dorsal region 
is negative contrast generated due to the high r2 relaxivity of 
the gadonanotubes. There was no observable change in the 
intensity of the dark spot over day long observation indicating 
that most of the injected gadonanotubes remained in the vicinity 
of the injection site.
Figure 5: (a) Schematic of the sample arrangement within the MRI. Representational two-dimensional 
images through a nanocomposite disc after (b) 2-h, (c) 24-h, (d) 3- days, (e) 5 days, and (f) 7 days. The 
higher (white) pixel intensities within the dark disc represent regions of higher water concentration. The 
high intensity surrounding the disc is the agarose gel (TE=15 ms).
Figure 6: Representative spin echo MR image of a rats dorsal region after 
subcutaneous injection of 100 µl (0.075 µmol/kg Gd) of a gadonanotube 
Pluronic F127 suspension ([Gd]=0.15 mM. TE=20 ms).
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4. Discussion
The objective of this study was to assess the in vitro cytotoxicity and MR imaging of 
gadonanotubes and nanocomposites, as well as in vivo small animal MRI studies using 
the gadonanotubes. This study was performed towards our final goal of evaluating the 
suitability of gadonanotubes-reinforced PLGA polymer nanocomposites as a model 
scaffold system for noninvasive MRI monitoring of the gadonanotube release during the 
degradation process of the scaffold and its eventual biodistribution upon release from 
the polymer matrix in vivo. PLGA was chosen as the polymer matrix because it is not 
only biocompatible and FDA approved polymer for human clinical application,22 but also 
shows biodegradabale characteristics suitable for the time scale for future in vivo MRI 
experiments.23, 24 Furthermore, previous MRI-based controlled release studies using PLGA 
served as a point of reference for our current and future MRI experiments.25
4.1 In vitro cell viability 
In vitro cytotoxicity testing is a standard method routinely used as an initial screening to 
examine cell response to biomaterials. It often provides useful information before starting 
more complex and expensive in vivo animal experiments. The 3T3 fibroblast-like cell 
line is a commonly accepted cell line for these evaluations.26 The LIVE/DEAD viability/
cytotoxicity assay (Molecular probes, Eugene, OR, USA) was preferred over the MTT 
assay to determine cytotoxicity levels due to its suitability for assaying directly carbon 
nanotube treated cells.8  
In case of the gadonanotubes-reinforced PLGA nanocomposites, the nanocomposites and 
the gadonanotubes upon release from the nanocomposites are the two main components 
that will interact with the surrounding tissues post implantation.  Therefore, we assessed 
their cytotoxicity to predict a possible tissue response to these components when implanted 
in vivo.
No cytotoxicity was observed for either the US-tubes or the gadonanotubes at 1-100 ppm 
concentrations in both extract dilution and direct contact assays (Table 1). The cells maintained 
their morphology (images not shown) and formed agglomerates around nanotube aggregates 
(arrows in Figure 3a). These results corroborate with other data on carbon nanotube toxicity 
as reported by our group and by others.8, 27 The lack of toxicity for the gadonanotubes is 
encouraging and represents to the best of our knowledge the first study profiling its in vitro 
cytotoxicity. This observation suggests robust sequestering of the Gd3+ metal ion within the 
carbon sheath of US-tube for least one day after their exposure to cells and biological media. 
However, longer time points exposure studies are clearly needed to ascertain if the Gd3+ 
metal ions leak out on prolonged exposure to biological cells and fluids.
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The extract dilution assays on the gadonanotubes/PLGA nanocomposites also did not 
display any toxic effects on the cells and their response was similar with PLGA composite, 
which was used as control (Table 1). Consequently, the favorable cytocompatibility of the 
nanocomposites allowed their further consideration for in vitro and in vivo MRI studies.
4.2 MRI 
The r2 (578 mM
-1s-1) relaxivity exhibited by the gadonanotubes is among the highest 
reported value for contrast agents at 7T21 and should afford better T2 weighted 
contrast enhancement for MRI. This large T2 relaxation effect is possibly due to the 
gadonanotubes’ superparamagnetism14 and magnetic susceptibility of the carbon 
nanotubes.28 Nanotechnology-based approaches in the design of MRI CAs have 
demonstrated great potential for the development of the next generation high-performance 
CAs. Currently, superparamagnetic CAs are mainly based on iron oxide crystals and can 
be broadly categorized as ultra-small superparamagnetic iron oxide particles (USIO) 
(mean diameter less than ~50 nm) and superparamagnetic iron oxide particles (SPIO) 
(mean particle diameter greater than ~50nm).29 These CAs exhibit substantially larger 
T2 relaxivity compared with Gd chelates in current clinical use, typically by an order of 
magnitude or more.29 The superparamagnetic gadonanotubes have substantially larger 
T1 relaxivity compared with paramagnetic Gd chelates in current clinical use (170 mM-1s-1 
vs. 4.0 mM-1s-1).14 The r2 values for the gadonanotubes reported in this article are the first 
attempt to characterize their efficacy as T2 contrast agents. These results suggest that 
gadonanotubes are useful T1 positive CAs at lower 1.5T fields and T2 negative CAs at 
higher 7T fields.
The high T2 relaxivity values shown by the gadonanotubes 1% Pluronic F127 
suspensions were further corroborated by the preliminary in vivo MRI studies 
(Figure 6). It has to be noticed that the excellent negative contrast was obtained 
at a low [Gd] concentrations ([Gd]=0.15 mM). There was no noticeable change 
in the intensity of the dark spot at the different times points indicating that most 
of the injected gadonanotubes are still present in the vicinity of the injection site. 
The in vitro MRI studies on the gadonanotubes/PLGA nanocomposites were performed 
to optimize the final scaffolds and imaging parameters for the eventual in vivo studies. 
Enhanced contrast (yellow arrows in Figure 5b-f) was noticed at the initial time points 
at the edges of the water front and at the later time points (days 5 and 7) throughout 
the disc. This effect may be due to the water molecules being in close proximity to the 
gadonanotubes getting released upon degradation of PLGA polymer. The bright areas 
indicated by the red arrows (Figure 5b-f) are probably caused by either susceptibility 
artifacts due to the water to solid disc transition or by artifacts induced by the high 
90
Chapter 5
concentration of gadolinium in this area, which induces local susceptibility artifacts. The 
release of gadonanotubes from the PLGA surface involves a series of degradation stages 
involving hydradation, depolymerization, mass loss and absorption of the polymer products. 
Future MRI studies should provide more insight into the kinetics of these processes, along 
with the accompanying morphological changes.
Although MRI as a noninvasive imaging technique is widely used in medicine and is 
an established method for imaging food structure and manufacturing process, very few 
studies have explored their efficacy in the field of pharmaceuticals.30, 31 Most of these 
studies have used MRI to elucidate the internal structure and controlled release of 
pharmaceutical dosage forms,32-34 to follow the time course of pharmaceutical processes 
such as mixing and extrusion,35-37 to assess in vivo behavior of dosage forms,38-40 and to 
map the biodistribution of gadolinium marked-control delivery systems from hydrogels and 
biopolymer implants.40-42 These investigations have illustrated the tremendous potential of 
MRI to map the transport, behavior, and the physiological response to delivery systems 
ranging from oral and parenteral matrix device to colloidal carriers for drug targeting. 
Till now, no studies have been done dealing with mapping the biodegradation release 
and in vivo fate of reinforcing agents upon release from biodegradable polymers by 
MRI. Ideally, such a study should provide information about individual agents or a small 
cluster of agents upon their release from the polymer matrix. However, the agents by 
themselves will show very poor contrast unless tagged with contrast agents to enhance 
their imaging in vivo. It is quite possible that distribution of the agents will be in the 
nanomolar or picomolar range. At such a low concentration, gadolinium CAs in current 
clinical use do not possess sufficiently large relaxivities to generate sufficient contrast. 
Such molecular imaging applications require that each Gd3+ center possess an extremely 
large relaxivity in order to induce sufficient signal intensity. The exceptionally large T2 
relaxivities of the gadonanotubes should provide sufficient signal/noise, even if they are 
present in the nanomolar concentration range and permit detection of small cluster of 
gadonanotubes by MRI. Currently, studies are underway in our lab to monitor by MRI the 
in vivo biodegradation release and distribution of the gadonanotubes from gadonanotubes/
PLGA nanocomposites and histologically correlate this distribution.
5. Conclusion
This study demonstrated by using a LIVE/DEAD cytotoxicity assay that gadonanotubes 
at concentrations between 1–100 ppm and gadonanotubes/PLGA nanocomposites upto 2 
wt% are cytocompatible in vitro. For the first time r2 relaxivity measurements were obtained 
for the superparamagnetic gadonanotubes. In vitro 7T MRI of the superparamagnetic 
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gadonanotubes [0.15 mM] suspended in a biocompatible 1% Pluronic F127 solution gave 
a r2 value of 578 mM
-1s-1; and showed excellent T2-weighted contrast enhancement for 
the MRI phantom imaging. Subcutaneous injection of this gadonanotube suspension into 
the dorsal region of rats also resulted in an excellent and prolonged negative contrast 
enhancement. The in vitro MRI of nanocomposite and their degradation process 
also showed strong gadonanotube water interactions. The study indicates that the 
gadonanotubes-reinforced PLGA nanocomposites are suitable as tissue engineering 
scaffolds to simultaneously achieve excellent mechanical reinforcement as well as 
monitoring by MRI of the biodegradation release and biodistribution of gadonanotubes in 
vivo.
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1. Introduction
Bone defects still form a considerable problem in health care and thus research is focusing 
on the development of new, and improvement of existing, bone substitution materials. A 
wide variety of bone tissue engineering scaffolds and composite bone filler materials have 
been proposed, a number of which based on poly(lactic-co-glycolic acid) (PLGA). PLGA 
is approved by the Food and Drug Administration for human clinical use, is biocompatible, 
and is tunable in biodegradability depending on the ratio of lactic to glycolic acid.1, 2 A 
common drawback in the use of PLGA-based composites is the mismatch in mechanical 
properties, as compared to natural bone. Incorporation of single-walled carbon nanotubes 
(SWCNTs) can significantly enhance the mechanical, electrical and thermal characteristics 
of composite scaffolds as used in tissue engineering.3-5 On the other hand, many concerns 
about the biosafety of CNTs and other nanomaterials have arisen during the last few years.6-9 
Synthetic polymers, like PLGA, are broken down and systemically removed from the body, 
but CNTs are nondegradable and body foreign. Although many recent studies report on 
the interaction between CNTs and cells or tissues in in vitro and in vivo situations, thus far 
the fate of CNTs after release from a degrading composite in vivo is largely unknown. This 
is mainly due to the limitations in conventional histological and microscopical techniques 
in observing the extremely small CNTs, unless they are aggregated. However, in vivo 
Raman spectroscopy,10 radio labeling of the CNTs,11-13 or gadolinium-labeled CNTs, so-
called gadonanotubes,14-16 can overcome this technical limitation. Chelates of gadolinium 
are widely used as contrast agents in biomedical magnetic resonance imaging (MRI). 
As the T1 and T2 relaxivity of gadolinium trapped in the CNTs is much larger than that 
of gadolinium in these chelates,15 the labeled CNTs can be used as contrast agents in 
MRI. Therefore, the aim of this study was to examine whether MRI of gadonanotubes is a 
suitable technique for CNT tracking in vivo and the second aim of the study was to examine 
the distribution pattern of gadonanotubes after release from a degrading PLGA scaffold. 
To achieve this, low-molecular weight PLGA scaffolds incorporated with gadonanotubes 
were produced and subcutaneously implanted in rats. Since this polymer is known to 
degrade almost completely in 40 days,17 we hypothesized that it is possible to monitor CNT 
release for a period up to 5 weeks with MRI. 
2. Materials and methods
2.1 Synthesis of gadonanotubes
SWCNTs (Sigma Aldrich, St. Louis, USA) were cut into ultra short (US) tubes by a chemical 
cutting method.18 Briefly, SWCNTs were fluorinated for 2 h at 50°C under 1% gaseous 
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fluoride diluted in helium. This step was followed by pyrolysis at 1000 ºC for 1 h under an 
inert atmosphere what lead to spontaneous cutting of the micron-long SWCNT into US-
SWCNTs. Besides cutting the tubes, this method also purified the US-tubes. In the next 
step, the US-tubes were filled with Gadolinium (Gd3+) by a solution-phase filling protocol.14 
This method involved stirring of the US-tubes with anhydrous GdCl3 (Sigma Aldrich) 
(1:1 ratio by weight) in deionized high-performance liquid chromatography grade water, 
followed by sonication for 1 h. Then, the solution was left undisturbed overnight upon 
the Gd3+-loaded US-tubes flocculated from the solution. The supernatant was decanted 
off and next the sample was washed with fresh deionized high-performance liquid 
chromatography grade water and batch sonicated to remove any unabsorbed GdCl3. This 
flocculation and washing procedure was repeated three times. The sample was then air-
dried and an inductively coupled plasma spectrometry analysis was performed to obtain 
the Gd3+ content. Finally, the filled US-tubes were thermally annealed to seal the carbon 
nanotube ends, thereby preventing leakage of the encapsulated Gd3+.
2.2 Preparation of gadonanotubes incorporated PLGA scaffolds
Disc-shaped scaffolds were prepared by dispersing 2 wt% gadonanotubes in low-molecular 
weight (average molecular mass of 5 kDa) PLGA (50:50 lactic-to glycolic-acid copolymer; 
Sigma Aldrich) polymer using an established procedure.3 Briefly, gadonanotubes were 
dispersed in chloroform by high shear mixing for 5 min and sonication for 15 min and 
then added into a PLGA/chloroform solution. This procedure was followed by 15 min of 
sonication, rotary evaporation, and vacuum drying. Finally, the composite material was 
cast into molds that produced solid discs of 6 mm in diameter and 1 mm in height. Besides 
the composite scaffolds, also one plain PLGA scaffold was produced by the same process 
to serve as a reference sample to asses for artifacts. The discs were sterilized by ultraviolet 
(UV) irradiation for 2 h.
2.3 In vitro phantom MR study
A concentration series of gadonanotubes ranging from 0.0002 to 20 wt% dispersed in 
agar were prepared in eppendorf tubes. Subsequently, spin echo MR measurements were 
performed with varying repetition time (TR) or echo time (TE) to characterize the MR 
relaxation behavior of the gadonanotubes at different concentrations. Applied parameters 
for these images were a TR ranging from 50 to 5000 ms with a fixed TE of 13 ms, and 
a TE ranging from 13 to 200 ms with a fixed TR of 2000 ms. From these images the 
signal intensities of all samples were measured using software on the MRI scanner-Image 
Display (MR Solutions Ltd., Surrey, UK). Here, a region of interest (ROI) was drawn in 
which the intensity was measured. 
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From these data, signal intensity-time curves were plotted and T1 and T2 values were 
calculated by fitting the curves using the following formulas:
Mt = M0 [1 – e(-(Ta + Tau)/T1)] and Mt = M0 x e
-TE/T2
In which: Mt= nuclear spin magnetization at time = t
M0= nuclear spin magnetization t=0
Ta= aquisition time
Tau = delay time between two excitation pulses minus Ta  (varied)
T1 = spin-lattice relaxation time
TE = echo time (varied)
T2 = spin-spin relaxation time
2.4 In vivo MRI
Essentially, a similar experimental approach was used as described previously for 
dispersed gadonanotubes.15 In the current study, six male Wistar rats, weighing ~250 g, 
were used. National guidelines for the care and use of laboratory animals were observed 
and the study was performed under Ethics Committee number DEC-2007-096. Five rats 
received a PLGA/gadonanotubes scaffold subcutaneously and the sixth rat received 
the plain reference PLGA scaffold. For this purpose, the rats were placed under general 
anesthesia (isoflurane/O2, N2O) and the dorsal skin was shaved, washed and disinfected 
with iodine. One full-thickness longitudinal incision of 1 cm was made through the skin on 
the right side of the spine. Subcutaneous pockets were created by blunt dissection with 
scissors and a PLGA/gadonanotube or PLGA scaffold was inserted. Finally, the wound 
was closed. All rats were analyzed on day 1 after implant placement. Although, MRI did 
not allow to analyze all animals simultaneously. Still, each rat was regularly measured at 
intervals of ~1 week (± 2 days) up to 5 weeks.
For each MR examination, the rats were placed in a custom build probe on top of a 
radiofrequency microstrip coil,19 consisting of a copper strip taped onto a 7-mm thick Teflon 
layer. The probe with the rat was then placed inside a 7-Tesla MR magnet (Magnex), with 
a horizontal bore of 200 mm, which was interfaced to a spectrometer (SMIS, MR Solutions 
Ltd.). Then, T1 weighted coronal multi-slice MR images (14 in total) with an image matrix 
size of 256x256 and a slice thickness of 1 mm were obtained. A TE of 15 ms was used, 
while the TR was about 1500 ms. The exact time was set by triggering the imaging on the 
breathing of the rats, which was, by inhalation anesthesia, ~38-44/min. From the images 
obtained in this way, signal intensities were measured in a ROI and in an internal control 
region in muscle tissue. After the final MRI measurement the animals were euthanized and 
the scaffolds with surrounding tissue were harvested and examined histologically.
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2.5 Histological analysis
The retrieved scaffolds with their surrounding tissue were fixed in 10% formalin, dehydrated 
in a series of ethanol and embedded in polymethylmethacrylate. Polymerization sections 
of 10 μm in thickness were prepared using a modified diamond-blade sawing microtome 
technique (Leica Microsystems GmbH, Wetzlar, Germany), stained with methylene blue 
and hematoxylin-eosin and examined with a light microscope (Leica Microsystems B.V., 
Rijswijk, the Netherlands).20 
2.6 Statistical analysis
All intensity measurements were performed in duplicate on a total of five rats. For statistical 
analysis the ratio of the ROI vs. the internal control region was calculated (n=5 for both 
groups). The mean of this data was used in an unpaired two-tailed t-test comparing to a 
hypothetical mean of 1.0. Data were tested on a normal distribution and a p-value of 0.05 
or less was considered to indicate significance. Calculations were performed in InStat 
software (v 3.05 Graphpad, Inc).
3. Results
3.1 In vitro phantom MR study
Series of images with different TR and TE were acquired from a range of dilutions of 
gadonanotubes dispersed in agar to obtain T1 and T2 values as a function of the 
concentrations of gadonanotubes. For each concentration signal intensity curve (Figure 
1), T1 and T2 values were generated (Table 1). These results indicate that, with the 
acquisition parameters used in the in vivo MRI of the study, very high concentrations of 
gadonanotubes will result in a negative contrast (T2 weighted), while low concentrations 
(less than about 2 wt%) will result in a positive contrast (T1 weighted). 
Table 1: T1 and T2 values and their standard deviations for a concentration series of gadonanotubes 
dispersed in agar are given in milliseconds. 
T1 (ms) SD (ms) T2 (ms) SD (ms)
0.0002 wt% 2789 94.53 102 2.40
0.002 wt% 2981 102.2 88.2 2.54
0.02 wt% 2570 83.49 84.3 2.16
2 wt% 1150 33.79 42.4 1.24
20 wt% 244.9 6.883 10.7 0.491
Values were calculated from the signal intensity – time curves. SD, standard deviation; T1, spin-lattice 
relaxation time; T2, spin-spin relaxation time.
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Figure 1: Signal intensity–TE and TR curves for a concentration series of gadonanotubes dispersed in 
agar. For the T1 curve a fixed TE of 13 ms was used (A) and for the T2 curve a fixed TR of 2000 ms 
was used (B). The intensity was determined in AU. TE, echo time; TR, repetition time; AU, arbitrary 
units (AU); T1, spin-lattice relaxation time; T2, spin-spin relaxation time.
3.2 In vivo MR imaging
All rats were analyzed at intervals of ~1 week (± 2 days) up to 5 weeks. MR images 
were created from the signals of water protons. In Figure 2, MR images of a rat with 
a PLGA/gadonanotube scaffold and of a reference rat with a plain PLGA scaffold are 
depicted. Images were made in the coronal plane of the rats; the spine of the rats appears 
slightly curved, due to small differences in positioning of the rats. With MRI at TR of 1500 
ms and TE of 15 ms, tissues are visible in gray tones, while the water-impermeable 
scaffolds appear as black disks due to the solid structure of the disks compared to tissue.
103
Chapter 6
Figure 2: Coronal magnetic resonance 
images of a rat that received a PLGA/
gadonanotubes scaffold (A, C, E) and of 
a rat that received a plain PLGA scaffold 
(B, D, F). Images show the rats from the 
start (A, B), 3 weeks (C, D) and end of 
the experiment (E, F). The head, tail, right 
side and left side of the rats are marked 
by *, #, R and L, respectively. The scaffold 
is marked in all images by a red outline. 
Susceptibility artifacts are visible around 
the scaffolds and are indicated with red 
arrows. An area with increased contrast 
due to the release of gadonanotubes from 
the degrading PLGA scaffold is indicated 
by a white outline (C). PLGA, poly(lactic-
co-glycolic acid).
Figure 3: The average ratio of the sample 
values and their internal control values in 
the time intervals for a total of five rats. * 
The average ratio is significantly increased 
around three weeks compared to a mean of 
1.0 (p≤0.05).
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In time, the size of the scaffolds decreased, as well as the negative contrast of the disk, 
due to the degradation and water uptake of the polymeric scaffolds. Around the scaffolds 
several bright spots were visible, considered susceptibility artifacts caused by the water to 
solid hydrophobic scaffold transition. These have no relation to the amount of gadolinium 
at the site, since the reference rat that received the pure PLGA scaffold showed the same 
artifacts. The MR images suggested that the scaffolds adapted a bent shape, starting after 
~1 week. In the five rats that received a PLGA/gadonanotubes scaffold, the signal intensity 
of the scaffold surrounding tissue significantly increased (T1 weighted), compared to the 
control areas, around week 3 (Figure 3). This indicates the release of gadonanotubes 
from the degrading scaffold into the surrounding tissue. A week later, the first elevated 
signal intensity was declined again to its original value. However, no increase in MR signal 
intensity was observed in body organs (like kidney, brain or liver), not even when the rats 
were repositioned over the radiofrequency coil to obtain more optimal images of these 
sites. 
3.3 Histological analysis
PLGA/gadonanotube scaffolds were retrieved without complications. Upon visual 
inspection, all scaffolds displayed heavy degradation, but maintained their shape (Figure 
4). No reference PLGA scaffold could be explanted, as this scaffold was undetectable after 
5 weeks, due to complete degradation. As a consequence, histological comparison of the 
tissue response between PLGA/gadonanotubes scaffolds and pure PLGA scaffolds was 
not possible. 
The light microscopical examination of the PLGA/gadonanotubes scaffold sections showed 
encapsulation of all scaffolds by a vascularized connective fibrous tissue capsule of ~20 
cell layers in thickness. The capsule tissue was fibrous but immature, as characterized 
by the presence of many fibroblasts, inflammatory cells, newly formed blood vessels, and 
little collagen. There was no apparent difference in thickness or vascularization of the 
fibrous tissue between the different explanted scaffolds. Within the scaffold material, some 
aggregated gadonanotubes were visible as black spots. Due to degradation, the scaffolds 
were fragmented and each fragment was separately encapsulated by fibrous tissue. The 
interstitium in between these fragments showed ingrowth of immature fibrous tissue as 
well. At the capsule-scaffold interface scattered foci of inflammatory cells were present. 
However, no giant cells, correlated to a foreign body giant response, were observed. 
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Figure 4: A) Histological cross section of a PLGA/gadonanotubes scaffold with surrounding tissue, 
magnified 2.5x. The section is stained with methylene blue and basic fuchsine. The black parts 
represent the scaffold material, which is fragmented. Some parts of the scaffold, indicated by the 
white arrows, are further degraded and therefore lighter in color. B) Histological cross section with 
a magnification of 10x. Each fragment of the scaffold material is individually surrounded by purple 
stained fibrous tissue. Most inflammatory tissue is located near the scaffold surface as indicated by 
the white arrow. C) Histological cross section with a 40x magnification. The black parts as well as 
the further degraded grey parts represent the scaffold material. The fibrous tissue surrounding the 
scaffold material parts is visible as the blue/purple stained tissue. Some of the cells from the tissue 
infiltrate the further degraded parts of the scaffold material as indicated by the white arrow.
4. Discussion
The aim of this study was to examine the distribution pattern of CNTs in an in vivo 
situation after release from a degrading scaffold by the means of MRI. As described 
before, gadonanotubes function as an excellent contrast agent for MRI in in vitro and 
in vivo applications, even at very low gadolinium concentrations.14-16 Based on in vitro 
testing, it is assumed that the gadolinium inside the gadonanotubes remains stable under 
physiological conditions.21 In a previous study, subcutaneously injecting a gadonanotubes 
solution (10 μl containing 3x105 mmol gadolinium) in rats, showed a negative contrast on 
the MR image as a result of high T2 relaxivity values. The injected solution was shown 
to be maintained in the vicinity of the injection site, but this was only assessed up to 24 
hours.15
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The current study demonstrates that CNTs are released from a degrading PLGA scaffold 
into the surrounding tissue, and demonstrates the possibility to monitor this process by 
MRI. An increase in signal intensity in the tissue surrounding the scaffold was observed 
around week 3. This increase disappeared soon thereafter. These observations are 
evidently the result of released gadonanotubes from the degrading PLGA scaffold. In 
contrast to the previously described in vivo study, where the rats received an injection 
with gadonanotubes, the monitored signal increased.15 This difference in signal evoked 
by the gadonanotubes is clearly explained by the in vitro phantom study results, that is, 
high concentrations of gadolinium result in a strong T2 effect on imaging, giving a negative 
contrast, whereas lower concentrations result in a T1 effect, giving a positive contrast. 
Comparison of the signal intensity of the measured rats that displayed an increase in 
signal intensity with the in vitro T1 and T2 measurements indicated that the concentration 
of gadonanotubes that is present in the tissue is very low. A more quantitative assessment 
of the gadonanotube level would require the in vivo measurement of T1 and T2.  
Although we aimed to follow the fate of the released CNTs, no changes in MR signal intensity 
were found in organs where the gadonanotubes might possibly aggregate, like kidneys, 
brain, spleen, and liver. However, this is not necessarily indicating that the gadonanotubes 
are systematically cleared from the body. It is still possible that very low quantities of 
gadonanotubes below the detection limits of the MR measurement have been present. It 
is too soon to claim that no CNTs aggregate in any of the organs, the experimental setup 
has to be optimized (by higher dosage, higher field strength, and/or dedicated coils) to 
make valid statements for this research question. Since our composite was developed for 
hard tissue regeneration it would be of great interest to asses different (bone) implantation 
sites. With the acquired knowledge from this study, in future studies it would be beneficial 
to increase the number of measurements, especially around the release period of week 
3, for instance, with other dedicated nano detection techniques such as high-resolution 
transmission electron microscopy. Moreover, it has been reported that carbon nanotubes 
present in blood are cleared quickly from the body trough the urinal and fecal excretion.12, 
13 Therefore, as an interesting positive control group a renal deficient model like the model 
described by Jost et al. could give some valuable new insights.22 In this model, renally 
impaired rats (ZSF1 rats) were used to determine the kidney retention of different contrast 
media. ZSF1 rats have a three- to eightfold decrease in creatinine clearance compared 
to commonly used rat lines like SHHF, SHR, and WKY. This model would be ideal as a 
positive control to observe agglomeration of the gadonanotubes and it also provides a 
possibility to examine potential kidney damage caused by retention of the nanotubes. 
In our histological evaluation degradation of the composite scaffolds could not be compared 
to the plain PLGA scaffold, as its retrieval was impossible due to complete degradation at
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the time of explantation. This was unexpected, although a fast degradation of the scaffolds 
was desired. Specifically a low-molecular weight PLGA was selected, known to degrade 
almost completely in 40 days. The degradation of such PLGA depends on many 
factors, like pH, degree of swelling, ionic strength, ion concentration, temperature, 
and buffering capacity.17, 23, 24 These factors cannot be completely controlled in an in 
vivo study and inter-animal differences will always occur. Besides these factors, the 
applied UV sterilization treatment is also known to reduce polymer chain length, thus 
increasing the degradation rate of PLGA. One hour of UV radiation was shown to 
already affect the degradation of PLGA nanofiber scaffolds.25 In our study all CNT 
containing scaffolds could be retrieved, although often fragmented. The difference in 
degradation of both scaffold types was unexpected and suggests a slowing effect of 
the incorporated gadonanotubes on the degradation rate. Unfortunately, no definite 
explanation can be given, as no material with a comparable composition has been 
described before. Also, literature is not consistent on the influence of CNTs on the 
degradation rate of polymeric scaffolds. One study reported an increase in degradation 
rate after the incorporation of multiwalled carbon nanotubes in poly(L-lactic acid),26 
whereas two other studies reported no effects of incorporated nonfunctionalized 
SWCNTs in poly(propylene fumarate) (PPF) and PLGA scaffolds, respectively, on the 
degradation rate.27, 28
Another technical note is that the MR images suggested that the scaffolds adapt to a 
bent shape in time. In contrast, explantation of the scaffolds showed that the scaffolds 
were not bent. The apparent folding in the MR images was probably caused by an 
irregular uptake of water in the scaffold as a result of which some of the areas of the 
scaffold were brighter than others in combination with some susceptibility effects. This 
implies that this experimental setup is not applicable to measure the effects of the 
gadonanotubes within the scaffold; however, this was not the intended goal of this 
study. 
Histological analysis showed the scaffolds to be surrounded by fibrous tissue, which 
is a natural occurrence after subcutaneous implantation of foreign body materials.29 
As described before, no comparison between the PLGA/gadonanotube scaffolds and 
the reference plain PLGA scaffold was possible due to complete degradation of the 
control. Therefore, it is recommended for future research to bring the histological 
analysis time point forward and also to expand it with a few time points around 3 weeks, 
as it is known now that the release occurs around week 3. In addition, histological 
examination of organs like the kidneys, brain, spleen and liver at the 3-week time point 
might prove to be valuable. 
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Detailed examination of the light microscopical sections showed the presence of foci 
of inflammatory cells at the scaffold-fibrous capsule interface, which were evidently 
attracted to remove the degradation products of the PLGA and possibly to remove 
the CNTs. However, no severe inflammatory reaction with the formation of giant 
multinucleated cells was observed with these quantities of PLGA and gadonanotubes. 
When comparing our data to earlier studies, designed to obtain information on the 
distribution of CNTs in vivo, the results are still debatable. Two approaches, with radiolabeled 
SWCNTs or multiwalled CNTs injected either intravenously or intraperitoneally in rats or 
mice, reported rapid clearance rates within 24 h of the CNTs through the renal excretion 
route, without significant retention in any of the secondary organs, like liver or spleen after 
24 h.12, 13 This would corroborate our current findings. However, another study reported 
injected iodine-125 labeled SWCNTs in mice to be distributed throughout the whole body 
(except the brain) and to accumulate in bone.11 It has to be emphasized that in these 
CNT distribution studies, body exposure to and transportation of CNTs was significantly 
enhanced compared to the current study, due to direct injection into the bloodstream or 
peritoneal cavity.
Before the first distribution studies even started many toxicity studies were already 
performed and toxicity in the pulmonary area and bloodstream was reported.8, 30-32 However, 
thorough purification of toxic residual metal catalysts33-35 as well as functionalization of the 
CNTs6, 8, 36 diminished toxicity to a great extent and thus it remains unclear up to what 
level such early information is still dependable. Additionally, in all these studies high 
concentrations of CNTs were used. In contrast, a recent rabbit implantation study with 
degradable PPF scaffolds containing US-SWCNTs reported a significant improvement in 
bone-healing capacity of the PPF/US-SWCNT composite, without any toxic effect of the 
released US-SWCNTs. Taking these reports into consideration, there is still a high interest 
in CNT application in tissue engineering constructs. Therefore, the further development of 
proper analysis techniques is still desirable.
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5. Conclusions
We conclude that MRI detection forms an excellent tool to follow the release of 
gadolinium-labeled nanoparticles from scaffold materials. On basis of our preliminary 
results, gadonanotubes were released from degrading PLGA scaffolds into the scaffold 
surrounding tissue around 3 weeks, followed by a rapid clearance from the site. However, 
the experimental setup requires optimization before more detailed conclusions on the 
final biological fate of gadonanotubes can be made. Such an effort will be essential 
before further explorations of CNTs in biomaterial and tissue engineering science can be 
considered.
110
Chapter 6
7. References
1.	 Li WJ, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. Electrospun nanofibrous structure: a 
novel scaffold for tissue engineering. J Biomed Mater Res. 2002; 60(4):613-621.
2. Smith LA, Ma PX. Nano-fibrous scaffolds for tissue engineering. Colloids Surf B 
Biointerfaces. 2004; 39(3):125-131.
3. Shi XF, Hudson JL, Spicer PP, Tour JM, Krishnamoorti R, Mikos AG. Rheological behaviour 
and mechanical characterization of injectable poly(propylenefumarate)/single-walled carbon 
nanotube composites for bone tissue engineering. Nanotechnology. 2005; 16(16):521-538.
4. Wang W, Watari F, Omori M, Liao S, Zhu Y, Yokoyama A, Uo M, Kimura H, Ohkubo A. 
Mechanical properties and biological behavior of carbon nanotube/polycarbosilane 
composites for implant materials. J Biomed Mater Res B Appl Biomater. 2007; 82(1):223-
230.
5. Abarrategi A, Gutierrez MC, Moreno-Vicente C, Hortiguela MJ, Ramos V, Lopez-Lacomba 
JL, Ferrer ML, del Monte F. Multiwall carbon nanotube scaffolds for tissue engineering 
purposes. Biomaterials. 2008; 29(1):94-102.
6. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines: II. 
Drug delivery and biocompatibility issues. Nanomedicine. 2008; 4(3):183-200.
7. Kipen HM, Laskin DL. Smaller is not always better: nanotechnology yields nanotoxicology. 
Am J Physiol Lung Cell Mol Physiol. 2005; 289(5):696-697.
8. Helland A, Wick P, Koehler A, Schmid K, Som C. Reviewing the environmental and human 
health knowledge base of carbon nanotubes. Cien Saude Colet. 2008; 13(2):441-452.
9. Kagan VE, Bayir H, Shvedova AA. Nanomedicine and nanotoxicology: two sides of the 
same coin. Nanomedicine. 2005; 1(4):313-316.
10. Biris AS, Galanzha EI, Li Z, Mahmood M, Xu Y, Zharov VP. In vivo Raman flow cytometry 
for real-time detection of carbon nanotube kinetics in lymph, blood, and tissues. J Biomed 
Opt. 2009; 14(2):021006.
11. Wang H, Wang J, Deng X, Sun H, Shi Z, Gu Z, Liu Y, Zhao Y. Biodistribution of carbon 
single-wall carbon nanotubes in mice. J Nanosci Nanotechnol. 2004; 4(8):1019-1024.
12. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, Bianco A, Kostarelos 
K. Tissue biodistribution and blood clearance rates of intravenously administered carbon 
nanotube radiotracers. Proc Natl Acad Sci U S A. 2006; 103(9):3357-3362.
13. Guo J, Zhang X, Li Q, Li W. Biodistribution of functionalized multiwall carbon nanotubes in 
mice. Nucl Med Biol. 2007; 34(5):579-583.
14. Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance MRI contrast agents. 
Int J Nanomedicine. 2006; 1(3):291-295.
15. Sitharaman B, Van Der Zande M, Ananta JS, Shi X, Veltien A, Walboomers XF, Wilson 
LJ, Mikos AG, Heerschap A, Jansen JA. Magnetic resonance imaging studies on 
gadonanotube-reinforced biodegradable polymer nanocomposites. J Biomed Mater Res A. 
2009; 93A(4):1454-1462.
16. Sitharaman B, Tran LA, Pham QP, Bolskar RD, Muthupillai R, Flamm SD, Mikos AG, Wilson 
LJ. Gadofullerenes as nanoscale magnetic labels for cellular MRI. Contrast Media Mol 
Imaging. 2007; 2(3):139-146.
17. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv Drug Deliv Rev. 1997; 28(1):5-24.
18. Gu Z, Peng H, Hauge RH, Smalley RE, Margrave JL. Cutting single-wall carbon nanotubes 
through fluorination. Nano Lett. 2002; 2(9):1009-1013.
19. Gambarota G, Veltien A, van Laarhoven H, Philippens M, Jonker A, Mook OR, Frederiks 
WM, Heerschap A. Measurements of T1 and T2 relaxation times of colon cancer metastases 
in rat liver at 7 T. MAGMA. 2004; 17(3-6):281-287.
111
Chapter 6
20. van der Lubbe HB, Klein CP, de Groot K. A simple method for preparing thin (10 microM) 
histological sections of undecalcified plastic embedded bone with implants. Stain Technol. 
1988; 63(3):171-176.
21. Hartman KB, Laus S, Bolskar RD, Muthupillai R, Helm L, Toth E, Merbach AE, Wilson LJ. 
Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano 
Lett. 2008; 8(2):415-419.
22. Jost G, Pietsch H, Sommer J, Sandner P, Lengsfeld P, Seidensticker P, Lehr S, Hutter 
J, Sieber MA. Retention of iodine and expression of biomarkers for renal damage in the 
kidney after application of iodinated contrast media in rats. Invest Radiol. 2009; 44(2):114-
123.
23. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 1996; 
17(2):103-114.
24. Vert M, Mauduit J, Li S. Biodegradation of PLA/GA polymers: increasing complexity. 
Biomaterials. 1994; 15(15):1209-1213.
25. Yixiang D, Yong T, Liao S, Chan CK, Ramakrishna S. Degradation of electrospun nanofiber 
scaffold by short wave length ultraviolet radiation treatment and its potential applications in 
tissue engineering. Tissue Eng Part A. 2008; 14(8):1321-1329.
26. Zhao Y, Qiu Z, Yang W. Effect of functionalization of multiwalled nanotubes on the 
crystallization and hydrolytic degradation of biodegradable poly(L-lactide). J Phys Chem B. 
2008; 112(51):16461-16468.
27. Sitharaman B, Shi X, Walboomers XF, Liao H, Cuijpers V, Wilson LJ, Mikos AG, Jansen JA. 
In vivo biocompatibility of ultra-short single-walled carbon nanotube/biodegradable polymer 
nanocomposites for bone tissue engineering. Bone. 2008; 43(2):362-370.
28. Armentano I, Dottori M, Puglia D, Kenny JM. Effects of carbon nanotubes (CNTs) on the 
processing and in-vitro degradation of poly(DL-lactide-co-glycolide)/CNT films. J Mater Sci 
Mater Med. 2008; 19(6):2377-2387.
29. Link DP, van den Dolder J, van den Beucken JJ, Cuijpers VM, Wolke JG, Mikos AG, Jansen 
JA. Evaluation of the biocompatibility of calcium phosphate cement/PLGA microparticle 
composites. J Biomed Mater Res A. 2008; 87(3):760-769.
30. Grubek-Jaworska H, Nejman P, Czuminska K, Przybylowski T, Huczko A, Lange H, 
Bystrzejewski M, Baranowski P, Chazan R. Preliminary results on the pathogenic effects of 
intratracheal exposure to one-dimensional nanocarbons. Carbon. 2006; 44(6):1057-1063.
31. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. Comparative 
pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci. 2004; 
77(1):117-125.
32. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, Radomski 
MW. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 
2005; 146(6):882-893.
33. Cui D, Tian F, Ozkan CS, Wang M, Gao H. Effect of single wall carbon nanotubes on human 
HEK293 cells. Toxicol Lett. 2005; 155(1):73-85.
34. Ding L, Stilwell J, Zhang T, Elboudwarej O, Jiang H, Selegue JP, Cooke PA, Gray JW, Chen 
FF. Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes 
and nano-onions on human skin fibroblast. Nano Lett. 2005; 5(12):2448-2464.
35. Pulskamp K, Diabate S, Krug HF. Carbon nanotubes show no sign of acute toxicity but 
induce intracellular reactive oxygen species in dependence on contaminants. Toxicol Lett. 
2007; 168(1):58-74.
36. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, Moore VC, Doyle CD, West 
JL, Billups WE, Ausman KD, Colvin VL. Functionalization density dependence of single-
walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett. 2006; 161(2):135-142.

Meike van der Zande, X. Frank Walboomers, Matthias 
Brännvall, Beatriz Olalde, Mariaje J. Jurado, 
J. Iñaki Álava, John A. Jansen
Acta Biomater. 2010; 6(11):4352-60
7
Genetic profiling of osteoblast-like cells cultured on a 
novel bone reconstructive material, consisting of 
poly-L-lactide, carbon nanotubes and 
microhydroxyapatite, in the presence 
of bone morphogenetic protein-2
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1. Introduction
Several new nanomaterials are finding their way into the field of bone tissue engineering, 
including carbon nanotubes (CNTs). CNTs have been shown to improve the mechanical 
and conductive characteristics of polymeric graft materials, with their unique electrical, 
mechanical, optical, thermal and magnetic properties. They are also proposed to increase 
osteoblast proliferation.1-4 In line with these results, several polymeric composites 
supplemented with CNTs have been developed in the field of bone tissue engineering.5-7 
One of these studies also proved that the material shows good qualities as a bone 
substitute in vivo.8 
Despite these promising reports, the biosafety of CNTs is a matter of great discussion. 
Toxicity studies with a negative outcome have been reported, however, these studies mainly 
focused on administration of highly concentrated pure CNTs through the transdermal, 
transmucosal or inhalational routes.9-14 Since there are only a few in vivo studies describing 
the effects of CNT-supplemented biomaterials, there is little knowledge on this topic. 
Therefore, one of the aims of this study was to gain more insight in the possible adverse 
effects of CNTs incorporated into a porous poly-L-lactic acid (PLLA) scaffold on osteoblast-
like cells by genetic profiling. The other aim of the study was to examine the osteogenic 
capacity of this novel composite material, in vitro. Consequently, microhydroxyapatite 
(µHA) was also incorporated into the scaffold, to enhance its osteophilicity,15, 16 and bone 
morphogenetic protein-2 was applied to induce osteoinductivity in the scaffold.17-21 Rat 
bone marrow cells, directed into an osteoblastic lineage, were seeded onto the scaffolds, 
and genetic profiling, scanning electron microscopy (SEM) and DNA- and alkaline 
phosphatase (ALP) assays were used for analysis. 
Increases in osteoblast proliferation and the expression of related genes were hypothesized 
for the scaffolds containing CNTs and μHA, and increases in osteoblast differentiation and 
the expression of related genes were hypothesized for the scaffolds with applied BMP-2. 
The scaffolds containing all three supplements were thought to show a greater (additive) 
effect on cell differentiation and greater expression of genes related to bone formation 
than scaffolds containing BMP-2 alone.
2. Materials and methods
2.1 Scaffold fabrication, characterization, preparation and loading with BMP-2
Previous studies reported that incorporating CNTs in polymeric scaffolds increases the 
compressive modulus of the material.5, 6 Therefore, porous disk-shaped PLLA substrates 
containing 1 wt% single-walled CNTs and 1 wt% µHA powder were made by a liquid-liquid 
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phase separation technique (TIPS). Chemical vapor deposition-produced CNTs with 
diameters of ~2 nm and lengths of several microns (Thomas Swan & Co.Ltd., Consett, 
UK) were used.  The purity of the CNTs was >70%, with a maximum metal oxide content 
of 5 wt%. To produce the substrates, 0.08% (w/v) CNTs and 0.08% (w/v) μHA powder 
(Plasma Biotal, Tideswell, Derbyshire, UK), with a mean particle size of 5 μm, were 
dispersed in a 87/13 (v/v) mixture of 1,4-dioxane (Sigma Aldrich, St. Louis, Missouri, USA) 
and distilled deionized water by sonication for 15 min. Subsequently, 8% (w/v) PLLA, with 
an average molecular weight of 104 kDa (Absorbable Polymer Technologies, Pelham, 
Alabama, USA), was dissolved in the CNT/μHA suspension at a temperature above the 
cloud point (ca. 63 ºC). The homogeneous dispersion was fast-frozen at -16 ºC overnight, 
after which solvents were removed by freeze-drying for 6 days. Cylindrical scaffolds with a 
diameter of 10 mm and a height of 15 mm, and disk shaped scaffolds of 6 mm in diameter 
with a thickness of 1 mm were prepared (further regarded as the composite scaffolds). 
The same process, but without the addition of the CNTs and μHA powder was used for the 
fabrication of plain PLLA control scaffolds.
The internal pore structure, morphology and porosity of the materials were characterized 
by SEM (JEOL JSM-5910 LV, Tokyo, Japan) on fracture-frozen cross-sections of the 
scaffolds and mercury intrusion porosimetry (Autopore 9220, Micromeritics Co. Norcross, 
Georgia, USA.). The glass transition temperature (Tg) was determined by differential 
scanning calorimetry and the Young’s modulus and maximum stress of the materials were 
determined by compression of the cylindrical samples to 10% at a crosshead speed of 20 
mm/min with an Instron 5500R mechanical tester (Instron Co., Norwood, MA, USA). The 
compressive modulus was defined as the initial linear modulus. 
All substrates were pre-incubated in 70% ethanol for 1 h, in PBS with 1% gentamycin/
fungizone (Gibco BRL, Life Technologies B.V. Breda, The Netherlands) for 2 h and in alpha 
Minimal Essential Medium (α-MEM; Gibco) with 10% fetal calf serum (FCS; Gibco) for 2 
h. Then, aliquots containing 100 ng BMP-2 (R&D Systems, Inc., Minneapolis, Minnesota, 
USA) were pipetted onto the substrates and subsequently lyophilized overnight.
2.2 Isolation and cell culture
Rat bone marrow (RBM) cells were isolated and cultured as described by Maniatopoulos 
et al..22 Briefly, RBM cells were obtained from femora of 40- to 43-day-old male Wistar 
rats. National guidelines for the care and use of laboratory animals were observed and 
the study was performed under Ethical Committee number DEC 2004156. Femora 
were washed in α-MEM with 0.5 mg/ml gentamycin and 3 μg/ml fungizone. Epiphyses 
were cut off and diaphyses were flushed with osteogenic culture medium (α-MEM 
supplemented with 10% fetal calf serum, 50 μg/ml gentamycin (all from Gibco), 
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50 μg/ml ascorbic acid, 10 mM Na-β-glycerophosphate and 10-8M dexamethasone (all from 
Sigma, Chemical Co., St. Louis, MO)). Subsequently, the RBM cells were incubated in a 
humidified atmosphere at 37 °C. The following day, the medium was refreshed to remove 
all non-adherent cells. After 7 days of primary culture, sub-confluent cells were detached 
using trypsin/EDTA (0.25% (w/v) trypsin/0.02% EDTA), concentrated and resuspended in 
osteogenic medium. Finally, the cells were seeded onto the substrates by placement of four 
substrates per milliliter cell suspension (6x105 cells/ml) for 4 h under continuous shaking 
on a rotating table to allow an even attachment of the cells. Thereafter, the scaffolds were 
incubated at 37 °C. 
All samples for each condition used for DNA, ALP and SEM analysis were present in 
triplicate, and the entire experiment was performed twice. For the genetic analysis, seven 
scaffolds of each condition were pooled to obtain adequate amounts of RNA. Here, too, 
measurements were always based on triplicate samples.
2.3 Total DNA analysis
After 1, 9 and 16 days of culture, the DNA content was determined in order to obtain 
information about cellular proliferation. The scaffolds were washed with PBS and the 
subsequent addition of 1 ml MilliQ deionised water to each scaffold, followed by 10 min 
sonication to lyse the cells. The scaffolds with MilliQ were stored at –20 °C. After thawing, 
the samples were centrifuged to remove the debris of the scaffolds and the supernatant was 
used in a PicoGreen dsDNA Quantation Kit (Molecular Probes, Leiden, The Netherlands). 
Briefly, 100 μl sample was added to 100 μl picogreen working solution in a 96-well plate and 
a standard curve was made. After 5 min incubation in the dark, the plate was read at 480 nm. 
The amount of DNA was determined based on the standard curve.
2.4 Alkaline phosphatase activity
The ALP activity was measured after 1, 9 and 16 days with the same samples as used for 
the DNA-content assay. For the ALP assay, 80 μl sample and 20 μl buffer (5 mM MgCl2, 0.5 
M 2-amino-2methyl-1-propanol (Sigma)) were added to 96-well plates and serial dilutions of 
4-nitrophenol were made as a standard curve. Subsequently, 100 μl of substrate solution (5 
mM paranitrophenylphosphate (Sigma)) was added to the wells and the plate was incubated 
for 1 h at 37 °C. The reaction was then stopped by the addition of 100 μl 0.3 M NaOH 
(Sigma) and the plate was read at 405 nm. The standard curve was used to calculate the 
ALP activity in the samples and the concentration of ALP was calculated, relative for the 
number of cells by the results from the DNA analysis. 
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2.5 SEM
SEM analysis was performed after 1, 9 and 16 days. The scaffolds were washed three times 
with PBS and fixated for 5 min in 2% glutaraldehyde. The substrates were washed for 5 min 
with 0.1 M sodium cacodylate buffer (pH 7.4), dehydrated in a graded series of ethanol, and 
dried in tetramethylsilane. The substrates were sputter-coated with gold and examined using 
a Jeol 6310 SEM. 
2.6 Genetic analysis 
Samples for genetic analysis were taken in the early differentiation stadium of the cells on 
day 9, to enable examination of the proliferation as well as the differentiation of the cells. 
The scaffolds were washed three times with PBS and stored in 5 ml RNAlater® (Ambion 
Inc., USA) at 4ºC. At the micro array facility, RNA was isolated from the cells with an 
RNeasy Micro kit (Qiagen, Hilden Germany). The concentration and purity of the RNA 
were determined by spectrophotometry (NanoDrop® ND-1000, NanoDrop technologies 
LLC, Thermo Fisher Scientific, Wilmington, Delaware USA) and the RNA integrity was 
measured on a 2100 Bioanalyzer (Agilent, Santa Clara, California, USA). After RNA 
amplification and labeling of 100 ng of total RNA of each sample, following standard 
protocols suggested by the manufacturer (http://www.affymetrix.com), the samples were 
hybridized onto Rat Genome RAE230 2.0 Arrays (Affymetrix) containing 31,099 probes. 
GCOS 1.4 (GeneChip Operating Software, Affymetrix) was used to generate the raw 
gene expression data and Partek Genomic Suit 6.09 (Partek inc. USA) was used for the 
bioinformatic analysis of the data. Gene ontology (GO) analysis was performed using 
the online tool DAVID 2007,23, 24 to identify relevant and statistically significant biological 
processes and signalling pathways.
2.7 Real-time polymerase chain reaction
Reverse transcription was performed on 1 µg of total RNA. The RNA, random primers (50-
250 ng) and 1 µl of the dNTP mix (10 mM each) were added to water to a total volume of 
15 µl. The mixture was heated to 65 °C for 5 min and then quickly chilled on ice. Then, 4 
µl 5x first strand buffer (250 mM Tris-Cl, pH 8.3, 375 mM KCl, 15 mM MgCl2) and 2 µl 0.1 
M dithiothreitol were added to the contents of the tube and after 10 min of incubation at 25 
°C, 1 µl (200 units) of SUPERSCRIPT II was added. The mixture was then incubated for 
50 min at 42 °C and the reaction inactivated by heating the mixture at 70 °C for 15 min. 
The resulting cDNA was used as a template in the real-time polymerase chain reaction 
(Q-PCR). 
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Four genes were selected to validate the results of the genetic analysis. These genes, 
namely dentin matrix protein 1 (DMP1), interleukin 6 (IL-6), bone gamma-carboxyglutamate 
protein 2 (bGLAP2) and reelin, were chosen because of their strong up- or down-regulation 
according to the genetic analysis. Since the target sequences of DMP1 and reelin were 
positioned inside an exon, an additional exon-exon primer set (set 2) in the immediately 
previous border regions was designed as well.
The Q-PCR mixture was composed of 12.5 µl iQ SYBR Green Supermix (2x mix contains; 
100 mM KCl, 40 mM Tris-HCl, pH 8.4, 0.4 mM each dNTP (dATP, dCTP, dGTP, dTTP), 50 
U/ml iTaq DNA polymerase, 6 mM MgCl2, SYBR Green I, 20 nM fluorescein and stabilizers) 
(BioRad, Hemel Hempstead, UK), 1.5 µl Forward Amplification Primer (10 µM) (Table 1), 
1.5 µl Reverse Amplification Primer (10 µM) (Table 1), 2 µl of cDNA, and 7.5 µl RNase free 
water. The total content of 25 µl per sample in the PCR reaction plate was mixed gently, 
and collected by brief centrifugation. Subsequently, the plate was placed in a CFX384 
Real-Time PCR Detection System (BioRad) and the reaction started after incubation at 
94 °C for 3 min. The measurements were performed by the following calculations, with 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as a control:
  (1) CT, gene of interest – CT, GAPDH = ΔCT 
  (2) ΔCT, sample - ΔCT, control = ΔΔCT 
  (3) Fold change relative to the control sample = 2-ΔΔCT
2.8 Calculations and statistical analysis 
Values of the DNA, and ALP assays were normally distributed. A statistical analysis was 
performed using an analysis of variance with post-hoc Tukey test. All data were tested on 
normal distribution and p-values of 0.05 or less were considered to indicate significance. 
Calculations were performed in InStat software (v 3.05 Graphpad, Inc). 
For the genetic analysis, Robust Multi-array Average (RMA) normalization was applied to 
the data. RMA is an algorithm used to create an expression matrix from Affymetrix data. 
Next, a linear regression model for the normalized data of each of the probe sets was 
applied to identify statistically significant genes, using a threshold of p<0.05. Differentially 
expressed genes were identified by comparing the gene lists corresponding to cells grown 
on the PLLA, PLLA + BMP2, composite and composite + BMP-2 scaffolds, as depicted 
in Figure 1. The specific effects of the composite and BMP-2 addition could thus be 
examined. The fold change (FC) of each probe set of the compared case-conditions was 
given, in which a positive FC value corresponds to an up-regulation of the specific gene 
and a negative FC corresponds to a down-regulation of the gene.
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Table 1: List of primers used for the Q-PCR.
Name Primers (set 1)
PCR 
product 
(bp)
Primers (set 2) 
PCR 
product 
(bp)
Dentin Matrix
Protein 1
GCCCATGGCAAATAGT
GACC (forward)
91
GACGGCACAATGG
GATAACT (forward) 
90
GAGACCACCAGCCGG
TCTAT (reverse)
GCAATGTTTACAGA
AGGCCC (reverse)
Interleukin-6
TCTTCAAACAAGAGATA
AAAGACTCAT (forward) 
115
ATGGTCTTGGTCCTTA
GCCA (reverse)
Bone Gamma-
carboxy-
glutamate 
Protein 2
AATGGACTTGGAGCC
CCAG (forward) 
93
GTCCGCTAGCTCGTC
ACAAT (reverse)
Reelin
AGTAAGCACTCGCAA
ACAAAAT (forward)
109
CCCTATCTCCCTCC
CACAAT (forward)
102
GATTCTTCATGGGTAT
CGCC (reverse)
GGACACGAAATGG
CAGTTAC (reverse)
3. Results
3.1 Scaffold characterization
The porosity, average pore size, Tg, compressive modulus and maximum stress values 
of the PLLA and composite scaffolds are depicted in Table 2. The mean pore size and 
Tg of both scaffolds differed, with the composite having larger pores and a higher Tg. 
Furthermore, the maximum stress value of the composite scaffold was significantly higher 
than that of the plain PLLA scaffold. 
Figure 1: Gene lists corresponding to cells grown on PLLA, PLLA + BMP2, composite and composite 
+ BMP-2 scaffolds were compared as depicted to examine the specific effects of the composite and 
of BMP-2 addition.
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3.3 ALP activity
Evaluation over time showed that the ALP activity in the PLLA, PLLA with BMP-2 and the 
composite group significantly increased between day 1 and 9. For the composite with 
BMP-2 group no significant differences in ALP activity between any of the time points were 
found (Figure 3). Comparing all groups separately within one time point showed significant 
differences in ALP activity between the PLLA and the composite, and between the PLLA 
with BMP-2 and the composite group on days 1, 9 and 16, i.e. the composite led to a 
significant decrease of ALP activity.
Figure 2: Cell proliferation curve (in 
ng ml-1) by a total DNA measurement. 
The error bars represent the standard 
deviations. Proliferation of cells seeded 
on the PLLA scaffold significantly 
increased between day 1 and 16 
(p=0.0318).
3.2 DNA content
The results of the assays were comparable between the two individual experiments. 
However, since these primary cells were derived from different rats, intra-animal differences 
prohibit the possibility of pooling the results. Therefore, always the results from the second 
experiment are shown. Cells seeded on PLLA scaffolds showed a significant increase in 
cell number between day 1 and 16. There were no significant differences with cells seeded 
on PLLA with BMP-2 scaffolds. On the composite and on the composite scaffolds with 
BMP-2 no significant increase in cell number was detected in time (Figure 2). 
Table 2: Scaffold characterization measurements
PLLA scaffold Composite scaffold p-value
Porosity (%) 85 87 -
Average pore size (µm) 66 103 -
Tg (°C) 58.6 66.5 -
Compressive modulus (MPa) 10.9 (±2.3) 12.5 (± 2.0) 0.2653
Maximum stress (MPa) 0.30 (±0.02) 0.39 (±0.02)* <0.001
* Significant increase vs. PLLA scaffold.
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3.4 SEM
SEM micrographs of the two scaffold types (PLLA and the composite), with and without 
cells and BMP-2, are shown in Figure 4. Without cells, the PLLA scaffold seemed to have 
a more open and porous surface compared to the composite. When seeded with cells, cell 
adhesion on the scaffolds was clearly visible in all groups as well as some extracellular 
matrix formation on day 16. The PLLA and PLLA with BMP-2 groups showed the formation 
of a mineralized extracellular matrix after 16 days. However, the addition of CNTs and µHA 
seemed to have a negative effect on cell growth and differentiation. Upon visual inspection, 
no matrix mineralization was observed in any of the samples.
3.5 Genetic analysis 
The list of probe sets that remained after removal of the control probe sets and probe sets 
with an expression change under a no-change threshold level was used to analyze the 
influence of BMP-2 and of the composite. All three experiments were comparable and 
comparisons of the differentially expressed genes (p < 0.05) between PLLA and PLLA with 
BMP-2, together with their counterparts, the composite and composite with BMP-2, showed 
a differential expression of 2345 genes. Comparison of the PLLA and the composite, 
together with their counterparts, the PLLA with BMP-2 and the composite with BMP-2, gave 
a differential expression of 3901 genes respectively (Figure 5). 
To further select these genes, a threshold of a minimum twofold difference in expression 
was set and the genes were selected by GO. As selection criteria only genes involved 
in: cell proliferation, (regulation of) cell cycle/growth, negative regulation of cellular 
metabolism, apoptosis, cell (matrix) adhesion, tissue development, skeletal development, 
vasculature development, and TFG-β-receptor-signaling pathways were selected. From 
the list of remaining genes, four extremely up- or down-regulated genes, namely dentin 
matrix protein 1, interleukin 6, bone gamma-carboxy-glutamate protein 2 and reelin, were 
Figure 3: ALP activity measurement 
results. ALP is an early differentiation 
marker and correlates to the 
differentiation of the cells. The error 
bars represent the standard deviations. 
The ALP activity significantly increased 
between day 1 and 9 for the PLLA, 
PLLA with BMP-2 and the composite 
group (p=0.0044, 0.0381 and 0.0285, 
respectively). ALP activity was also 
significantly different between the 
PLLA and the composite group, on day 
1 (p=0.0466), day 9 (p=0.0072) and 
day 16 (p=0.0499).
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Figure 4: SEM micrographs of a PLLA scaffold (A) and a composite scaffold (B), both at a magnification 
of 250x. Micrographs of PLLA (C), PLLA + BMP-2 (D), composite (E) and, composite + BMP-2 
scaffolds (F) seeded with RBM cells after 16 days, at a magnification of 500x. The arrows indicate the 
cells, the inlays show the formation of a mineralized extracellular matrix.
validated by Q-PCR. The results correlated with the results obtained from the gene 
expression array, although they were somewhat lower and the primers for the Il-6 gene were 
not effective in replicating the gene (data not shown). 
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Figure 5: Venn diagram showing the effects of the composite and of added BMP-2 on four groups 
(I-IV) of differentially expressed genes. The numbers represent the numbers of probe sets before and 
after setting a threshold of FC >2 and filtering with respect to biological processes/pathways.
Again the influences of BMP-2, and the composite on gene expression was analyzed by 
comparing the PLLA and PLLA with BMP-2 groups with the composite and composite 
with BMP-2 groups and by comparing the PLLA and the composite groups with the PLLA 
with BMP-2 and the composite with BMP-2 groups. In this way, four groups of genes were 
formed: group I comprised the resulting genes for the effect of composite formation only, 
group II was the resulting genes for the effect of the composite, irrespective of BMP-2 
addition; and group III contained the resulting genes for the effect of composite formation 
in combination with added BMP-2. Group IV, was the resulting genes with regard to the 
addition of BMP-2 to a plain PLLA scaffold (Figure 5). A detailed list of all selected genes, 
corresponding to the four groups as depicted in Figure 5, is given in Table 3. Positive or 
negative FC values in this table indicate an up-or down-regulation, respectively, of the 
specific genes.
4. Discussion  
Composite scaffolds with 1 wt% of CNTs and µHA were prepared for this study. CNTs at 
concentrations as low as 0.05 wt% and up to 10 wt% were described as improving the 
mechanical properties of polymeric scaffolds.5, 6 However, by increasing the amount of 
incorporated CNTs, scaffolds were also reported to become more brittle. Therefore, in this 
study a concentration of 1 wt% CNTs was selected for preparation of the composites. Also 
a concentration of 1 wt% µHA was selected since already a thin coating of hydroxyapatite 
has been shown to have a positive effect on bone formation15 whereas the addition of too 
much hydroxyapatite might lead to brittleness of the scaffold as well. Characterization 
of the scaffolds indeed showed an increase in maximum stress value for the composite 
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scaffold, but the increase in compressive modulus was not significant. This is most likely 
due to the higher pore diameter of the composite scaffolds.
Since only one type of composite scaffold was used in this study, one could argue that 
the observed effects cannot exclusively be accredited to one of the specific additions. 
However, we chose to do this based on both theoretical and practical grounds. The goal 
of this study was to examine a novel material for bone tissue engineering, a composite 
incorporating both CNTs and µHA, in combination with BMP-2. Composites with only CNTs 
or µHA incorporated could never act as the ideal reference material, since depletion of one 
of the additions would result in a completely new material with its own physico-chemical 
characteristics and morphology.
The main aim of this study was to examine the effects of a porous composite scaffold 
incorporating both CNTs and µHA. However, as described above, by changing the 
composition of a scaffold the morphology of the scaffold will also change, which in turn, 
could well affect the behavior of the cells. As described by Murphy et.al., different pores 
sizes and surface area influence the cell attachment and migration of the cells.25 Scaffolds 
with mean pore sizes between 120 and 190 µm showed an increase in cell attachment 
and a decrease in cell migration towards the centre of the scaffold with decreasing pore 
size. However, this increase in cell attachment did not result in a significant increase in 
proliferation for the lower mean pore sizes. Decreasing the pore size even further to 85 
µm resulted in a decrease in both cell attachment and migration, but not to a significant 
decrease in cell proliferation. Even though a different material and different cells were 
used for this study, according to these results it might be possible that cell behavior in the 
current study was slightly altered on the composite scaffolds due to the varying pore size. 
To examine the effects of the composite scaffold on cell behavior, genetic profiling arrays, 
DNA and ALP analysis, and SEM imaging were used. In addition, the influence of such a 
composite on the action of the most prominent growth factor in bone tissue engineering, 
i.e. BMP-2, was studied.
Table 3: Specifications of all differentially expressed genes in group I, II, III and IV. 
Transcript ID Pathway Symbol Name FC p-value
Group I
1368474_at CA Vcam1
vascular cell adhesion 
molecule 1
4.14 0.0008
1367918_at CA Fez1
fasciculation and 
elongation protein zeta 1 
(zygin I)
-2.13 <0.0001
1373957_at CA Reln reelin -2.31 0.0090
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Table 3: continued 
Transcript ID Pathway Symbol Name FC p-value
Group II BMP2- BMP2+ BMP2- BMP2+
1372013_at RCC+CG Ifitm1
interferon induced 
transmembrane protein 1 
(predicted)
4.83 4.43 <0.0001 <0.0001
1368558_s_at RCC+CG Aif1
allograft inflammatory 
factor 1
5.35 3.34 0.0071 0.0323
1369484_at RCC+CG Wisp2
WNT1 inducible signaling 
pathway protein 2
1.94 2.55 <0.0001 <0.0001
1370282_at RCC+CG Csrp1
cysteine and glycine-rich 
protein 2
–3.39 –3.73 <0.0001 <0.0001
1387873_at RCC+CG Wfdc1
WAP four-disulfide core 
domain 1
–3.00 –3.84 <0.0001 <0.0001
1369191_at A Il6 interleukin 6 6.23 9.30 0.0006 0.0002
1370333_a_at A Igf1 insulin-like growth factor 1 6.92 5.18 0.0003 0.0010
1367850_at A Fcgr3
Fc receptor, IgG, low 
affinity III
3.66 3.52 0.0044 0.0053
1387011_at A Lcn2 lipocalin 2 4.27 3.64 0.0032 0.0062
1367784_a_at A Clu clusterin 3.68 3.09 0.0004 0.0009
1386935_at A Nr4a1
nuclear receptor subfamily 
4, group A, member 1
2.19 3.07 0.0005 <0.0001
1367881_at CMA Ptpns1
protein tyrosine 
phosphatase, non-
receptor type substrate 1
2.19 2.24 0.0013 0.0011
1368187_at TD Gpnmb
glycoprotein 
(transmembrane) nmb
4.06 3.64 0.0002 0.0004
1388204_at TD Mmp13
matrix metallopeptidase 
13
4.88 2.99 0.0002 0.0021
1372690_at TD Rtn4rl1 reticulon 4 receptor-like 1 –2.05 –1.93 0.0086 0.0132
1393756_at TD Dmp1 dentin matrix protein 1 –3.29 –4.40 0.0133 0.0043
Group III
1393891_at CP Col8a1
procollagen, type VIII, 
alpha 1 (predicted)
4.58 <0.0001
1368527_at CP Ptgs2
prostaglandin-
endoperoxide synthase 2
3.00 0.0025
1370957_at CP Il6st
interleukin 6 signal 
transducer
2.30 <0.0001
1370941_at CP Pdgfra
platelet derived growth 
factor receptor, alpha 
polypeptide
2.20 0.0003
1377916_at CP Slfn2 schlafen 2 (predicted) 2.00 0.0010
1387122_at A Plagl1
pleiomorphic adenoma 
gene-like 1
2.54 0.0153
1367973_at A Ccl2
chemokine (C-C motif) 
ligand 2
2.46 0.0003
1367576_at A Gpx1 glutathione peroxidase 1 2.37 0.0014
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Table 3: continued
Transcript ID Pathway Symbol Name FC p-value
Group III (continued)
1367898_at A Bnip3l
BCL2/adenovirus E1B 19 
kDa-interacting protein 
3-like
2.30 0.0005
1371353_at A Sqstm1 sequestosome 1 2.13 0.0003
1367899_at A F2r
coagulation factor II 
(thrombin) receptor
2.04 0.0042
1370690_at A hspa9A
heat shock 70kDa protein 
9A (predicted)
2.00 0.0077
1367568_a_at SD Mgp matrix Gla protein 2.44 0.0055
1369773_at SD Bmp3
bone morphogenetic 
protein 3
-2.82 0.0028
1387330_at SD Mepe
matrix extracellular 
phosphoglycoprotein with 
ASARM motif (bone)
-3.01 0.0016
1368836_a_at SD Agc1 aggrecan 1 -3.23 0.0014
1369142_at SD Bglap2
bone gamma-
carboxyglutamate protein 
2
-7.32 <0.0001
Group IV
1371186_at CMA Itgb6 integrin, alpha 6 -2.06 0.0015
1373957_at CA Reln reelin -2.37 0.0077
1370965_at CP Tcf8 transcription factor 8 -2.02 0.0052
1369884_at CP Fgf7 fibroblast growth factor 7 -2.07 0.0005
1372299_at CP Cdkn1c
cyclin-dependent kinase 
inhibitor 1C (P57)
-2.11 0.0010
1377089_a_at CP Tspan5 tetraspanin 5 -2.15 0.0027
1372168_s_at CP Igfbp6
insulin-like growth factor 
binding protein 6
-2.26 0.0005
1393891_at CP Col8a1
procollagen, type VIII, 
alpha 1 (predicted)
-5.10 <0.0001
1368836_a_at SD+BR Agc1 aggrecan 1 3.70 0.0007
1369142_at SD+BR Bglap2
bone gamma-
carboxyglutamate protein 
2
3.48 0.0014
1387330_at SD+BR Mepe
matrix extracellular 
phosphoglycoprotein with 
ASARM motif (bone)
2.92 0.0019
1369773_at SD+BR Bmp3
bone morphogenetic 
protein 3
2.78 0.0031
1393756_at SD+BR Dmp1 dentin matrix protein 1 2.71 0.0296
1371052_at SD+BR Nog noggin 2.50 0.0031
1370047_at SD+BR Enpp1
ectonucleotide 
pyrophosphatase/
phosphodiesterase 1
-2.25 0.0002
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Table 3: continued
Transcript ID Pathway Symbol Name FC p-value
Group IV( continued)
1383003_at SD+BR Bm1
leukocyte cell-derived 
chemotaxin 2 (predicted)
-2.40 0.0002
1368829_at SD+BR Fbn1 fibrillin 1 -2.51 <0.0001
1388920_at SD+BR Bmp6
bone morphogenetic 
protein 6
-3.27 <0.0001
1375138_at A Timp3
tissue inhibitor of 
metalloproteinase 3
3.24 0.0055
1378739_at A Cidec
similar to cell death-
inducing DFFA-like 
effector c
2.37 0.0016
1367576_at A Gpx1 glutathione peroxidase 1 -2.31 0.0016
1369194_a_at A Cdkn2a
cyclin-dependent kinase 
inhibitor 2A
-2.88 0.0065
1387122_at A Plagl1
pleiomorphic adenoma 
gene-like 1
-3.03 0.0065
1371840_at VD Edg1
endothelial differentiation 
sphingolipid G-protein-
coupled receptor 1
2.86 0.0001
1386080_at VD Hey1
hairy/enhancer-of-split 
related with YRPW motif 1
2.05 0.0005
Abbreviations: CA, Cell Adhesion; RCC, Regulation of Cell Cycle; CG, Cell Growth; A, Apoptosis; CMA, 
Cell Matrix Adhesion; TD, Tissue Development; CP, Cell Proliferation; SD, Skeletal Development; BR, 
Bone Remodeling; VD, Vasculature Development.
According to the DNA assay results, the formed composite had no significant effect on 
the proliferation rate of RBM cells on day 9. In accordance with these results, in the gene 
expression array analysis, we identified five up- or down-regulated genes connected to 
cell growth and regulation of the cell cycle in group II (Table 2 and Figure 5), but the data 
suggested no specific preference for proliferation. Group III, on the other hand, contained 
five differentially regulated genes connected to cell proliferation and examination of 
these genes revealed that one of the genes might lead to a specific increase in RBM 
cell proliferation; the up-regulated prostaglandin-endoperoxide synthase 2 (better known 
as Cox-2) gene. The enzyme this gene is coding for is implicated to play a critical role in 
fracture repair, and is an essential mediator in the bone formation and resorption process. 
An up-regulated expression of this gene might therefore lead to an increase of osteoblasts; 
however it might also lead to an increase of osteoclasts.26 In contrast to our hypothesis, 
the results from all assays overall indicate that incorporation of CNTs and µHA has no 
significant effect on the proliferation of RBM cells. 
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The ALP assay results on day 9 suggested a negative effect of the formed composite on 
the differentiation of the cells. However, the gene expression array results from the first two 
groups indicated the expression of most genes connected to skeletal development and bone 
formation to remains unchanged (Table 2). Nevertheless, several selected genes in group 
II, related to tissue development in our GO analysis, could be connected to a decrease in 
differentiation of the cells and extracellular matrix formation: first, the up-regulated gene 
coding for matrix metallopeptidase-13 (Mmp13), which is responsible for the degradation 
of extracellular matrix components, and secondly, the down-regulated gene coding for 
dentin matrix protein 1 (Dmp1), which is an essential protein in odontoblast and osteoblast 
maturation processes.27 The third group (Table 2, group III) showed a differential expression 
of several selected genes involved in skeletal development. The down-regulation of bone 
gamma-carboxyglutamate protein 2 (Bglap2 or osteocalcin) and the up-regulated matrix 
Gla-protein (Mgp) were most interesting. Bglap2 is an important protein in the formation of 
extracellular matrix, constituting about 1-2% of the total bone protein and binding strongly 
to apatite and calcium. Mgp inhibits calcification by binding calcium ions and crystals and 
antagonizing BMP-2.28 Between the selected genes in the apoptotic pathway, there is 
one more striking gene that might account for the decrease in bone forming processes, 
namely the gene coding for the chemokine (C-C motif) ligand 2 (Ccl2). Amongst others 
this protein promotes the differentiation of osteoclast precursors and plays a major role 
in their recruitment and fusion.29 Our study set-up did not specifically asses for osteoclast 
formation; however, such cells could also be formed from bone marrow and therefore 
require further study. Of all the selected genes in the third group, there was only one gene 
coding for a protein that might actually lead to an increase in RBM cell differentiation, which 
is the down-regulated gene coding for bone morphogenetic protein-3 (Bmp-3). This growth 
factor negatively influences bone formation by antagonizing other osteogenic BMPs.30, 31 
However, our SEM observations also indicated that the composite led to the absence of 
matrix mineralization. Taking all our results into consideration, it can be concluded that the 
composite most probably led to a decrease in RBM cell differentiation, and thus in this regard 
seems to be unsuitable to support bone formation.
The addition of BMP-2 to both types of scaffolds had no influence on the proliferation of the 
cells on day 9, according to the DNA assay results. The gene expression array results on the 
other hand, showed several selected genes connected to proliferation pathways (Table 2, 
group IV). However, none of the proteins these genes code for are known to directly regulate 
RBM proliferation. The down-regulated gene coding for the insulin-like growth factor binding 
protein 6 (Igfbp6) is most interesting, since this protein inhibits insulin growth factor-II (Igf-II). 
Igf-II is an autocrine growth factor and induces an anti-apoptotic effect.32 Therefore, down-
regulation of Igfbp6 might indirectly lead to down-regulated RBM proliferation. 
129
Chapter 7
Based on the results of the ALP assay, the addition of BMP-2 is suggested to increase cell 
differentiation. In the literature, BMP-2 is also known to increase RBM cell differentiation.17, 
19, 20  In accordance with this knowledge, many genes related to skeletal development were 
found to be affected by the addition of BMP-2. Most interesting genes were the up-regulated 
genes coding for Bglap2, Dmp1, Bmp-3 and noggin, and the down-regulated gene coding 
for bone morphogenetic protein-6 (Bmp-6). As discussed above Bglap2 and Dmp1 are 
both positive modulators of bone formation. However, contrasting a positive regulation 
of bone formation, Bmp-3 and noggin both antagonize the action of osteogenic BMPs, 
including the osteogenic Bmp-6, which was accordingly down-regulated.33-35 Bmp-3 might 
be up-regulated as a negative feedback mechanism to BMP-2. Even though the affected 
expression of some genes indicated a possible negative regulation of bone formation, the 
strong positive regulation of Bglap2 and Dmp1 suggests that bone formation is induced 
by the addition of BMP-2. Strikingly, ALP and SEM investigation even show that the 
composite to a certain extent can diminish the favorable action of BMP-2. After addressing 
our hypothesis about the additive effect of the composite scaffolds containing BMP-2 on 
cell differentiation and genes related to bone formation, we suppose the opposite to be 
true. Group III contains genes that, in the presence of BMP-2, have different expression 
levels, which appears to be determined by the absence or presence of the composite 
material. Many genes direct to a down-regulation, instead of an up-regulation, of pathways 
favorable for bone formation. The reason for this remains unclear.
Besides genes involved in cell proliferation and bone formation, genes involved in the 
apoptotic pathways were also considered. The underlying rationale for selecting these 
genes is the remaining question whether the added materials have a negative effect on 
viability of the cells. Incorporation of CNTs and μHA lead to the expression of several genes 
that can be associated with adverse effects, like the up-regulated genes coding for vascular 
cell adhesion molecule-1 (Vcam1), Interleukin-6 (Il-6), insulin-like growth factor 1 (Igf-1) and 
Wnt1 inducible signalling pathway protein 2 (Wisp2). Vcam1 is known to trigger inflammatory 
reaction proteins,36 while the overexpression of Il-6 and Wisp2 and the disorganization of 
Igf-1 can lead to several disease states and multiple types of cancer.37-39 Even more genes 
were selected in the third group, where the composite was combined with added BMP-2. 
Eight up-regulated genes related to apoptotic pathways were selected, of which three genes 
(pleiomorphic adenoma gene-like 1 (Plag1), chemokine (C-C motif) ligand 2  (Ccl2) and 
BCL2/adenovirus E1B (Bnip3l)) are correlated with tumor growth when overexpressed.29, 40-
44 The up-regulated gene coding for Ptgs2, involved in the cell proliferation pathway, is also 
known to play an important role in several pathophysiological states including inflammation, 
arthritis, angiogenesis, bone absorption and colon cancer.45, 46
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The addition of only BMP-2 leads to differential expression of genes coding for proteins 
mainly correlated to inflammatory reactions. The most interesting genes were the up-
regulated genes coding for tissue inhibitor of metalloproteinase 3 (Timp3), gluthatione 
peroxidase 1 (Gpx1), and cyclin-dependent kinase inhibitor 2a (Cdkn2a). The Timp3 
protein leads to an increased risk of inflammation and all other proteins indirectly down-
regulate anti-apoptotic gene expression.47 
These results suggest that the addition of BMP-2 alone could lead to (minor) inflammation, 
whereas the composite, and especially the combination of the composite with BMP-2, 
suggests the possibility of serious complications. These findings, however, are based 
solely on genetic profiling results. Only very few in vivo studies describe the local 
effects of CNTs, either pure or incorporated in composites, either with or without BMP-
2, in a bone tissue environment. In these studies good biocompatibility is reported.8, 48, 49 
However, none of these studies examined the systemic, or long-term influences of these 
materials. Regarding the results presented in this study, further research on these effects 
is recommended.
5. Conclusion
Taking all results together, it can be concluded that a porous PLLA composite incorporating 
CNTs and µHA had no significant effect on the proliferation of RBM cells and most probably had 
an adverse effect on RBM cell differentiation. The addition of BMP-2 also had no significant 
effects on the proliferation of RBM cells, but confirmed RBM cell differentiation and indicated 
positive effects on bone formation. Regarding the possibility of undesired side effects of the 
additions, the gene expression results suggest more pressing complications resulting from 
the incorporation of CNTs and µHA into the scaffolds, since many of the expressed genes 
were directly connected to tumorigenesis. The combination of the composite with BMP-2 
seems to provoke an even stronger undesirable reaction. 
Based on these results, incorporation of CNTs and µHA in a PLLA bone reconstruction 
scaffold, with or without the addition of BMP-2, is presumed to be contra-indicated for in vivo 
application.
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1. Introduction
Among the many engineered nanomaterials that recently have become available, carbon 
nanotubes (CNTs) are exceptionally interesting, because of their unique physicochemical 
properties. In 1985, Kroto et al. discovered the first fullerene, a buckyball composed 
entirely of carbon atoms.1 Soon thereafter, in 1991, CNTs were described by Iijima.2 CNTs 
are composed of a single or multiple graphene sheets rolled into a cylinder, resulting in 
either single-walled (SWCNT) or multiwalled (MWCNT) structures. They are characterized 
by extreme strength-to-weight and -aspect ratios, a high surface area, tensile strength, 
thermal stability, electrical conductivity, and a high chemical inactivity. The global market 
for CNTs in 2009 was estimated at approximately $103 million, with a growth rate of ~59%.3 
This vast growth greatly increases human exposure to CNTs.  
1.1 CNTs in medicine
For medical applications, CNTs are regarded promising for drug delivery, biosensing, 
medical imaging, and production of biomaterials. In the latter, CNTs receive much attention, 
particularly in bone tissue engineering research. Because of an aging society, there is a 
high demand for new or improved artificial bone constructs. Conventional materials include 
bioactive and nonbioactive cements, metals and high-molecular-weight materials (i.e., 
natural or synthetic polymers). Thus far, the last group has limited success in the repair 
of large bone defects, because of the lack of mechanical strength compared with natural 
bone. Incorporation of CNTs can induce mechanical stability4-7 and CNTs also have the 
potential to be functionalized with growth factors or drugs. Therefore, tissue engineering 
constructs could benefit enormously from CNT application.
1.2 Toxicity 
Clearly, CNT application beholds great promises and is actively introduced in medicine. 
However, nanomaterials are also associated with hazardous effects on cells and tissues 
and CNTs may pose unknown risks to human health. The structural resemblance 
between SWCNTs and asbestos for instance,8 warrants a concern for pulmonary toxicity.9 
Additionally, the high surface area of CNTs makes them more biologically active.10 Finally, 
the small size of CNTs might facilitate easy cellular uptake and translocation of the 
particles directly into the blood stream, causing them to spread over the entire body.11 The 
high durability of the carbonaceous particles may lead to prolonged aggregation in tissues. 
CNTs used in degradable tissue engineering scaffolds potentially will be released in the 
body in time and could be redistributed to distant organs. Therefore, it is most important 
to survey all possible effects of CNTs in different parts of the body in order to make a valid 
risk assessment. Currently, several reviews on the toxic potential of CNTs have already
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been published, summarizing and discussing both in vitro and in vivo results.12-16 However, 
to asses toxic potential, CNTs should be tested in different environmental conditions and 
through several exposure routes. Dose, size, surface area, surface functionalization and 
crystalline structure should be highly standardized. These parameters are important 
factors when evaluating and understanding toxicity, and as there is much variability in 
these factors, it is difficult to make informed and conclusive assessments about biological 
effects of CNTs. The aim of this work was to perform an extensive review of literature in an 
effort to gain an improved understanding of the toxicity of CNTs in vivo.
2. Materials and methods
2.1 Search strategy 
The targets of interest in this review are experimental studies describing the effects in 
tissues and organs and/or the systemic effects of CNTs exposed to nondeficient mammalian 
animal models. A comprehensive search in the database of the National Library of Medicine 
(http://www.ncbi.nlm.nih.gov) up to the 5th of March 2010 was conducted. Only original 
animal research publications in English were considered. The applied combinations of 
keywords are provided in the flow chart in Figure 1. In addition to the database search, the 
reference list of related review articles and publications selected for inclusion in this review 
were systematically screened.
2.2 Critical appraisal and selection criteria
Titles from all studies were independently selected and evaluated by two authors (M.v.d.Z. 
and R.J.). Discrepancies were resolved by consensus. This process was repeated on 
abstracts and full-text articles (Figure 1). Data from full-text articles were documented in 
data extraction sheets (Table 1). There was no restriction to length, diameter or purity of 
the CNTs, but reports based on covalently functionalized CNTs were excluded. Further, 
only reports describing statistical analysis based on a group size of five animals or more 
were included.
3. Results and discussion
Literature research resulted in 27 articles after final selection (Figure 1). Articles that were 
discarded after screening full-text articles7, 17-55 are given in Table 2. The database of the 
National Library of Medicine was used as the point of origin for this literature research, 
and although a large portion of the reports on this subject is present in this database, 
some reports might be missed. Therefore, all references of related research and review
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Figure 1: Schematic flowchart depicting the article selection processes
articles were thoroughly searched for additional articles. However, no other database 
was used for the literature research, because we aimed to focus primarily on biomedical 
literature. The minimal group size that was used as a selection criterion for this review 
could not be based on a statistical calculation on the minimal number of animals required 
to produce valid results, because all cited studies are based on different methods and 
conditions. Therefore, a minimal group size of five animals was chosen as a general 
estimation, to avoid inclusion of studies with a too low repetition number.
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Table 1: Data extraction form that was used for 
article evaluation 
Data extraction form
Publication
Abstract
CNT Type (SWCNT or MWCNT)
characteristics Length
Diameter
Purity
Dose
Preparation
Study design Animal model
Exposure route
Analytical methods
Sampling dates
Statistical Group size
design Type of analysis
Results
Local effects Inflammation (e.g. cell count)
Fibrosis (e.g. collagen 
deposition)
Effects in organs Inflammation
Oxidative stress
Aberration or loss of function
Organ weight/volume
CNT aggregation
Systemic effects Body weight
Immunological responses
Oxidative stress
Genotoxicity
Mutagenicity
Conclusions
Surprising is the low number of only three 
reports describing in vivo toxicity study 
results based on covalently functionalized 
CNTs, acquired by this systematic 
search, because in vitro toxicity studies 
indicate that functionalization might 
decrease the toxic potential of CNTs.16, 
56-58 Obviously, there is still a lot of 
knowledge to gain, concerning risk 
assessment, from studying covalently 
functionalized CNTs in vivo. Included 
studies59-85 were categorized on type of 
CNT (either SWCNT or MWCNT) and 
animal model. An overview is presented 
in Tables 3 and 4. Because of limited 
availability of information on mainly the 
carcinogenic potential, biodistribution, 
and biomaterials topics, some articles 
that did not meet the inclusion criteria will 
also be discussed in this review.
3.1 Local toxicity
3.1.1 SWCNTs
Mouse model. The effects of SWCNTs 
on lung tissue have been examined in 
several studies by histopathology. All 
studies were characterized by local inflammatory reactions.63, 66-68 Pharyngeal aspiration 
of highly purified SWCNTs, for instance, lead to strong granulomatous responses with 
significant fibrosis of the alveolar septa at 28 days postexposure.67, 68 Nonpurified SWCNTs, 
with an iron content of 17.7 wt%, induced even stronger inflammatory reactions.63
Although pharyngeal aspiration and intratracheal instillation are very common techniques, 
both techniques are based on a single exposure of a bolus of SWCNTs, but aggregation of the 
hydrophobic SWCNTs affects their dispersion. To study the influence of SWCNT aggregation 
in a pharyngeal aspiration model, a highly dispersed preparation of SWCNTs was compared 
with a standard SWCNT preparation. Eighty percent of the standard prepared SWCNTs were 
deposited in the lungs as large aggregates, in contrast to the highly dispersed SWCNTs, 
which showed improved dispersion throughout the lung tissue without aggregation.  
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Table 2: Excluded full text articles
References Reason of exclusion
[17-32] Statistics not published
[7, 33-40] Insufficient size of animal groups
[41-45] Animal group size not published
[46, 47] Mouse/rat strain with deficiency
[48-50] CNTs functionalized
[51-53] In vitro study
[54, 55] No use of CNTs
Both preparations induced a similar inflammatory response, but the highly dispersed 
preparation was more effective in inducing a fibrotic response.66 Obviously, inhalation 
mimics natural exposure to SWCNTs best. Although formation of stable aerosols was long 
time problematic though because of SWCNT aggregation, newly developed aerosolization 
techniques solved this problem. Herewith, pulmonary toxicity of pharyngeally aspirated and 
inhaled SWCNTs was compared. Although both techniques induced an acute inflammatory 
and fibrotic reaction, inhalation proved to be more potent in causing local inflammation.63
3.1.2 MWCNT
Mouse model. MWCNT toxicity studies on pulmonary tissues also indicated induced 
inflammation. In one example, intratracheal instillation demonstrated acute dose-dependent 
granulomatous inflammation, persisting until the end of the study at 2 weeks.75 Also, epithelial 
injury and a significant increase in goblet cells, leading to mucus hypersecretion, were 
reported in the airway.74 Inhalation studies corresponded with these results, demonstrating 
pulmonary inflammation as well.73, 76 In one of the inhalation studies, acute inflammation 
was followed by fibrosis, starting around 2 weeks and persisting until 6 weeks.73 Fibrosis 
reached into the subpleura, indicating migration of the MWCNTs. The other study did 
not indicate significant airway fibrosis, but evaluation was done over a short 2-week time 
frame.76 Comparing MWCNT inhalation to intratracheal instillation demonstrated that the 
course of inflammation differs for both methods. This was suggested to be caused by an 
altered size and distribution pattern of MWCNT aggregation.47 However, this latter study 
did not meet our inclusion criteria. 
Rat model. Inhalation of MWCNTs in a rat model led to similar results as observed in the 
mouse model. Two studies reported inflammation and fibrosis at 90 days postexposure.79, 
80 The course and severity of inflammation seemed to be dependent on the exposure 
dose and time. Exposure for 13 weeks, 6 h per day, 5 days a week, to doses between 
0.1 and 6 mg/m3 clearly showed dose-dependent pathological changes starting at a dose 
of 0.4 mg/m3,79 whereas a single 6-h exposure to 11 or 241 mg/m3 MWCNTs led to an
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inflammatory response only for the high dose.80 It can be concluded from these studies 
that both nonfunctionalized SWCNTs and MWCNTs may lead to local acute and chronic 
inflammatory responses in pulmonary tissue. 
3.2 Organ and systemic toxicity
3.2.1 SWCNT
Mouse model. The described local pulmonary toxicity after pharyngeal aspiration of SWCNTs 
is supported by bronchoalveolar lavage (BAL) fluid examination. A rapid dose-dependent 
increase in inflammatory cells and markers was reported in several studies, and within 2 
months this response developed into an early fibrogenic response.68 Observed responses 
for nonpurified SWCNTs containing 17.7 wt% of iron were again more prominent.63 The 
highly dispersed preparation, as described earlier, also showed a significant induction of 
inflammatory cells in BAL fluid when compared with a standard preparation66 and inhalation 
even resulted in a two- to fourfold increase of cellular inflammation, inflammatory cytokines 
and profibrotic markers when compared to pharyngeal aspiration.63
Further, a close crosstalk between pulmonary and systemic responses was reported by 
simultaneous expression of acute and chronic inflammatory markers in both BAL fluid 
and blood.61 On the other hand, pulmonary and cardiac toxicity were suggested not to be 
connected, because there was no significant ischemia/reperfusion injury after pharyngeal 
aspiration.59
Rat model. In rats, however, the number of arterial baroreflex sequences was decreased 
during 4 weeks  by intratracheal instillation of SWCNTs, and such impairment of arterial 
baroreflex function is considered predictive for cardiac mortality. However, the exact purity 
of the SWCNTs, and therefore the influence of metal contaminants, was not described.69 
Moreover, SWCNTs as well as MWCNTs were reported to accelerate thrombosis 
development in a rat model with FeCl3-induced carotid artery thrombosis.
71 In short, 
exposure of SWCNTs may lead to pulmonary inflammation and fibrosis. It also seems to 
influence systemic inflammation and might induce other pathological responses. Research 
on this topic is, however, in its very early stages.
3.2.2 MWCNT
Mouse model. In close correlation with the observed local responses of intratracheally 
instilled MWCNTs, a dose-dependent increase of inflammatory cells and markers as 
well as profibrotic markers was reported in BAL fluid and lung tissue. Additionally, a 
proinflammatory T-cell response and proliferation of B-cells was observed, the latter 
indicating an allergic response.75 Also, systemic inflammation was demonstrated by
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expression patterns of inflammatory markers in blood after intratracheal instillation or 
pharyngeal aspiration of MWCNTs.61, 75 SWCNTs, were more potent in inducing these 
pulmonary and systemically inflammatory responses.61
In contrast to these results, inflammatory or fibrotic responses in BAL fluid or lung tissue 
were absent, 14 days post-MWCNT inhalation, and systemic immunosuppression was 
induced.78 The absence of significant inflammation was suggested to be due to the low 
doses that were used and to the short measurement period of 14 days. The response to 
low doses of inhaled MWCNTs may manifest over several months. In correspondence with 
this study, another inhalation study reported only mild pulmonary inflammation 14 days 
postexposure, after using a higher dose.76 
Pulmonary exposure to MWCNTs may happen concomitantly with exposure to air 
pollutants and several common pollutants are known to affect pulmonary responses. 
Ozone, for instance, may cause acute pulmonary toxicity and enhance chronic respiratory 
diseases.77 It was therefore hypothesized that ozone might increase the adverse effects of 
MWCNT exposure. The opposite appeared to be true. Pharyngeal aspiration of MWCNT 
in combination with ozone exposure induced tolerance to acute and chronic pulmonary 
inflammation caused by MWCNTs.77 
Besides pulmonary toxicity, MWCNTs were also reported to be involved in hepatoxicity. 
Intravenous injection led to inflammation of the liver after 60 days.72
Rat model. In the mouse model, inhalation of MWCNTs did not lead to significant pulmonary 
inflammation after 14 days. After 90 days, however, a single inhalation exposure to 
MWCNTs in rats, led to dose-dependent inflammogenicity in BAL fluid and lung tissue. 
Nonpurified MWCNTs (containing 0.53 wt% of cobalt) induced stronger reactions than 
purified MWCNTs.80 Chronic inhalation of relatively low doses also resulted in dose-
dependent pulmonary toxicity and in significant increases in lung weight after 3 or 9 
months.79, 81 Clinical signs of toxicity, mortality or changes in body or organ weight were not 
observed though, but after 13 weeks or more, translocation of the MWCNTs into the lung-
associated lymph nodes was demonstrated at overload conditions79 and slight neutrophilia 
was observed for the highest dose.81 Surprisingly, in the rat model, intratracheal instillation 
of MWCNTs did not lead to significant inflammation of lung tissue. The authors suggested 
that this could be due to the low exposure dose, compared with other studies. Nonetheless, 
apoptosis in lung tissue was significantly induced, but it remains debatable whether this 
would lead to pathological effects.83 
Besides metal contaminants surface-bound oxygen and structural defects in CNT walls 
have been hypothesized to influence the toxic potential of CNTs, because both are 
implicated to play a role in the induction of oxidative stress.82, 84 Therefore, MWCNTs 
were ground (gMWCNTs), to create fibers with wall defects, and compared with
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untreated MWCNTs by intratracheal instillation. At 60 days postexposure, both types 
of MWCNTs induced lung inflammation and fibrosis, but gMWCNTs were cleared more 
rapidly from the lungs.85 A follow-up study demonstrated that inflammatory and fibrotic 
responses in the lung induced by gMWCNTs were reduced by heat treatment at 600 
°C (removal of surface-bound oxygen and metal oxides) and even further reduced by 
treatment at 2400 °C (elimination of metal clusters and ablation of structural defects). 
Reintroducing structural defects by a second grinding procedure after the 2400 °C heat 
treatment illustrated the return of inflammation. This underlines the negative influence 
of metal residues and also of surface-bound oxygen and structural defects.82 All results 
together suggest pulmonary toxicity of MWCNTs and indicate the possibility of MWCNTs 
to affect other systems in the body as well. However, to establish a more accurate reading 
on the systemic toxic potential of MWCNTs, more research is required.
3.3 Oxidative stress
3.3.1 SWCNT
Oxidative stress is associated with cell death and is caused by an imbalance between 
oxidants and antioxidants. The connection between nano-toxicity and excessive oxidative 
stress is widely accepted, and especially, lungs are susceptible to oxidative injury. Analysis 
of oxidative stress could therefore be a major indicator of toxic potential. 
Markers indicating oxidative stress have been reported to increase after SWCNT exposure 
in several pulmonary studies in mice, while antioxidant reserves decreased. In these 
studies, oxidative stress was described to be dependent on time and dose and correlated 
with the course of observed inflammatory response.63, 67, 68 Intravenous injection led to high 
levels of oxidative stress markers in the lungs as well and also in the liver. The observed 
oxidative stress was associated to SWCNT accumulation, which was high in both organs.64
Metal catalyst residues are capable of inducing oxidative stress.63 However, several of 
the studies described above were conducted with highly purified SWCNTs, indicating an 
intrinsic capacity of SWCNTs to induce oxidative stress. The exact underlying mechanism 
is not yet understood, although an important role in maintenance of oxidative balance was 
discovered for the antioxidant vitamin E. Mice fed a vitamin E- deficient diet, compared 
with mice on a normal diet, showed a significant decrease in pulmonary antioxidants after 
SWCNT exposure, indicating severe oxidative stress. As a consequence, levels of pro-
inflammatory and fibrotic markers increased.67 Even though the mechanism connecting 
oxidative stress to toxicity is yet to be discovered, it can be concluded that SWCNTs play 
a significant role in the induction of oxidative stress.
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3.3.2 MWCNT
In contrast to SWCNTs, the potential of MWCNTs to generate oxidative stress is 
controversial. Inhalation or pharyngeal aspiration of MWCNTs in mice failed to induce stress 
markers in either lung tissue or blood.77, 78 However, intravenous injection of MWCNTs in 
mice induced oxidative stress markers in the liver72 and gene expression analysis in the 
spleen demonstrated a significant increase in oxidative stress marker NAD(P)H.78 Further, 
in a rat model, several genes related to oxidative stress were upregulated in lung tissue 
after inhalation of MWCNTs.80 
3.4 Interference with allergies and pathogenic infections
3.4.1 SWCNT
Various ultrafine particles are described to promote immune responses to allergens in 
both humans and animals. High adjuvant capacity of ultrafine particles is correlated 
with a small particle size in combination with a large surface area.86 Incorporating these 
characteristics, SWCNTs might be potent adjuvants. Intranasal and subcutaneous 
exposure in combination with the allergen ovalbumin in mice indeed proved high adjuvant 
capacity of SWCNTs. Inflammatory cells and cytokines in both BAL- and lymph-fluid dose-
dependently increased, as well as immunoglobulins, related to allergic responses, in 
blood.60
SWCNT exposure may also occur concomitantly with pathogenic infections and enhance 
the natural response against infection. To examine this theory, SWCNTs were pharyngeally 
aspirated, followed by exposure to Listeria monocytogenes. Acute and chronic inflammation 
in the lung significantly increased, supporting the theory. Surprisingly, despite the stronger 
inflammatory response, bacterial clearance decreased.65 The bacterial endotoxin 
lipopolysaccharide (LPS) is a constituent of air pollutants and is known to induce systemic 
inflammatory response syndrome (SIRS). SIRS is often accompanied by coagulopathy 
and SWCNTs were imposed to enhance toxic responses related to LPS. Combinatory 
intratracheal instillation of SWCNTs and LPS confirmed this hypothesis. Pulmonary and 
systemically inflammatory reactions were moderately induced by SWCNT and blood 
coagulation was disturbed.62 SWCNTs obviously interfere with preexisting allergies and 
with natural responses against pathogenic infections.
3.4.2 MWCNT
Exposure of mice to MWCNTs by various routes, such as inhalation, subcutaneous injection 
and intratracheal or intranasal instillation in combination with ovalbumin, was in consensus 
with observed responses to SWCNTs. Increased inflammatory responses were reported, 
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compared with MWCNT exposure or ovalbumin sensitization only.60, 74, 76 Additionally, the 
susceptibility to airway fibrosis increased76 and immunoglobulin expression increased in 
blood. SWCNTs however, proved to be a more potent adjuvant than MWCNTs.60
3.5 Carcinogenic potential 
Inflammatory responses, fibrosis, and oxidative stress are all associated with lung cancer.87-89 
Therefore, the carcinogenic potential of CNTs is much debated. Unfortunately, only a limited 
number of studies have considered the carcinogenic potential of CNTs. One of these studies 
examined the occurrence of mutations in the κ-ras oncogene, which is often implicated in 
pulmonary tumorigenesis of mice exposed to chemicals.90, 91 Within the first week after SWCNT 
inhalation in mice, mutations in the κ-ras locus were identified, which persisted until the end of 
the study at 28 days. Pharyngeal aspirated SWCNTs, on the other hand, did not induce these 
mutations, implying that the exposure route greatly influences SWCNT behaviour.63 Another 
study examined the potential of ground MWCNTs, with or without structural defects, to induce 
mesothelioma formation in rats. Twelve months after intraperitoneal injection, no mesothelioma 
was observed.82 These results however, should be interpreted with caution, because this model 
is reported to mainly respond to long fibres.92 Folkmann et al. described genotoxic potential of 
SWCNTs administered by oral gavage in rats. In this study, SWCNTs were demonstrated to 
oxidatively damage DNA in liver and lung tissue after 24 hours.70 Genotoxicity analysis in vitro 
on collected urine from rats that received SWCNTs by oral gavage confirmed this potential,51 
although, this study did not meet the inclusion criteria of this review. 
Described below are some other studies reporting on the ability of CNTs to induce 
mesotheliomas, which did not meet the inclusion criteria but are essential to broaden the 
perspective on the carcinogenic potential of CNTs. Probably the most debated study is that by 
Takagi et al..19 Here, MWCNTs were intraperitoneally injected in p53 heterozygous mice and 
mesothelioma developed after 6 months. This model is sensitive to genotoxic carcinogens and 
reactive oxygen species-related carcinogenesis.93, 94 However, the model has been suggested 
to be too sensitive, resulting in overestimation of carcinogenic potential. Further, the used 
dose (3 mg/mouse) was considered exceptionally high and may have culminated in extensive 
abdominal fibrosis causing death by constriction ileus.95, 96 A succeeding study by Poland et al. 
intraperitoneally exposed a nondeficient mouse model (C57Bl/6) to much lower doses of 50 
μg MWCNT per mouse and described the effects on the mesothelial lining of the body after 
7 days.35 MWCNTs induced a length-dependent inflammatory reaction, whereby long fibres 
demonstrated asbestos like behaviour. Whether this response would sustain and develop into 
mesotheliomas is speculative. From these results it is clear that more toxicological research is 
necessary to determine the carcinogenic potential, but some of the studies suggest to proceed 
with caution.
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3.6 Biodistribution 
Biodistribution profiles give crucial information on the fate of CNTs that entered the body. 
Only one study fulfilled the review inclusion criteria and described SWCNTs to remain in the 
body for at least 90 days after intravenous injection in mice, without causing severe clinical 
signs of toxicity. The weight of lungs and spleen significantly increased in combination 
with high SWCNT aggregation in the lungs. In the spleen, aggregation was low, and low 
levels of aggregation were also detected in the liver.64 Other studies on CNT distribution 
did not suffice the inclusion criteria, because of the use of functionalized CNTs. In most of 
these studies, CNT functionalization was a necessary aid to increase solubility or achieve 
CNT detection. Therefore, these studies will be described in this section nonetheless. 
Polyethylene glycol (PEG)-functionalized SWCNTs have an increased solubility and were 
injected intravenously in mice. After 1 day, the liver and spleen predominantly took them up 
and removal occurred steadily during 3 months. Necropsy, histology and blood chemistry 
measurements illustrated no toxic effects of the PEG-SWCNTs. Injection of a higher dose of 
100 μg/mouse, instead of 20 μg/mouse, demonstrated additional uptake in the in the lung, 
leg bone, kidney, intestine and stomach after 1 day.36 Also predominant uptake in the liver 
followed by lungs, spleen and kidneys was reported for radioactive carbon (14C)-labelled 
MWCNTs, which were intravenously injected in rats. Between 1 and 14 days, MWCNTs were 
slowly eliminated from organs, but rapidly from blood through renal excretion.17 In contrast 
to reported CNT aggregation in organs, indium (111In) diethylene triamine pentaacetic acid 
(DTPA) functionalized SWCNTs and technetium (99mTc) functionalized MWCNTs injected 
intravenously and intraperitoneally, respectively, revealed a rapid clearance from the body 
through urinary or fecal secretion without aggregation. Blood circulation half-life was either 
up to 3.5 h for the 111In-DPTA-SWCNTs or 5.5 h for the 99mTc-MWCNTs.22, 50
To finally illustrate the influence of exposure route on the distribution pattern of CNTs, 
distribution of taurine functionalized MWCNT (tau-MWCNT) was compared after 
intravenous injection, intratracheal instillation and oral gavage. Intravenously injected 
tau-MWCNTs accumulated predominantly in the liver, followed by lung and spleen and 
remained until 28 days. Intratracheal exposure led to accumulation mainly in the lungs 
and was gradually eliminated after 28 days, and oral gavage led to distribution in the small 
and large intestine and stomach. About 74% was already excreted through the feces after 
12 hours.49 Different exposure routes might clearly lead to complete different distribution 
patterns, and even though no severe clinical toxic signs were described, enduring CNT 
accumulation was reported several times and should be considered when establishing 
toxic potential.
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3.7 CNTs in biomaterials
Several tissue-engineered constructs significantly improved from a material science 
perspective, by CNT application.6, 97 Unfortunately, no studies thus far focussed exclusively 
on the adverse effects of CNT introduction in biomaterials. Few studies, however, 
described local effects after CNT implantation or implantation of CNT-doped constructs. 
Mostly, a mild inflammatory reaction is described and good biocompatibility of CNTs in 
tissue-engineered constructs is suggested, but this is still a matter of debate. Below, a 
summary of these studies is given. It must be noted however, that none of these studies 
met the inclusion criteria of this review. 
Subcutaneous implantation of alginate gel constructs with incorporated SWCNTs in 
rats induced locally an acute followed by chronic inflammatory reaction. Nevertheless, 
CNTs were suggested to be noncytotoxic, because an equal reaction was observed for 
the plain alginate construct and was ascribed to the surgical procedure.23 Another study 
also indicated good biocompatibility of SWCNTs. Here, poly(propylene fumarate) (PPF) 
constructs with incorporated SWCNTs were subcutaneously implanted in rabbits and led to 
minimal cellular encapsulation and no increase in the inflammatory response as compared 
with plain PPF scaffolds.7 Further, only a mild inflammatory response without neutrophil 
infiltration or necrosis was reported after subcutaneous implantation of MWCNTs of two 
different lengths in rats. However, due to the absence of a control group in this study, 
the influence of the surgical procedure could not be established. Longer fibers, though, 
seemed to result in stronger inflammation.24 Also in a bony environment, such as the skull 
periosteum or tibial bone of mice, biocompatibility of MWCNTs was suggested, as the CNTs 
induced only slight cellular inflammation. The same response was observed for MWCNTs 
implanted in the muscle in combination with recombinant human bone morphogenetic 
protein-2. In this model, MWCNTs even accelerated ectopic bone tissue formation.32
In contrast to the studies above, implanted SW- and MWCNTs were also reported 
to behold toxic potential. Implantation in rat gluteal muscle led to acute followed by 
chronic inflammatory reactions. The MWCNTs formed large aggregates and attracted 
multinucleated cells. SWCNTs were not encapsulated, but translocated to the lymph nodes 
and induced oxidative stress18 The difficulty in the interpretation of these studies lies again 
in the lack of standardization. Different surgical procedures, doses and (combinations 
of) materials were used, as well as different analysis methods. Further, in most of these 
studies toxicity analysis was not the main target, resulting in superficial results. Extensive 
research on this topic is necessary to judge the toxic potential of CNTs for biomaterial 
applications. Noninvasive imaging techniques, such as MRI labelling and detection,98 will 
be vital to assess long-term distribution of CNTs from degrading biomaterials.
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4. Recommendations and conclusions
An enormous amount of factors have been described to be of influence on the toxic 
potential of CNTs, complicating interpretation and comparison of the different studies. In 
future studies, better standardization of particle characterization, for example, dose, size, 
surface area, surface functionalization and crystalline structure is a prerequisite, because 
each of these factors could severely influence toxic potential. With this knowledge, the 
sensitivity and validity of currently existing analytical methods could be better standardized, 
and specific endpoints for different types and sizes of CNTs should be obtained. Further, 
analytical tools for the detection and characterization of CNTs should be further developed, 
because this still poses a problem in many situations and is often the limiting factor in 
toxicity assessments. Finally, in vivo risk assessments often rely on exposure of animals 
to high concentrations under artificial conditions, which limits the interpretation of the data. 
Therefore, in vivo assessments should focus on chronic exposure of lower concentrations, 
whereby dose-metrics studies would facilitate the interpretation highly.
When focussing on the current information, starting with the material characteristics, the 
presence of metal residues and surface-bound oxygen, as well as structural defects in the 
walls of CNTs, induce toxic potential. Subsequently, the dispersion and distribution pattern 
of CNTs, which is in turn influenced by the exposure route, and prolonged accumulation in 
the body also largely influence toxic potential, and finally, preexisting conditions such as 
allergies, pathological infections or exposure to air pollutants interfere with the responses 
to CNTs as well. Low standardization of these factors between the many studies on the 
subject makes it almost impossible to formulate a conclusion on CNT toxicity in animal 
models. However, it is safe to say that both SWCNTs and MWCNT have the capacity 
to induce pulmonary toxicity when administered via pulmonary route. Systemic toxicity, 
toxicity on other systems of the body and carcinogenicity of CNTs, however, is indicated 
in some studies and contradicted in others. Therefore, far more insight in this paradox is 
required. This also makes it premature to say anything about the implications of CNT use 
in tissue-engineered constructs, and for now, it can only be recommended to focus on the 
development of new standardized protocols and detection techniques, and further utilize 
CNTs with caution.
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1. Summary and address to the aims
From a clinical point-of-view, there is a high demand for the development of new or 
improved synthetic bone grafts. Polymer materials constitute a major segment of the 
many engineered synthetic bone grafts. These grafts have proven applicability for the 
repair of small bone defects, but have limited use in the repair of larger defects. Limitating 
factors amongst others are the poor mechanical properties compared to natural bone, 
and the low in-growth of bone forming cells. Development of polymeric composite 
materials provides the possibility to abolish these limitations. For instance, the addition 
of hydroxyapatite and bone morphogenetic protein-2 (BMP-2) in and onto the scaffolds, 
grants the bone grafts improved osteoconductivity and osteoinductivity respectively. Also, 
introducing nanomaterials into polymeric composites has the potential to improve material 
characteristics to great extent. One of the most promising nanomaterials for bone tissue 
engineering constructs are carbon nanotubes (CNTs), which are described to improve the 
mechanical characteristics of the constructs. Several nanocomposites based on polymer-
CNT mixtures have already been proposed.
In this thesis, all studies deal with the potential use of novel nanocomposites as bone 
reconstructive materials. A general introduction on bone tissue engineering and a 
description of the aims of this thesis are given in chapter 1. Each following chapter 
discusses a separate study. This summary addresses the aims as described in the first 
chapter in successive order.   
1. What is the current state of the art in nanomaterials for bone reconstruction?
In chapter 2 we concluded that nanomaterials might play an important role in future (bone) 
tissue engineering applications, regarding the many positive reports on nano-ceramics, 
-fibers, and CNTs. The materials have the ability to improve biocompatibility, mechanical, 
and electrical properties of bone tissue engineering constructs. These constructs can even 
be further modified by incorporation of biological agents. On the other hand, toxicological 
issues associated with the nanoscale size of these materials might have a negative effect, 
which is most evident for CNTs. Therefore, extensive research on each new application of 
nanomaterials is required.
2. What are the effects of different growth factors with varying concentrations, and 
in different combinations, on the proliferation and differentiation of bone marrow 
derived osteoblast-like cells in vitro?
Combined application of transforming growth factor β-1 (TGFβ-1) and BMP-2 to stimulate 
osteogenic expression in vitro was investigated in chapter 3. TGFβ-1 and BMP-2 fulfill
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specific roles in the formation of new bone. COLLOSS® E, a bone-derived collagen 
product containing a variety of naturally occurring growth factors, was also used. 
Growth factors were administered to osteoblast-like cells from rat bone marrow (RBM). 
Proliferation and differentiation were monitored up to 24 days, by measuring total DNA 
content, alkaline phosphatase (ALP) activity, and calcium content. Genetic expression of 
a set of differentiation markers at day 7 was measured by Q-PCR. Adding BMP-2 alone 
induced high proliferation rates, compared to the growth factor supplemented groups, 
and it induced high differentiation rates, compared to the control group. Adding TGFβ-1 
combined with BMP-2, TGFβ-1 alone, or COLLOSS® E resulted in a significant decrease 
in proliferation rate, but an increase in differentiation rate, compared to the control group. 
Additive or synergistic effects of application of TGFβ-1 and BMP-2 were not observed. The 
observed effects of COLLOSS® E mainly resembled those of TGFβ-1 application alone. 
On basis of these observations we concluded that BMP-2 is the most suitable candidate 
for osteogenic stimulation of RBM cells in these settings.
3.  What are the release and bioactivity profiles of BMP-2, released from a porous 
poly(L-lactic acid) (PLLA) scaffold with incorporated CNTs and microhydroxyapatite 
(µHA)?
Novel composites based on PLLA have been described. The bone response of such 
polymer-based composites usually is improved by the addition of BMP-2. However, 
released BMP-2 is cleared almost immediately from the site of implantation by diffusion, 
whereas a prolonged retention of BMP-2 onto the scaffold has been suggested to be more 
favorable. Besides the ability to improve the mechanical strength and osteoconductivity of 
polymeric scaffolds, both CNTs and µHA have been described to facilitate such retention 
of BMP-2 when incorporated into a composite scaffold. We therefore radiolabeled BMP-2 
and loaded it onto plain PLLA and composite PLLA/CNT/µHA scaffolds, as described in 
chapter 4. Subsequently, the scaffolds were implanted subcutaneously for five weeks in 
rats, and BMP-2 release was measured. Release started with an initial phase of quick 
release, followed by a gradual release of BMP-2. Both scaffold types comprised the same 
in vivo release properties for BMP-2. The bioactivity of the BMP-2 remained unaltered. 
Based on these results we concluded that incorporated CNTs and µHA did not affect BMP-
2 release from composite scaffold materials.
4.  What are the properties of CNTs, labeled with gadolinium (gadonanotubes), for 
magnetic resonance imaging (MRI) purposes?
Chapter 5 reports about the in vitro cytotoxicity and MRI studies of Gd3+ions-
doped ultra-short single-walled CNTs (gadonanotubes), gadonanotubes reinforced
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poly(lactic-co-glycolic acid) (PLGA) polymer nanocomposites and in vivo small animal 
MRI studies using the gadonanotubes. These studies were performed to explore the 
suitability of gadonanotubes-reinforced PLGA polymer nanocomposite as a model 
scaffold for noninvasive MRI to evaluate nanotube release during the degradation process 
of the scaffold and their biodistribution upon release from the polymer matrix in vivo. 
The gadonanotubes at 1-100 ppm and the gadonanotubes/PLGA nanocomposites (2 
wt% gadonanotubes) did not show any cytotoxicity in vitro as demonstrated using the 
LIVE/DEAD viability assay. For the first time, r2 relaxivity measurements were obtained 
for the superparamagnetic gadonanotubes. In vitro 7T MRI of the superparamagnetic 
gadonanotubes ([Gd] = 0.15 mM) suspended in a biocompatible pluronic F127 solution, 
gave a r2 value of 578 mM
-1s-1. Upon subcutaneous injection of the gadonanotubes 
suspension into the dorsal region of rats, the high r2 value translated into excellent and 
prolonged negative contrast enhancement of in vivo T2 weighted proton MRI images. The 
in vitro characterization of the nanocomposite discs and their degradation process by MRI, 
showed strong influence of the gadonanotube on water proton relaxations. These results 
indicate that the gadonanotubes/PLGA nanocomposites are suitable for further in vivo 
studies to track by MRI the biodegradation, release and biodistribution of gadonanotubes.
Therefore, in the following chapter 6 we aimed to develop a MRI technique to examine 
the distribution pattern of CNTs after release from a degrading PLGA scaffold in vivo. 
Five rats received a PLGA scaffold with incorporated gadonanotubes subcutaneously. 
The rats were analyzed up to 5 weeks, subsequently euthanized, followed by histological 
evaluation of the explanted scaffolds with their surrounding tissue. A significant increase in 
intensity of the scaffold surrounding tissue was shown in the time period around 3 weeks, 
as compared to internal control areas. The intensity declined soon thereafter. This is 
suggested to be caused by the release of gadonanotubes from the degrading scaffold into 
the surrounding tissue. Histological imaging showed encapsulation by connective fibrous 
tissue and some mild inflammation around the scaffolds. From this study, we concluded 
that magnetic resonance imaging is an excellent technique to study the biological fate 
of gadonanotubes. However, to formulate solid conclusions on the distribution pattern of 
gadonanotubes in vivo the experimental setup requires further optimization.
5. What are the effects of porous CNT and µHA doped PLLA scaffolds, on the in vitro 
genetic expression profiles of osteoblast-like cells, in the presence of BMP-2?
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In bone tissue engineering composite materials have been introduced, combining a 
degradable polymer matrix with, for instance, CNTs to improve mechanical properties, 
or with µHA to improve osteoconduction. The addition of BMP-2 can further improve the 
biological response to the material. However, the influence of such elaborate composite 
formation on osteoprogenitor cells is unknown. 
In our study described in chapter 7, RBM cells were cultured on porous PLLA and 
composite scaffolds, with or without added BMP-2. Cell proliferation and differentiation 
was studied using DNA, ALP activity, and scanning electron microscopic (SEM) analysis. 
Further, genetic profiles were examined by microarray investigation. Results showed 
that the composite scaffold had no significant effect on the proliferation of RBM cells, 
but indicated a negative effect on cell differentiation. The addition of BMP-2 also had 
no significant effect on the proliferation of RBM cells, but differentiation towards the 
osteogenic lineage was confirmed. In the arrays results, the addition of BMP-2 alone led 
to expression of genes involved in (minor) inflammation. The composite scaffold, and even 
more distinctly the combination of the composite scaffold with BMP-2, led to expression 
of genes, based on gene ontology, connected to tumorigenesis. Therefore, we concluded 
that CNT- and μHA- containing composite materials are not recommended as a bone 
restorative material.
6. What current information is available on toxicological aspects of carbon nanotubes? 
Amongst the engineered nanomaterials, especially CNTs have received considerable 
attention for application in tissue engineering scaffolds. CNTs are considered promising 
on behalf of their physicochemical properties, yet such nanomaterials also have been 
associated with potentially hazardous effects on human health. Chapter 8 presents a 
systematic review of literature, to gain insight in the toxicity aspects of CNTs in vivo. After 
screening of literature through defined inclusion and exclusion criteria, and subsequent 
data extraction, we concluded that pulmonary administered CNTs have the capacity to 
induce toxicity in the lung area. However, conclusions for other organs, or on systemic 
toxicity, are yet premature. In addition, the carcinogenic potential of CNTs is also still 
ambiguous, since contradictive results are presented. Intrinsic factors, like material 
characteristics and associated distribution- and agglomeration patterns are of influence 
on the toxic potential of CNTs. Similarly, environmental factors like the exposure route, 
pre-existing allergies, pathological infections, or air pollutant exposure are significant. In 
spite of the many reports published currently, more studies will be required to gain full 
understanding of the toxic potential of CNTs and especially the underlying mechanisms. 
For this end, development of standardized protocols and reliable nanodetection techniques 
will form prerequisites.
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2. Closing remarks and future perspectives
The studies presented in this thesis provide a further insight on the behaviour of growth 
factors, nanocomposites and CNTs in vitro and in vivo. Based on the results, BMP-
2 proved to be an adequate osteogenic stimulant for osteoblast-like cells from RBM in 
vitro. Consequently, BMP-2 was used throughout the following studies when growth factor 
application was relevant. 
Furthermore, results indicated that incorporation of CNTs and μHA in PLLA nanocomposites 
enhanced mechanical characteristics, but did not prolong the release of BMP-2 in vivo, 
which was in contrast with our initial hypothesis. Nevertheless, we believe that in our set 
up, there was limited presence of the doped materials directly on the surface. Further 
research examining the influence of a better or higher availability of CNTs and μHA on the 
composite surface on growth factor release could still be interesting. 
Research on CNT distribution is hampered by the limited capacity of conventional detection 
techniques. Therefore, we developed a novel technique, based on MRI, to detect gadolinium 
labelled CNTs in vivo. MRI is a non-invasive technique, providing the possibility to visualize 
and track CNTs in vivo, for instance after release from a degrading composite. Other research 
areas in medicine however, could also greatly benefit from this technique.
By this technique CNT release from low molecular weight PLGA scaffolds was described to 
occur after three weeks, followed by a systemic clearance from the body. No aggregation in 
organs was reported. However, the possibility of CNT concentrations below the detection 
limit of this technique should be taken into account and no conclusive statements can be 
made at this point. Therefore, further research to increase the sensitivity of this technique 
is highly recommended. Furthermore, with the gained knowledge, the study design could 
be expanded for future research. More analysis around three weeks post-implantation, 
including extensive histological analysis would be beneficial. The extremely small size 
of the CNTs is a point of concern in this respect, as in routine histological analysis the 
presence of CNTs could easily be overlooked. The addition of a renal deficient model in 
future animal studies could be used to circumvent such problems, as this model could 
serve as a positive control for CNT agglomeration. Furthermore, this model would also 
be useful to study gadolinium labelled CNT agglomeration by MRI, since it is described to 
be an excellent model to examine the retention of different contrast media in the kidney.
Finally, we addressed the possibility of adverse side effects of a PLLA/CNT/μHA 
nanocomposite, by studying gene expression profiles of osteoblast-like cells cultured onto 
the composite. The expression of many genes directly connected to tumorigenesis was 
induced by the nanocomposite, which causes reason for concern. However, these results 
are based on in vitro research and it would be interesting for future research to implant
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these nanocomposites in an animal model and examine gene expression profiles in 
animal tissues. Furthermore, it would be beneficial to add a group with a nanocomposite 
composed of PLLA and CNTs to the study design. This would help to determine the exact 
influence of CNTs on these results and could also help understanding the mechanisms 
associated with CNT introduction in the body. Our systematic review indicates the need 
for such research, since the extent and mechanisms of adverse effects of CNTs are still 
inconclusive.
Samenvatting, slotopmerkingen & 
toekomstperspectieven
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1. Samenvatting en evaluatie van de doelstellingen
Vanuit een klinisch oogpunt bekeken is er een grote vraag naar de ontwikkeling 
van nieuwe of verbeterde synthetische botvervangers. Een groot deel van de vele 
ontwikkelde synthetische botvervangers wordt gevormd door materialen bestaande uit 
polymeren. Deze materialen hebben hun toepasbaarheid bewezen voor het repareren 
van kleine botdefecten, maar het gebruik van deze materialen voor de reparatie van 
grote botdefecten is beperkt. De limiterende factoren zijn o.a. de slechte mechanische 
eigenschappen in vergelijking met natuurlijk bot en de slechte ingroei van botvormende 
cellen. Het ontwikkelen van polymeer-composiet materialen geeft de mogelijkheid deze 
limitaties te overkomen. Botvervangende materialen kunnen bijvoorbeeld een verbeterde 
osteoconductiviteit en osteoinductiviteit verkrijgen door de toevoeging van hydroxyapatiet 
en bone morphogenetic protein-2 (BMP-2) in en op de matrix. Bovendien, kunnen de 
mechanische eigenschappen van polymeer-composieten enorm verbeterd worden door 
de toevoeging van nanomaterialen. Een van de meest veelbelovende nanomaterialen, 
voor de ontwikkeling van botweefselconstructen, zijn carbon nanotubes (CNT’s), waarvan 
beschreven is dat ze de mechanische eigenschappen van de constructen kunnen 
verbeteren. Verschillende nanocomposieten, bestaande uit een polymeer-CNT mix zijn 
reeds voorgesteld.
Alle studies, beschreven in dit proefschrift, handelen over het mogelijke gebruik van 
nieuwe nanocomposieten als botreconstructie materialen. Een algemene introductie 
in bot tissue-engineering en een beschrijving van de doelstellingen van dit proefschrift 
worden gegeven in hoofdstuk 1. Elk volgend hoofdstuk beschrijft een aparte studie. Deze 
samenvatting evalueert de doelstellingen, zoals beschreven in het eerste hoofdstuk, in 
opeenvolgende volgorde. 
1. Wat zijn de nieuwste ontwikkelingen op het gebied van nanomaterialen voor 
botreconstructie?
In hoofdstuk 2 concludeerden we dat nanomaterialen een belangrijke rol in toekomstige 
(bot) tissue engineering toepassingen zouden kunnen gaan spelen, wanneer gekeken 
wordt naar de vele positieve rapportages over nano-keramieken, -vezels en CNT’s. De 
materialen bieden de mogelijkheid om de biocompatibiliteit, mechanische-, en elektrische 
eigenschappen van bot tissue engineering constructen te verbeteren. Deze constructen 
kunnen zelfs verder aangepast worden door incorporatie van biologische agentia. 
Daarentegen is er nog weinig inzicht in de toxicologische vraagstukken, welke het meest 
opvallend zijn voor CNT’s, die geassocieerd worden met de nano-grootte van deze 
materialen. Daarom is uitvoerig onderzoek, voor elke nieuwe toepassing waarin gebruik 
gemaakt wordt van nanomaterialen, een vereiste.
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2. Wat zijn de effecten van verschillende groeifactoren in verschillende concentraties 
en in verschillende combinaties, op de proliferatie en differentiatie van osteoblast-
gelijkende cellen, afgeleid van beenmerg, in vitro?
In hoofdstuk 3 werd de gecombineerde toevoeging van transforming growth factor β-1 
(TGFβ-1) en BMP-2, om osteogene expressie in vitro te stimuleren, onderzocht. TGFβ-1 en 
BMP-2 vervullen beiden specifieke rollen in de formatie van nieuw bot. COLLOSS® E, een 
product afgeleid uit bot dat een veelzijdigheid aan natuurlijk voorkomende groeifactoren 
bevat, werd eveneens gebruikt. De groeifactoren werden toegediend aan osteoblast-
gelijkende cellen, afgeleid van rattenbeenmerg (RBM). Proliferatie en differentiatie van 
de cellen werd gedurende 24 dagen onderzocht door de totale hoeveelheid DNA, alkaline 
fosfatase (ALP) activiteit, en calcium te meten. De genetische expressie van bepaalde 
differentiatiemarkers werd, door middel van Q-PCR, bepaald op dag 7. Toevoeging van 
enkel BMP-2 induceerde hoge proliferatiesnelheden vergeleken met de andere groeifactor 
gesupplementeerde groepen, en het induceerde hoge differentiatiesnelheden vergeleken 
met de controlegroep. Toevoeging van TGFβ-1, TGFβ-1 gecombineerd met BMP-2, of 
COLLOSS® E resulteerde in een significante afname van de proliferatiesnelheid en in 
een verhoging van de differentiatiesnelheid, vergeleken met de controle groep. Additieve 
of synergistische effecten na toevoeging van TGFβ-1 in combinatie met BMP-2 werden 
niet waargenomen. De geobserveerde effecten van COLLOSS® E waren grotendeels 
vergelijkbaar met die van TGFβ-1. Op basis van deze waarnemingen concludeerden we 
dat, onder deze omstandigheden, BMP-2 de meest geschikte groeifactor voor osteogene 
stimulatie van RBM cellen is.
3.  Hoe zien de vrijgifte- en bioactiviteitsprofielen van BMP-2, dat vrijkomt van een 
poreuze poly(L-lactic acid) (PLLA) matrix waarin CNT’s en microhydroxyapatiet 
(µHA) zijn geïncorporeerd, eruit?
Er zijn al meerdere composieten, gebaseerd op PLLA, beschreven. De botrespons 
op dergelijke polymeer gebaseerde composieten, wordt veelal verbeterd door de 
toevoeging van BMP-2. Echter, vrij BMP-2 wordt doorgaans direct verwijderd van 
de implantatieplaats als gevolg van diffusie. Daarom wordt een verlengde retentie 
van BMP-2 op de matrix als meer wenselijk gesuggereerd. Buiten het vermogen 
van zowel CNT’s als µHA (geïncorporeerd in de matrix) om de mechanische sterkte 
en osteoconductiviteit van polymeer composieten te verbeteren, wordt beschreven 
dat ze ook de retentie van BMP-2 op de matrix zouden kunnen verhogen. Om dit te 
onderzoeken hebben we radioactief gelabeld BMP-2 aangebracht op een pure PLLA 
matrix en op een PLLA/CNT/µHA composiet matrix, zoals beschreven in hoofdstuk 4. 
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Vervolgens werden beide matrices subcutaan geïmplanteerd in ratten gedurende vijf 
weken en werd de vrijgifte van BMP-2 gemeten. De vrijgifte bestond uit een initiële fase 
waarin BMP-2 snel vrijgelaten werd, gevolgd door een fase van geleide vrijlating. Beide 
matrices vertonen dezelfde vrijgifte-eigenschappen voor BMP-2 in vivo. De bioactiviteit 
van het BMP-2 bleef onveranderd. Gebaseerd op deze resultaten, concludeerden we dat 
CNTs en µHA, geïncorporeerd in een PLLA composiet, geen effect hadden op de vrijgifte 
van BMP-2.
4.  Wat zijn de eigenschappen van CNT’s, gelabeld met gadolinium (gadonanotubes), 
voor magnetic resonance imaging (MRI) doeleinden?
In hoofdstuk 5 worden in vitro cytotoxiciteit en MRI studies beschreven van ultra 
korte enkelwandige CNT’s met geïncorporeerde Gd3+ ionen (gadonanotubes) en van 
gadonanotubes versterkte poly(lactic-co-glycolic acid) (PLGA) polymeer nanocomposieten. 
Ook worden in vivo MRI studies in kleine proefdieren beschreven waarbij gadonanotubes 
gebruikt zijn. Deze studies zijn uitgevoerd om de geschiktheid van PLGA nanocomposieten, 
versterkt met gadonanotubes, te evalueren als modelmatrix voor non-invasieve MRI om 
de vrijgifte en de biodistributie van nanotubes tijdens het degradatie process van de matrix 
in vivo te kunnen onderzoeken. De LIVE/DEAD test toonde aan dat gadonanotubes (1-
100 ppm) en gadonanotubes/PLGA nanocomposieten (2 gewichtsprocent) in vitro niet 
cytotoxisch waren. Ook zijn voor het eerst r2 relaxatie metingen verkregen voor de 
superparamagnetische gadonanotubes. In vitro 7T MRI van de superparamagnetische 
gadonanotubes ([Gd] = 0,15 mM), gesuspendeerd in een biocompatibele pluronic 
F127 oplossing, resulteerde een r2 waarde van 578 mM
-1s-1. Na subcutane injectie van 
de gadonanotubes-suspensie in de dorsale regio van ratten, werd de hoge r2 waarde 
vertaald in een uitstekende en verlengde verhoging van het negatief contrast van in vivo 
T2 gewogen proton MRI beelden. De MRI in vitro karakterisatie van de nanocomposiet 
schijfjes en hun degradatieproces toonde een sterke invloed van de gadonanotubes op 
water proton relaxaties aan. Deze resultaten duiden aan dat de gadonanotubes/PLGA 
nanocomposieten geschikt zijn voor in vivo studies om de biodegradatie, de vrijgifte en de 
biodistributie van gadonanotubes te evalueren. 
We hebben ons daarom in het volgende hoofdstuk 6 tot doel gesteld een MRI techniek te 
ontwikkelen waarmee het distributiepatroon van CNT’s, na vrijgifte van een degraderende 
PLGA matrix, in vivo onderzocht kan worden. In 5 ratten werd subcutaan een PLGA 
construct met geïncorporeerde gadonanotubes geplaatst. De ratten werden vervolgens 5 
weken geanalyseerd. Hierna werden ze gedood, gevolgd door een histologische evaluatie 
van de geëxplanteerde materialen en het omliggende weefsel. 
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Na ongeveer 3 weken werd een significante verhoging in de intensiteit van het weefsel 
rondom het construct waargenomen in vergelijking met interne controle regio’s. Spoedig 
hierna verlaagde deze intensiteit. Dit suggereert dat gadonanotubes, vrijgekomen uit 
het degraderende construct, deze verhoging in intensiteit in het omliggende weefsel 
hebben veroorzaakt. Histologische analyse toonde inkapseling van het construct, in 
connectief fibreus weefsel en een milde onsteking aan. Aan de hand van deze resultaten 
concludeerden we dat de biodistributie van vrijgekomen gadonanotubes uitstekend 
onderzocht kan worden met behulp van MRI. Echter, om solide conclusies te kunnen 
formuleren over de biodistributie van gadonanotubes in vivo, dienen de experimentele 
instellingen verder geoptimaliseerd te worden.
5. Wat zijn de effecten van poreuze PLLA composieten, met geïncorporeerde CNT’s 
en µHA, op de genetische expressieprofielen van osteoblast-gelijkende cellen in 
vitro, in de aanwezigheid van BMP-2?
In bot tissue-engineering onderzoek zijn verschillende composietmaterialen geïntroduceerd 
waarin een degradeerbare matrix bestaande uit polymeren gecombineerd wordt met, 
bijvoorbeeld CNT’s om de mechanische sterkte te verbeteren, of met µHA om de 
osteoconductie te verbeteren. Door BMP-2 toe te voegen kan de biologische respons op 
het materiaal verder geoptimaliseerd worden. Echter, de invloed van een dergelijk complex 
materiaal op bot voorlopercellen is onbekend.
In onze studie, beschreven in hoofdstuk 7, werden RBM cellen gekweekt op poreuze 
PLLA en composietmaterialen, met of zonder toegevoegd BMP-2. Celproliferatie en 
-differentiatie werd bestudeerd aan de hand van DNA, ALP-activiteit en scanning 
electronenmicroscopische (SEM) analyse. Verder werden genetische expressieprofielen 
onderzocht met behulp van microarray analyse. Resultaten toonden aan dat het composiet 
geen significant effect op de proliferatie van RBM cellen had, maar suggereerden een 
negatief effect op de differentiatie van de cellen. De additie van BMP-2 had eveneens 
geen significant effect op de proliferatie van de RBM cellen, maar osteogene differentiatie 
werd wel bevestigd. In de resultaten van de genexpressie-analyse leidde de toevoeging 
van BMP-2 tot een expressie van genen die betrokken zijn bij een (lichte) ontsteking. 
Het composietmateriaal, en sterker nog, het composietmateriaal in combinatie met BMP-
2, leidde tot een expressie van genen die gerelateerd zijn aan tumorigenese. Hieruit 
concludeerden we dat CNT- en µHA bevattende composietmaterialen  niet aan te bevelen 
zijn voor gebruik als botreconstructieve materialen.
6. Welke informatie is momenteel beschikbaar over de toxicologische aspecten van 
carbon nanotubes? 
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Onder de ontwikkelde nanomaterialen hebben voornamelijk CNT’s veel aandacht gekregen 
voor toepassing in tissue-engineering constructen. CNT’s worden als veelbelovend 
beschouwd vanwege hun fysisch-chemische eigenschappen, echter, nanomaterialen 
worden eveneens geassocieerd met potentieel gevaarlijke effecten op de humane 
gezondheid. Om inzicht te verkrijgen in de toxiciteitsaspecten van CNT’s in vivo wordt in 
hoofdstuk 8 een systematische review van de literatuur gepresenteerd. Na het screenen 
van de literatuur, met inachtname van duidelijk gedefinieerde inclusie- en exclusiecriteria, 
en de daaropvolgende data-extractie, hebben we geconcludeerd dat CNT’s die via de 
pulmonaire route worden toegediend over de capaciteit beschikken om toxiciteit in de 
longen te veroorzaken. Echter, conclusies met betrekking tot toxiciteit in andere organen, 
of systemische toxiciteit zijn momenteel nog prematuur. Bijkomend, worden tegenstrijdige 
resultaten beschreven, met betrekking tot het carcinogene potentieel van CNT’s. 
Intrinsieke factoren, zoals materiaaleigenschappen en geassocieerde distributie- en 
agglomeratieprofielen, zijn duidelijk van invloed op het toxisch potentieel van CNT’s. Op 
gelijke wijze hebben omgevingsfactoren, zoals de blootstellingsroute, reeds bestaande 
allergieën en bacteriële infecties, of blootstelling aan luchtvervuiling, ook een significante 
invloed op het toxisch potentieel van CNT’s. Ondanks de vele studies die tot dusverre 
zijn gepubliceerd, zijn meer studies benodigd om een goed inzicht te verkrijgen in het 
toxisch potentieel van CNT’s en in de onderliggende mechanismen. Gestandaardizeerde 
protocollen en betrouwbare detectiemethoden van nanomaterialen vormen hiervoor een 
vereiste. 
2. Afsluitende opmerkingen en toekomstperspectieven
De studies beschreven in dit proefschrift verschaffen een beter inzicht in het gedrag van 
groeifactoren, nanocomposieten en CNT’s in vitro en in vivo. Gebaseerd op de resultaten, 
heeft BMP-2 bewezen een adequate stimulant te zijn voor osteoblast-gelijkende cellen in 
vitro. Zodoende werd BMP-2 gedurende de volgende studies gebruikt, wanneer toediening 
van een groeifactor relevant was. Bovendien toonden de resultaten aan, dat de incorporatie 
van CNT’s en µHA in PLLA nanocomposieten de materiaalkarakteristieken verbeterde, 
maar de retentie van BMP-2 op het materiaal niet verlengde in vivo. Dit in tegenstelling 
tot onze hypothese. Echter, we vermoeden dat er met de gebruikte experimentele 
instellingen maar een beperkte hoeveelheid van de geïncorporeerde materialen direct 
aan het oppervlak aanwezig was. Meer onderzoek, waarin de invloed van een betere of 
hogere beschikbaarheid van CNT’s en µHA aan het oppervlak wordt geanalyseerd, kan 
interessante resultaten opleveren.
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Onderzoek naar de distributie van CNT’s wordt momenteel belemmerd door de 
gelimiteerde detectiecapaciteit van conventionele detectiemethoden. Daarom hebben we 
een nieuwe techniek ontwikkeld, gebaseerd op MRI, om gadolinium gelabelde CNT’s in 
vivo te kunnen detecteren. MRI is een non-invasieve techniek die de mogelijkheid biedt 
om CNT’s zichtbaar te maken en in de tijd te volgen in vivo, bijvoorbeeld gedurende het 
vrijkomen uit een degraderend composiet. Op andere gebieden in het medisch onderzoek 
kunnen echter ook grote voordelen behaald worden uit deze techniek. Aan de hand van 
de resultaten, verkregen met behulp van deze techniek, is beschreven dat CNT vrijgifte 
van een laag moleculair PLGA composiet plaatsvindt na ongeveer 3 weken, gevolgd door 
systemische verwijdering uit het lichaam. Echter, er moet rekening gehouden worden met 
de mogelijkheid dat er CNT concentraties aanwezig kunnen zijn die onder de detectie 
grens van deze techniek liggen. Op dit moment kunnen dus nog geen onweerlegbare 
conclusies gemaakt worden. Daarom wordt verder onderzoek naar het verhogen van de 
gevoeligheid van deze techniek sterk aanbevolen. Bovendien zou met de huidige kennis de 
studieopzet voor een vervolgstudie uitgebreid kunnen worden. Uitgebreide analyse rond 
3 weken na implanatatie, inclusief een uitvoerige histologische analyse, is aanbevolen. 
Mogelijk levert de extreem kleine grootte van de CNT’s hier problemen op, aangezien de 
aanwezigheid van CNT’s tijdens histologische analyse gemakkelijk over het hoofd gezien 
kan worden. Het toevoegen van een diermodel met een deficiënte nierfunctie zou gebruikt 
kunnen worden om dit probleem te ondervangen, daar dit model zou kunnen dienen als 
een positieve controle voor CNT agglomeratie. Bovendien zou dit model eveneens zeer 
behulpzaam kunnen zijn om agglomerende gadolinium gelabelde CNT’s te bestuderen 
met behulp van MRI, aangezien een dergelijk model als een uitstekend model wordt 
beschreven om de retentie van verschillende contrastmedia in de nier te bestuderen.
Tot slot hebben we ons gericht op het onderzoeken van mogelijk ongewenste neveneffecten 
van een PLLA/CNT/µHA nanocomposiet. Hiervoor zijn genexpressie profielen bestudeerd 
van osteoblast-gelijkende cellen die gekweekt waren op het composiet. Vele genen, 
gerelateerd aan tumorigenese, vertoonden een verhoogde expressie, wat zorgelijk is. 
Echter, deze resultaten zijn gebaseerd op in vitro onderzoek en het zou zeer interessant 
zijn om deze nanocomposieten in een vervolgstudie te implanteren in een diermodel en de 
genexpressie profielen in verschillende weefsels te onderzoeken. Het zou zeer nuttig zijn 
om tevens een groep met een nanocomposiet bestaande uit PLLA en CNT’s toe te voegen 
aan de onderzoeksopzet. Hiermee zou de exacte invloed van de CNT’s op de resultaten 
bepaald kunnen worden. Bovendien kan hiermee een beter inzicht verkregen worden 
in de mechanismen die geassocieerd zijn met de introductie van CNT’s in het lichaam. 
Onze systematische review toont aan dat dergelijk onderzoek noodzakelijk is, aangezien 
de mate van ongewilde neveneffecten nog altijd onbekend is, evenals de onderliggende 
mechanismen.
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verbaasd over de snelheid waarmee jij respons geeft. Ook heb ik diep respect voor de 
manier waarop jij als afdelingshoofd en hoogleraar ook nog overzicht weet te houden over 
de nieuwste ontwikkelingen op wetenschappelijk gebied. Ik ben zeer verheugd dat ik op 
jouw afdeling mocht promoveren en zal altijd met veel plezier hieraan terugdenken.
Dr. X.F. Walboomers, beste Frank, jouw expertise en begeleiding zijn enorm belangrijk 
geweest voor de totstandkoming van dit proefschrift. Je hebt altijd overzicht weten te 
houden over de voortgang van mijn onderzoek en belangrijker, je hebt mij het inzicht 
gegeven om efficiënt en doelgericht orde te scheppen in (mijn) chaos, waarbij zo nu en 
dan het stellen van een strakke deadline van grote waarde was. Jouw deur staat altijd 
open om even binnen te wandelen en onze gesprekken gingen vaak gepaard met een 
goede dosis humor. Dat vele wegen naar Rome leiden heb ik letterlijk en figuurlijk aan den 
lijve ondervonden tijdens de vele meetings in Europa. Hierbij waren de discussies met 
onze Europese vrienden toch altijd wel weer een hoogtepunt, evenals de gang langs de 
douane, wat jou toch altijd een heel stuk gemakkelijker afging dan mij.
Dr. J.G.C. Wolke, beste Joop, jouw rasechte Amsterdamse mentaliteit en ongezouten 
mening waardeer ik zeer. Jij bent altijd bereid geweest je oneindige materiaalkundige 
kennis over calciumfosfaten en polymeren te delen, waar ik veel van geleerd heb. 
Prof. dr. O.C. Boerman, beste Otto, hartelijk bedankt voor de prettige samenwerking en 
voor je zeer deskundige advies. Ik ben blij dat onze inspanningen hebben geleid tot een 
gezamenlijke publicatie. Ook wil ik Annemarie Eek bedanken voor haar inspanningen bij 
het labelen van de groeifactoren.
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Prof. dr. A. Heerschap, beste Arend jij bent van grote waarde geweest in ons MRI onderzoek. 
Deze studies bleken niet altijd even gemakkelijk en hebben ons voor vele problemen 
geplaatst die vaak mijn kennisniveau ontstegen. Ik waardeer het enorm dat jij, tijdens deze 
goede samenwerking, ons hebt bijgestaan met je rijke kennis en enthousiasme, wat heeft 
geleid tot een succesvolle afsluiting van deze studies. Onmisbaar is ook de hulp van Andor 
Veltien geweest, waarmee ik samen heel wat uurtjes bij de MRI gezeten heb. Bedankt 
hiervoor.
Dr. A.G. Mikos, dear Tony, I highly value your opinion and knowledge. Thank you very 
much for your excellent contributions to my research, especially on the studies I performed 
together with Balu.  
Dr. B. Sitharaman, dear Balu, I really enjoyed our work together. The MRI technique, as well 
as the gadonanotubes you introduced me to, were like discovering a whole new world to me. 
With this work I crossed a new boundary, which was very inspiring. Thank you for sharing 
your extensive knowledge with me, and I highly appreciate the effort you took to explain the 
MRI-related technicalities to me.  
Furthermore, I would like to thank all the partners collaborating in the Nanobiocom project for 
their excellent help and work. Some people I would like to address in particular. 
For his superior leadership en coordination of the project, I would like to thank Dr. J.Iñaki Álava. 
Also, I would like to thank Maria J. Jurado and Beatriz Olalde for their extensive work on the 
scaffold materials, that were used in many of the studies described in this thesis, and for their 
help on all the technical questions I had about the scaffolds. 
Finally, I want to thank Mathias Brännvall for all his efforts in the gene expression study, and 
for helping me finding my way through the enormous amounts of data. I learned a lot from 
this experience.  
Alle biotechnici en dierverzorgers van het CDL, van zowel de afdeling grote- als kleine 
dieren, hartelijk dank voor jullie uitstekende ondersteuning tijdens de verschillende studies 
die zijn uitgevoerd in het CDL. 
Dan nu weer terug naar de afdeling Biomaterialen. Een van de redenen, dat ik de tijd op 
deze afdeling als zo goed heb ervaren, zijn natuurlijk de mensen geweest. Een mengeling 
van zeer uiteenlopende persoonlijkheden zorgde keer op keer weer voor heel goede, of juist 
heel foute, gesprekken in de koffiekamer en daarbuiten. Als ik aan verhalen in de koffiekamer 
denk, moet ik meteen aan Lise denken. Lise, tot op de dag van vandaag ben ik nog niemand 
tegen gekomen die grotere verhalen kan vertellen dan jij. Het was altijd weer een feest om 
te horen wat je nu weer meegemaakt had. Nog leuker vond ik het om zelf zo nu en dan ook 
een plekje te veroveren in deze verhalen, na bijvoorbeeld een avond gezellig stappen, wat
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overigens ook een expertise van jou is! Ook al woon je nu in Londen, ik hoop dat we contact 
blijven houden en snel weer eens een gezellige avond uit kunnen gaan. 
Als ik aan geluid in de koffiekamer denk, dan denk ik meteen aan het gebulder van jou 
Jeroen. Wanneer jij begint te lachen, heb je meteen iedereen mee. Ik zal je aparte humor 
en open persoonlijkheid zeker missen.
Buiten de koffiekamer heerste ook in “mijn” kamer altijd een topsfeer, natuurlijk dankzij mijn 
leuke kamergenoten! Ik wil dan ook graag zowel de “oudere” generatie; Dennis, Esther, 
Walter, Lise en Weibo als de “nieuwere” generatie; Edwin, Wei en JinLing bedanken voor 
de gezelligheid en ook voor alle goede (al dan niet werkgerelateerde) discussies die we 
gevoerd hebben. To translate for my foreign ex-roomies: Thanks for your sociability and 
for all the nice discussions we had (workrelated or not). 
Eddie, vooral met jou heb ik natuurlijk veel discussies gevoerd over de opkomende 
problemen in ons nano-onderzoek en andere wereldproblemen;). Jouw uitgesproken 
mening zorgde er altijd weer voor dat deze gesprekken nooit saai waren. En niet 
onbelangrijk, als echte lowlander ben jij altijd in voor een biertje na werktijd, wat veel 
memorabele momenten heeft opgeleverd.
Dan is er de “analistenkamer” nog, wat zouden we zonder onze analisten moeten! Natasja 
uit Hapsburg, bedankt voor al je hulp bij het zagen en kleuren van mijn coupes. Vincent 
en Martijn, ik heb genoten van jullie gekke buien en vond het leuk kennis te maken met 
jullie artistieke talenten. Anja, je werkt inmiddels al een tijdje niet meer bij de afdeling 
Biomaterialen, maar jouw nietsontziende oog in het lab en je personality zal ik niet snel 
vergeten. Bedankt voor alle goede hulp.
Zoals al wel duidelijk is geworden, heb ik ook vele goede herinneringen aan de gezamenlijke 
uitjes en borrels buiten werktijd. Dit onderstreept de goede collegialiteit op de afdeling. 
Therefore, I would like to thank all you biomaterialists for your support, interest that you 
have shown, healthy critisism, and sociability!
Naast promotieonderzoek was er voor mij ook de kunstacademie. Dit vormde voor een 
heerlijke combinatie van twee totaal verschillende werelden. In beide werelden kan ik 
helemaal opgaan en beide werelden hebben een plekje in mijn hart veroverd. Ik wil dan 
ook graag mijn docenten, met name Arnoud de Blauw en Nico Schulte, bedanken voor 
de vele leerzame werkbesprekingen. Ik heb genoten van het enthousiasme en de passie 
waarmee jullie je visie over kunst uiten. Ook wil ik jullie bedanken voor de interesse die 
jullie toonden in mijn onderzoek en voor alle geduld en begrip, want het is niet altijd 
gemakkelijk geweest.
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Verder wil ik de mensen bedanken die niet zozeer een aandeel in de totstandkoming van 
dit proefschrift hebben geleverd, maar die wel zeer belangrijk voor mij zijn. 
Lieve Isabel en Barry, wij kennen elkaar al vele jaren en gaan er nog vele bij plakken! Jullie 
zijn er altijd voor mij en mijn dank daarvoor is groot. Isabel, na vele jaren oefenen hebben 
wij aan een half woord genoeg om elkaar te begrijpen, iets wat ik diep koester.
Karin, Miranda en Debby. Samen met Bel & Bar zijn wij inmiddels ook al weer aardig wat 
jaartjes een heel hechte club. Ook al kan ik er niet meer zo vaak bij zijn als ik zou willen, 
de Brabantse gezelligheid laat het nooit afweten als ik samen met jullie ben. Ik hoop met 
jullie nog vele steden te gaan veroveren tijdens onze meidenweekenden (sorry Barry, 
zonder jou dus).
Lorette, Cindy en Catharina ofwel Lot, Cin & Cat. Jullie bewijzen dat Haagse directheid 
gecombineerd met Groningse nuchterheid een solide fundering geeft voor een goede 
vriendschap. De vele gezellige momenten die we samen hebben meegemaakt smaken 
naar meer. Ik hoop dat er nog veel mogen volgen (samen met kleine Tess).
Tom, Loes en Marian. Samen echte HLO-nerds door dik en dun, ik ben blij dat onze 
vriendschap na al die tijd nog steeds stand houdt. Tom, met niemand anders kan ik mijn 
voorliefde voor foute films zo goed delen als met jou. Op naar de volgende filmavond, Finn 
kan het niet vroeg genoeg leren!
Charlotte, wij hebben elkaar leren kennen op de kunstacademie en ook al heb jij de 
aspiratie om docent te worden al snel weer verruild voor een aanstormende carrière in de 
journalistiek, een goede vriendschap was snel gevormd. Ook samen met Lieke zijn er al 
vele onvergetelijke momenten geweest en er gaan er zeker nog vele volgen.
Lieve pa, ma en Taco, jullie liefde en onvoorwaardelijke steun vormen een belangrijke 
en vertrouwde basis voor mij. Jessica, tot mijn vreugde versterk jij deze basis al vele 
jaren en nu hebben jij en Taco je eigen basis gecreëerd voor Liam. Liam, jij snapt er 
allemaal nog niks van, maar een glimlach, of nog beter, een goede schaterlach van jou 
is genoeg om mijn dag goed te maken. Pa en ma, jullie hebben me altijd gestimuleerd 
en de vrijheid  geboden om mijn grenzen te kunnen verleggen. Zonder jullie was dit nooit 
mogelijk geweest en mijn dank voor alles wat jullie voor me hebben gedaan is dan ook niet 
in woorden te omschrijven.
Tot slot, lieve Chris, mijn rots in de branding. Ik kan altijd op jou rekenen en jij maakt mij 
enorm gelukkig. Het zijn drukke tijden geweest en je moet soms helemaal gek geworden 
zijn van mij, hopelijk kunnen we binnenkort genieten van rustigere tijden. 
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